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Abstract 
 
 Positron emission tomography (PET) is a high resolution, non-invasive functional 
imaging technique used for observation of biochemical processes in vivo. This thesis 
describes work towards using this imaging modality to better understand the processes 
of the major inhibitory neurotransmitter gamma(γ)-amino butyric acid (GABA). The 
GABAergic system is understood to be involved in many neurological diseases and 
disorders including Alzheimer’s disease, epilepsy, schizophrenia, autism and depression. 
In the GABAergic system, GABA receptors and transporters are targets for drug 
development as well as investigation as biomarkers. While imaging of the post-synaptic 
GABAergic receptor subtype GABAA is possible with the use of [11C]flumazenil 
([11C]FMZ), there is no complimentary PET radiotracer enabling in vivo imaging of GABA 
in pre-synaptic neurons. Located pre-synaptically and in high abundance in areas such 
as the cortex and basal ganglia, GABA Transporter subtype 1 (GAT-1) presents as an 
interesting target for pre-synaptic GABA imaging. Studies have shown an increase in 
GAT-1 expression, especially in the cortex, in the schizophrenic brain. GAT-1 is 
responsible for removal of GABA from the synaptic cleft, thereby ending its action on post-
synaptic GABA receptors. Tiagabine was approved by the FDA in 1997 and remains the 
only GAT-1 inhibitor available today. Many structure activity relationship (SAR) studies 
have sought to improve the selectivity and affinity of tiagabine for GAT-1. Some research 
has been successful in the radiolabeling of these compounds for imaging for preclinical 
evaluation, but as of yet, no radiotracer has proven successful or advanced to widespread 
 xx 
clinical use. To address this urgent need in functional neuroimaging, this work is focused 
upon developing a GAT-1 selective, blood-brain barrier (BBB) permeable radiotracer for 
use in PET imaging of the GABAergic system.  
 The synthesis and preliminary evaluation of a number of novel GAT-1 selective 
PET tracers is described herein. Scaffolds with high affinity and excellent selectivity for 
GAT-1 were used as leads for adaptation into new PET radiotracers. Successful 
[18F]radiofluorination of one scaffold was promising, but subsequent in vivo evaluation 
indicated poor BBB permeability. Additional studies using carbon-11 to label additional 
small molecule GABA uptake inhibitors were undertaken to test our hypothesis that low 
brain uptake was due to the highly polar zwitterionic nipecotic acid moiety. As the acid 
group is necessary for high affinity binding to GAT-1, it cannot be simply removed or 
esterified. Therefore, future efforts in GAT-1 radiotracer design will need to investigate 
carboxylic acid bioisosteres in an attempt to improve brain uptake while maintaining 
affinity for GAT-1. Our preliminary efforts in this direction have focused upon a GAT-1 
inhibitor bearing a thiazolyl bioisostere.  Synthesis and preliminary evaluation of the new 
radiotracer are also described in this thesis, and the reasonable affinity for GAT-1 and 
excellent brain uptake show good promise for 2nd generation radiotracers going forward.  
1 
 
Chapter 1  
Introduction 
 
A. Positron Emission Tomography (PET) Imaging 
Positron emission tomography (PET) is a non-invasive, high resolution, in vivo 
imaging modality that utilizes radiopharmaceuticals (PET tracers) to detect biological 
targets for the development of therapeutics, diagnosis of disease, and monitoring of 
treatments. The field of PET involves a bench to bedside path from the production of 
radionuclides, through radiochemistry, to administration and imaging of the 
radiopharmaceutical (Figure 1-1).1  
Figure 1-1: Bench to bedside path of a radiopharmaceutical. 
2 
 
Radionuclides can decay using one or more of six different paths depending on 
the energy and instability of the atoms. These methods of decay are described based on 
what particles are emitted or captured by the isotopes: spontaneous fission, isomeric 
transition, alpha (α) decay, beta (β-) decay, positron (β+) decay, or electron capture.2 For 
PET imaging, atoms that reach stability via beta-plus (positron, β+) emission are used to 
label bioactive molecules. These radiotracers are designed to be both selective and 
specific, with potent binding to their targets, while the radiochemistry is aimed at creating 
high-specific activity tracers. Specific activity refers to how much radioactivity there is per 
amount of molecular tracer (Ci/mmol). Both the potency and the specific activity allow 
PET imaging to be done with a microdose of the tracer (≤100 micrograms),3 far below a 
pharmacological dose, attenuating the risk of toxicity or altering the natural state of the 
Figure 1-2: Beta decay of a positron emitting isotope. 
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subject. Production of these radiotracers take place in automated synthesis modules 
housed in lead lined boxes known as hot-cells.  
 
 Radionuclide Production 
Radionuclides are atoms with excess nuclear energy, causing them to be unstable. 
Radionuclides can exist in nature, but the majority are produced with either a generator, 
nuclear reactor, or particle accelerator.2  Generators contain a ‘parent’ radionuclide which 
decays producing the desired daughter nuclide. The daughter nuclide can then be 
removed from the parent, via elution with saline or other methods, which then produces 
more of the desired radionuclide. For this reason, generators are sometimes referred to 
as ‘cows’ as they are ‘milked’ for the daughter nuclide. The parent nuclide could be the 
Figure 1-3: [68Ga]-labeled PET tracers. 
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product of uranium fission, a decay product from 233U, or a product from a nuclear reactor 
or accelerator. The 99Mo/99mTc generator is one of the most used in nuclear medicine, 
and the 68Ge/68Ga generator is becoming more widely used with the development and 
uptick in use of radiotracers such as 68Ga-DOTATATE and 68Ga-PSMA, Figure 1-3, for 
imaging of neuroendocrine tumors, and prostate cancer respectively.4   
  Nuclear reactors are devices that allow the initiation and containment of nuclear 
reactions involving neutrons, and are typically defined as either power or research 
reactors. Power reactors harness the thermal energy given off by fission reactions and 
convert it to electricity (Figure 1-4). Research reactors are of interest to produce 
radioisotopes for use in imaging and radio-therapies. Contrary to the energy producing 
power reactors, research reactors require the input of energy, and are solely used as to 
produce radionuclides.5,6 Being able to control and accelerate neutrons is difficult due to 
their lack of charge, but the ability to control these reactions via a nuclear reactor enables 
access to many different interesting isotopes. The isotopes formed by nuclear reactors 
are the results of various nuclear reactions that take place when a neutron collides with 
an atom’s nucleus.  Radioisotopes are produced by bombarding a source (a specific 
Figure 1-4: Schematic of a nuclear power reactor. Image from the public domain. 
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element, or mixture of elements) with a neutron beam, initiating a nuclear reaction and 
resulting in a radionuclide. For example, technetium-99m (99mTc), the most widely used 
radioisotope in nuclear medicine, is produced from its parent molybdenum-99 (99Mo). This 
parent isotope can be produced in a nuclear reactor via a variety of routes, depending on 
the parent nuclide, and the nuclear reaction that takes place. Two such routes, and the 
most common, are the fission of uranium-235 (235U), and the bombardment of 
molybdenum-98 (98Mo) with neutrons, followed by neutron capture.7 This reactor-
produced 99Mo can then be used in a generator and 99mTc can be eluted as described 
above.  
A third source for radionuclides, particle accelerators, are devices that use 
magnetic fields and high voltages to accelerate charged particles and concentrate them 
into a single ‘beam’. Accelerators can be large, such as the Large Hadron Collider (LHC) 
that is used primarily for experimental physics, or about the size of a washing machine, 
Figure 1-5: Inside of a GE PETTrace cyclotron. Image courtesy of GE. 
Scheme 1-1: Production of 99Mo by 
nuclear fission or proton bombardment. 
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such as a medical radionuclide producing cyclotron (Figure 1-5). Cyclotron types are 
stratified by size, energy capability, or types of beams and radionuclides produced. In-
house cyclotrons typically produce fluorine-18 and carbon-11 via proton irradiation of 
different targets.8   
The production of 99Mo via reactors was discussed above, but, because of the 
shortage of reactors capable of producing 99Mo, including the shutdown of a main nuclear 
reactor in Australia,9 other methods of producing the radionuclide have been investigated. 
This includes the proton irradiation of 100Mo in a cyclotron to obtain 99mTc via the 
100Mo(p,2n)99mTc nuclear reaction.7,10  Another example is the production of [18F ]fluoride, 
in which oxygen-18 enriched water is irradiated with a proton beam. The oxygen-18 then 
goes through the nuclear reaction 18O(p,n)18F. The [18F]fluoride is obtained as a solution 
in the oxygen-18 enriched water; [18F ]fluoride can then be isolated via solid phase 
extraction or other methods, and then be used in radiofluorination reactions as discussed 
below.  
Cyclotrons can also irradiate gaseous targets, such as in the production of carbon-
11. The target is typically filled with 14N-nitrogen enriched O2 gas and irradiated with a 
proton beam. Carbon-11 is produced as [11C]carbon dioxide ([11C]CO2), via the 
14N(p,)11C nuclear reaction. [11C]CO2 can then be used directly or undergo subsequent 
reactions to obtain other reagents (Scheme 1-9). Cyclotrons are also used to produce a 
multitude of other isotopes.8 The examples given are some of the most common, 
especially when used for PET imaging, and both fluorine-18 and carbon-11 are utilized in 
this research. 
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Table 1-1: Commonly used radionuclides and important values. Emax is maximum energy of positron during decay. 
Rmax is maximum range of positron in water. Rmean is mean range of positron in water. 
 
 [18F]Fluorine labeling 
  Fluorine has long been incorporated into drug-like molecules by medicinal 
chemists to alter lipophilicity and protect metabolic soft spots.11 As such, it has likewise 
been of interest to radiochemists who incorporate [18F]fluorine into bioactive molecules, 
either as a bioisostere of a hydrogen atom or in place of a [19F]fluorine or other halogen 
atom, to produce PET tracers. The existence of [18F]fluorine was first reported in 1937 by 
AH Snell.12 With a 109.7-minute half-life, low positron energy (Emax=0.65 MeV), and ready 
availability (from medical cyclotrons) in both nucleophilic and electrophilic forms, 
[18F]fluorine has been widely used to prepare PET radiotracers since its discovery. The 
almost two-hour half-life of [18F]fluorine is useful not only to radiochemists, as there is 
more time for syntheses, but also for clinical utility. Tracers incorporating [18F]fluoride, as 
Scheme 1-2: Abbreviated summary of [18F]Fluorine reagent preparation. 
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well as [18F]fluoride itself are regularly synthesized at cyclotron facilities and transported 
to surrounding PET centers that do not have a cyclotron on-site. Because of this, it is 
common that researchers translate [11C]carbon radiotracers to [18F]labeling, enabling 
more widespread use of these radioactive tools.13,14 The low positron energy is key for 
the resolution of images produced with [18F]fluorine labeled radiotracers; the lower the 
energy of the positron, the closer the annihilation event is to the location of the positron 
decay, increasing resolution. Reflecting these characteristics, many reactions have been 
developed for incorporating fluorine-18 into bioactive molecules, and developments have 
been discussed in a number of articles covering  both the primary literature as well as 
patent applications.1,4,11,15–27 
Scheme 1-3 Production of a palladium (IV) nucleophilic [18F]fluoride source from 
electrophilic [18F]F2. 
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  Electrophilic [18F]fluorine can be produced by the 20Ne(d,α)18F reaction and is 
formed as [18F]F2 gas. For those working with a proton-only cyclotron, it is also possible 
to produce [18F]F2 gas via a two-step procedure. First a target containing [18O]O2 gas is 
bombarded with protons to produce [18F]fluoride which adheres to the walls of the target. 
The rest of the [18O]O2 gas is collected and the target is filled with F2 enriched gas and 
bombarded once again with protons to encourage isotopic exchange of 18F for 19F in the 
F2 gas.28 This [18F]F2 gas can be used as a fluorinating reagent itself or it can be used to 
produce other electrophilic fluorinating agents such as [18F]XeF2,29 [18F]AcOF,30 or 
[18F]DAST31 (shown in Scheme 1-2). Syntheses with these reagents require complicated 
purification methods because of the 19F present in the carrier gas, and so called a “carrier-
added” reaction. This can lead to low specific activity and yields.21,22 Specific activity (SA), 
measured in Ci/mg, or molar activity, measured in Ci/mmol, is the ratio of activity to the 
mass (or moles) of the tracer in the sample. Not every molecule in a radiotracer sample 
contains a radionuclide; if the SA is too low it would be necessary to inject too high of a 
mass of tracer to achieve an acceptable count/activity level.32  
Scheme 1-4:Nucleophilic demetallation production of [18F] FDOPA. 
10 
 
  To combat the typically low specific activities resulting from electrophilic 
fluorinations, Hooker and Ritter worked to develop an electrophilic source of [18F]fluorine 
in the form a palladium (IV) complex (shown in Scheme 1-3).33 This high specific activity 
reagent, 1.10, is synthesized from a nucleophilic [18F]fluoride source, without the need for 
F2 gas. This reagent is incredibly helpful for radiotracers inaccessible via nucleophilic 
fluorinations, but the disadvantages include the comparatively complicated palladium 
complex precursors, which also require additional quality control testing, and the need for 
a two-step procedure prior to radiolabeling of the precursor. Still, this palladium complex 
is encouraging in adapting traditional fluorination methods to radiochemistry.  
  
Electrophilic [18F]fluorine has also been utilized in electrophilic aromatic 
substitution via demetallation of precursors such as those for production of L-3,4-
dihydroxy-6-[18F]fluorophenylalanine ([18F]FDOPA), from 1.1534 and 1.1735(Figure 1-4). 
Although this method allowed the fluorination of electron-rich aryl molecules, the 
[18F]FDOPA was produced in low specific activity due to these methods being carrier (F2 
gas) added. Efforts have been ongoing to find a high yielding, robust synthesis of 
[18F]FDOPA, as it finds use in the imaging of neuropsychiatric disorders and diseases, 
and the detection of neuroendocrine tumors (NETs) and types of pancreatic cancer. This 
radiotracer began as an amino acid metabolism imaging agent where low specific activity 
production was acceptable, but as the use of [18F]FDOPA expands to oncological 
Scheme 1-5:Metabolism of [19F]FDOPA to norepinephrine. 
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diagnosis, specific activity becomes more important. It was found that too low of specific 
activity in [18F]FDOPA doses could cause pharmacological effects in patients with 
neuroendocrine tumors due to the [18F]FDOPA being converted to noradrenaline in 
cancerous cells (Scheme 1-5).36 In contrast to the electrophilic methods described above, 
aromatic substitution using nucleophilic [18F]fluoride produces high specific activity 
tracers, although preparing fluorinated compounds from organometallic precursors is a 
recent development in which research is ongoing.20–22 This chemistry is further below.   
 In the Scott Lab, a number of fluorine-18 chemistry methods are used on a regular 
basis, the majority of which involve the use of nucleophilic [18F]fluoride. Nucleophilic 
[18F]fluoride can be produced with a cyclotron via the 18O(p,n)18F nuclear reaction, as 
described above. Using this aqueous ion in reactions requires purifying it via solid phase 
extraction, typically by trapping the [18F]fluoride on a quaternary methylammonium (QMA) 
cartridge and eluting the [18F]fluoride with a phase transfer catalyst (PTC) and a basic 
counterion (usually K2CO3). This is followed azeotropic drying, relying on the PTC to 
solubilize the nuclide in a polar aprotic reaction solvent. In order for the [18F]fluoride to be 
available for use in nucleophilic reactions, it is necessary to disrupt and discourage the 
strong hydrogen bonds it forms in water; this is where the PTC (e.g. cryptands such as 
Kryptofix2,2,2) comes into play.37 Although it has long been believed that the polar aprotic 
solvent is necessary for successful [18F]fluorination, work done by Stewart and coworkers 
has suggested that an ethanol water mixture could provide both a “greener” and safer 
way of producing mass produced radiotracers such as [18F]FDG.38 Using the solvated 
[18F]fluoride in nucleophilic aromatic and aliphatic substitution reactions is one of the most 
used and straightforward radiofluorination techniques, given that the desired precursor 
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can withstand the sometimes harsh reaction conditions. This method requires a precursor 
with an excellent leaving group such as a chlorine atom, nitro (NO2-) or trimethylamine 
(NMe3+), adjacent to an electron withdrawing group, as well as a high reaction 
temperature.21 This will allow for a simple one-pot method resulting in high yields and 
specific activity. Of these nucleophilic substitutions, halogen exchange (halex) reactions, 
where [18F]fluoride displaces a halogen such as chlorine, are highly attractive due to the 
stability of the precursors and the reliability of the reactions. 
 Use of nucleophilic [18F]fluoride for radiofluorination of aliphatic groups is relatively 
straightforward and similar to the SNAr reactions for aromatic fluorinations. A main 
difference here is there is no need for an activating group to be added to the precursor. 
However, it is still necessary to protect any areas that could be subject to attack by the 
nucleophilic [18F]fluoride and have an excellent leaving group such as triflate or tosylate.1 
One such example of an aliphatic fluorination is the production of 
[18F]fluoroethoxybenzovesamicol ([18F]FEOBV), which is used for PET imaging of the 
vesicular acetylcholine transporter (VAChT).39 In this reaction, shown in Scheme 1-6, a 
tosylate group (1.19) is replaced with nucleophilic fluoride (1.20).  
Scheme 1-6: Radiofluorination to produce the VAChT PET tracer, [18F]FEOBV. 
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  When an electron rich aryl group requires radiolabeling, the chemistry has 
historically proven more complicated. A traditional SNAr radiofluorination reaction 
depends on the electron poor (electrophilic) nature of the substrate so that the electron 
rich (nucleophilic) [18F]fluoride can attack. Initially, it was possible to fluorinate on 
unactivated or electron rich aryl rings using nucleophilic [18F]F2, but, as discussed above, 
this results in low specific activity and therefore is not an attractive method for use in the 
clinic. To utilize high specific activity nucleophilic [18F]fluoride, radiochemists depended 
on creative use of protecting groups to change the electronics of a precursor, or would 
radiolabel a precursor that could then undergo transformations such as oxidations to 
obtain the desired functional groups.22  
A simple example of this is the production of [18F]flumetamol (1.23, trade name 
Vizamyl), for the imaging of amyloid burden (Scheme 1-7). In order to activate what is an 
electron withdrawing ring in the final product an aldehyde is used as a protecting group 
for the aniline. Radiofluorination provides the desired product, albeit after additional, and 
harsh, deprotection steps.40 Although these methods were successful in producing the 
Scheme 1-7: Multi-step radiochemical synthesis of [18F]Vizamyl 
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desired products, clinical streamlined production with complicated chemistry is not 
sustainable. Daily production of radiotracers depends on quick (necessary due to the 
short half-life of the radionuclide) and straightforward syntheses with the fewest possible 
steps. Introduction of lengthy and complicated syntheses would increase the cost of 
radiopharmaceuticals (due to reagents, time, etc. needed for the syntheses), increase the 
failure rate of tracer production, and require more complicated training of each 
radiochemist (leading to another increase in cost). This has given rise to considerable 
research into development of facile methods for the direct radiofluorination of diverse 
aromatic and aliphatic substrates.  
  Following Hooker and Ritter’s work with Pd(IV) described above (Scheme 1-3), 
Scott and Sanford introduced copper-catalyzed [18F]fluorination reactions of aryl-
iodonium salt precursors.41 Progress to develop a mild, adaptable, repeatable and robust 
nucleophilic fluorination of electron rich aryl rings has been ongoing, and is now its own 
niche in the field of radiochemistry; the search is on for a shelf-stable precursor with a 
facile synthesis. These qualities will encourage the adaptation of the method by other 
labs and potentially clinical tracer production. Techniques from a variety of labs 
demonstrate the ability to use [18F]KF∙K2,2,2 for the aryl fluorination of variously substituted 
aryl groups.19,20,42 Examples of this can be seen in the adaptation of aryl fluorinations from 
the traditional organic chemistry lab to the radiochemistry lab, such as those resulting 
Scheme 1-8: Radiofluorination of electron rich boronic 
acid or BPin precursors. 
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from the collaboration of Melanie Sanford’s and Peter Scott’s groups.16,17,26 Specifically, 
it was reported in 2015 that the copper-mediated nucleophilic fluorination of aryl borane 
species reported by the Sanford group is easily translated to radiochemistry, Scheme 1-
8.16,43 This is due to the high tolerance of various functional groups on the precursor, and 
also because of the use of KF, which, as discussed above, is a readily prepared and 
common radiofluorination reagent, in the [18F]KF form. However similar these reactions 
may seem, optimization was required due to the differences in radiochemistry as 
compared to traditional organic chemistry, including the determination of the best eluent 
system for the production of [18F]KF. In this specific example, it was found that a weakly 
basic mixture of K2CO3 and KOTf (1:73 ratio) increased the yield of the fluorination 
reaction by eluting 80% of the [18F]fluoride off of the separation cartridge. The Scott group 
later reported successful resolution of two hurdles encountered when automating of this 
novel aryl fluoride synthesis: separation of a byproduct, as well as the order of addition of 
the reagents.44 It is necessary to determine the specific order of reagent addition in 
automated radiochemical syntheses so that the synthesis module can be prepared 
accordingly as adjustments to the synthesis cannot be made after the activity has been 
delivered to the hot cell. Because of the breadth and sheer volume of the work done in 
this space many reviews have covered this subject.1,20–23,45  
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 Carbon-11 Labeling 
  Labeling bioactive molecules with [11C]carbon is attractive as carbon atoms exist 
in all organic molecules and this radioactive nuclide can be incorporated into a multitude 
of scaffolds with no effect on the chemical composition or biological behavior of the 
molecule.1,46,47 However, in order to incorporate this radionuclide into molecules, special 
attention must be given for two main reasons: (1) it has a very short half-life of 20 minutes 
requiring quick and reliable procedures, and (2) carbon-11 is produced from a cyclotron 
as 11CO2 gas and so it is almost always necessary to perform multiple steps prior to 
labeling the precursor (Scheme 1-9). For this purpose, automated chemistry modules 
have been developed, such as the TracerLab FXC-Pro from GE, that contain appropriate 
equipment to transform the cyclotron produced carbon-11 reagent into other reagents.48  
  For a standard methylation reaction, [11C]CO2 is reduced to [11C]CH4 using Ni and 
hydrogen. This [11C]CH4 is then pushed through a furnace containing I2 at 750°C to 
produce [11C]methyl iodide (1.28, [11C]MeI). [11C]MeI can be used for methylation or can 
Scheme 1-9: A summary of [11C]carbon chemistry methods. 
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be transformed further by passing over a AgOTf column, resulting in the more reactive 
[11C]methyl triflate (1.29, [11C]MeOTf). These methylating reagents can then be used 
either in reactor (in solution) or ‘loop’ chemistry. The reactor is akin to organic chemistry 
in a round-bottomed flask, while loop chemistry is a radiochemistry variant of flow 
chemistry. In the former, the solvated precursor is added to the reactor as part of the 
reaction set-up, and the methylating reagent ([11C]MeI or [11C]MeOTf)  is bubbled through 
the solution. Any deprotections, or further chemistry is then completed in the reactor. For 
loop chemistry, the precursor is loaded into an HPLC injection loop and the solvent is 
dried/removed, leaving the precursor on the walls of the loop. The methylating reagent is 
then passed through the loop and reacts with the pre-loaded precursor. The product can 
then be directly injected into a semi-preparative HPLC system for purification. Although 
[11C]methylation chemistry is the more common approach to synthesizing carbon-11 
labeled radiotracers, it is also possible to use the [11C]CO2 directly from the cyclotron, in 
methods using CO2 fixation chemistry.47 This can be used to access a variety of chemical 
reagents and radiotracers possessing higher oxidation states without the need for 
additional reduction-oxidation chemistry steps in the hot-cell.46,47 These methods can 
produce functional groups such as carbamates (1.33), amides, carboxylic acids, etc.  
Scheme 1-11: Production of [11C]acetate. 
Scheme 1-10: Production of [11C]carbamates. 
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Access to carbamates via a one pot synthesis was reported by Hooker and coworkers,49 
which demonstrated a simple and efficient method for the direct incorporation of [11C]CO2 
into radiopharmaceuticals; however, as carbamates are not an overly common functional 
group, one-pot methods with access to other functional groups are still desired (Scheme 
1-10).  For production of various other residues, it is first necessary to convert the 
[11C]CO2 to a more reactive species. As mentioned above, these conversions need to be 
high yielding and rapid. Grignard reagents are an attractive group of versatile reagents, 
and are used regularly in the production of [11C]acetate (1.36) for myocardial imaging, 
Scheme 1-11.50 These organometallic reagents are also used in the production of more 
complicated reagent/intermediates such as [11C]carboxymagnesium halides (Scheme 
).1,51 This requires use of fresh Grignard reagents, commercial or freshly synthesized, as 
atmospheric CO2 can decrease specific activities and yields. A brief summary of [11C] 
chemistry can be found in Scheme 1-9. 
Scheme 1-12: Conversion of [11C]CO2 to carboxymagnesium halide and subsequent 
production of reagents. 
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 Common PET Tracers 
  PET imaging is a powerful tool used in a variety of fields including oncology,52,53 
cardiology,54,55 and neurology.56,57 As such, a multitude of tracers exist for use in each of 
these fields, and sometimes are used in multiple fields. The most common radionuclides 
used are 18F-fluroine and 11C-carbon, while use of 68Ga-gallium is increasing in use as 
the technology and tracers become available. Each of the fields in which PET imaging is 
heavily used (oncology, neurology and cardiology), benefit from PET as the onset of 
symptoms, progress of disease and response to treatment vary so drastically between 
patients. Using specifically targeted radiotracers, doctors are able to both increase patient 
quality of life, as well as advance understanding of pathophysiology of a host of diseases.
  Considered the powerhouse of PET imaging, [18F]fludeoxyglucose ([18F]FDG) is 
used in cardiac, neurological and oncological imaging. Uptake of the fluorinated sugar 
can highlight areas of increased metabolism, such as in tumors, or indicate loss of brain 
activity. First produced by the Brookhaven National Laboratory, [18F]FDG is now produced 
at a multitude of centers worldwide and, of the 2 million PET scans conducted in the US 
each year, the vast majority are conducted with [18F]FDG. [18F]FDG, as a fluorinated 
glucose derivative, is taken up by cells the same as glucose would be via the glucose 
transporter (GLUTs), which leads to an increase in uptake in areas of increased 
metabolism such as tumors, and a decrease in uptake in areas of cell death, as in 
neurodegenerative diseases. It is a trapped metabolite trace, referring to how it is taken 
up by cells, but once phosphorylated by hexokinase (HK), the resultant [18F]FDG-6-
phosphate ([18F]FDG6P) cannot enter the mitochondria (Figure 1-7). The radioactive 
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metabolite [18F]FDG6P accumulates in the cells; in cancer cells, a downregulation of 
glucose-6-phosphatase (G6P) causes [18F]FDG6P to accumulate at even higher levels.58 
 The long-time use, extensive characterization, FDA approval, ability for 
reimbursement, and widespread availability of the tracer itself allows [18F]FDG to be used 
for a plethora of imaging applications. As more specific tracers are developed targeting 
biomarkers in individual diseases, [18F]FDG remains to serve as the benchmark to which 
these novel tracers are compared. Its disadvantage lies in its unselective nature; FDG is 
a non-specific marker of glucose metabolism. Fortunately, there are a host of more 
selective radiotracers based on both endogenous substrates as well as carefully 
engineered molecular scaffolds. 
  Oncological imaging presents an interesting target as the image produced must 
differentiate between healthy tissue and the cancerous tumor. For this reason, often it is 
either the fuel (FDG or acetate) or building blocks (amino acids) that are used to image 
cancer cells. PET radiotracers used in oncological imaging, besides [18F]FDG,  include 
Figure 1-6: Uptake of glucose as compared to uptake of [18F]FDG. 
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[11C]acetate (1.36), [11C]methionine (1.41), [11C]choline (1.42), [18F]fluoromethylcholine 
(1.43), [18F]fluroDOPA (1.16), [68Ga]DOTATATE (1.1), and [68Ga]PSMA (1.2).52,59–61   
Acetate, as an endogenous substrate, has low toxicity risks and a straightforward 
synthesis. This radiotracer has applications in both cardiology and oncology, but its first 
application was in the study of myocardial oxygen utilization. This small molecule 
radiotracer finds utility in imaging prostrate and bladder cancer, as well as hepatocellular 
carcinoma (HCC) and renal cell carcinoma (RCC).59 The wide utility and straightforward 
synthesis often make this tracer a common one in the toolboxes of PET centers. Prostate 
cancer is also imaged with choline, both in its [11C] and [18F] labeled forms. Both 
[11C]choline and [18F]fluoromethylcholine are also used in the imaging of gliomas.60,62 
[11C]Methionine (1.41, [11C]MET) finds use in the imaging of a broad range of cancers, 
including head and neck as well as lung and breast cancers. An S-[11C]-methylated 
derivative of an endogenous amino acid [11C]MET is incorporated into proteins, lipids, 
RNA and DNA, offering higher sensitivity than [18F]FDG.63  
  PET tracers incorporating [68Ga]gallium have become increasingly popular both 
because of the availability of [68Ga]-generators and the development and evaluation of a 
series of prostate specific membrane antigen (PSMA) ligands, as well as DOTATATE 
which binds to the overexpressed somatostatin receptors in neuroendocrine tumors 
(NETs).52,64,65 PSMA has been shown to be increased at levels up to 1000-fold in prostate 
cancer, offering an excellent target for imaging of this cancer.52 [68Ga]PSMA-11 (1.2) is a 
Figure 1-7: Commonly used PET Radiotracers. 
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common PSMA imaging agent, which accumulates even in small metastases. The ability 
to label PSMA ligands with different radionuclides enables the production of [177Lu]PSMA, 
a partner radiotherapeutic to [68Ga]PSMA-11, making PSMA-11 an excellent companion 
diagnostic agent.52 [68Ga]PSMA-11 has been shown to be a highly selective and useful 
agent in detection and staging in prostate cancer. A more recently developed [18F]-labeled 
compound, fluciclovine (trade name Axumin) has also shown to be useful.52 Comparisons 
of studies completed with [68Ga]PSMA-11 or [18F]axumin indicate that both of these 
tracers have utility in the detection and monitoring of prostate cancer and related 
metastases.65,66 Another [68Ga]-labeled PET imaging agent, [68Ga]DOTATATE (1.1) is 
used in the detection of neuroendocrine tumors. The synthesis of this tracer involves the 
complexing of gallium-68 in the macrocyclic dodecanetetraacetic acid (DOTA), which is 
coupled with a somatostatin analogue tyrosine-3-octreotate (Tyr3-octreotate or TATE).64 
The DOTA chelating group can also be coupled with other somatostatin receptor targeted 
molecules, such as octreotide to form (DOTA-Phe-Tyr)octreotide (DOTATOC); however, 
DOTATATE has much higher affinity (10 fold, 0.2±0.04 nM vs. 2.5±0.5 nM) to 
somatostatin receptor subtype 2 (sst2), the subtype with upregulation in neuroendocrine 
tumors, in vivo.67  
  Neurological imaging is a multi-faceted, ever changing, and incredibly interesting 
field. Within neuroimaging, the heterogeneity of neurons and regions in the brain dictates 
the necessity for a broad range of tracers, much like the different types of cancers. 
[18F]FDG is of course applied to neurological imaging, in that it can depict regions of the 
brain that have decreased glucose consumption, as in neurodegeneration as a result of 
dementia (Figure 1-8).  
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Although [18F]FDG enables the imaging of glucose metabolism in the brain, the 
development of tracers selective for neurotransmitter systems, protein aggregates, 
enzymes or other more specific targets can offer more specific information. For example, 
dementia is a large area of study, and investigators are interested in understanding the 
pathology of the diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), or 
dementia with Lewy bodies (DLB), as well as attempting to detect the onset earlier and 
monitoring patient response to treatment. Following the theories resulting from biological 
work, PET seeks to offer in vivo evidence. An important goal of imaging in dementia is 
the differentiation between dementias such as Alzheimer’s Disease (AD), Parkinson’s 
Disease Dementia (PDD), Dementia with Lewy Bodies (DLB) or Frontotemporal Lobe 
Dementia (FTLD). Alzheimer’s disease, currently understood as the most common type 
of dementia, is characterized by protein aggregates in the form of amyloid beta plaques 
(Aβ) and tau neurofibrillary tangles.57 [11C]Pittsburgh compound B (1.45, [11C]PIB), the 
first radiotracer developed for the imaging of amyloid-beta plaque burden, is helpful in 
determining if a patient does indeed have amyloid burden, Figure 1-8.68,69  
Figure 1-8: Comparison of FDG and PiB PET scans in AD vs 
healthy controls. FDG displayed as glucose metabolic rate 
(rCMRglc). Reproduced with permission from Ref {Klunk 2004} 
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Since the development of [11C]PiB, three other amyloid targeting PET imaging 
agents have been approved by the FDA. [18F]Florbetapir (1.46, AMYViD, [18F]AV-45) was 
developed through work done by University of Pennsylvania researchers, and further 
investment by Avid Pharmaceuticals (which was later acquired by Eli Lilly).70 AMYViD 
was approved by the FDA in 2012,71 and is similar to [11C]PiB as it also images amyloid 
burden, but the use of [18F]fluorine, with a 109 minute half-life, allows more widespread 
use of the tracer. Two other compounds imaging amyloid burden and labeled with 
[18F]fluoride include [18F]flutemetamol (1.23, Vizamyl), and [18F]florbetaben (1.47, 
NeuraCeq), approved by the FDA in 201372 and 201473 respectively. This information can 
then be used to populate clinical trials for anti-amyloid therapy, and patients can receive 
follow-up PET scans to confirm whether the therapy is indeed clearing plaques. Although 
it is agreed that imaging of amyloid burden could be instrumental in detection of early 
onset AD,74 these [18F]-labeled imaging agents need to be better characterized through 
further investigation.75,76 
Figure 1-9: FDA approved amyloid beta PET radiotracers. 
25 
 
A more recent development from Avid and Eli Lilly is the 18F-labeled tau imaging 
agent [18F]AV1451 (1.48, fluortaucapir, Figure 1-10), licensed from Siemens. When 
compared to another tau imaging agent [18F]THK5351 (1.49) in AD or frontal temporal 
lobe dementia (FTLD) human tissues, [18F]AV1451 was found to be better suited to 
imaging AD, while [18F]THK5351 was more prominent in FTLD tissue.77 Discovery and 
preliminary evaluation of another tau neurofibulary tangle (NFT) imaging agent, [18F]-MK-
6240 (1.50), was reported in 2016 by researchers from Merck.78 These preliminary 
studies in non-human primates, as well as additional work in post-mortem human brain 
tissue, indicate that MK-6240 has excellent selectivity for NFT.79  Despite the preliminary 
success with these Tau imaging agents, off target binding has been found and so work 
towards an optimal Tau tracer is ongoing.79 
Figure 1-10: PET radiotracers for the imaging of tau-protein burden. 
Figure 1-11: Nicotinic AChR PET radiotracer 
used in imaging of Parkson's patients. 
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Mild cognitive impairment and dementia can also be associated with Parkinson’s 
Disease. Tracers targeting the dopaminergic and cholinergic system are often used to 
assist in treatment plan development. A clinical study done with [18F]flubatine, 1.51, 
Figure 1-11, a PET tracer targeting the nicotinic acetylcholine receptor, confirmed that 
some patients with PD could benefit from a therapeutic plan to restore acetylcholine 
production.80  
Both PD and AD, along with other neurological disorders such as drug addiction 
and mood disorders, have roots in the serotonergic system. Serotonin and other small 
amino acids depend on the vesicular monoamine transporter 2 (VMAT2) for release into 
the synaptic cleft. Imaging of this transporter is possible through use of (+)-α-
[11C]dihydrotetrabenazine ([11C]DTBZ (1.52), Figure 1.12).81,82 Studies with [11C]DTBZ 
and other tracers such as [11C]carfentenil (1.53) (targeting the mu (μ)-opioid receptor), 
have helped to define addiction as a brain disease, advancing understanding of brain 
behavior and encouraging treatment development in this area.83   
Flumazenil (FMZ) is an antagonist of GABAA receptors that binds the 
benzodiazepine (BZD) binding site. First developed to counteract the effect of BZD 
overdoses, FMZ was translated to PET imaging as a [11C]-labeled radiotracer ([11C]1.55), 
and later was [18F]-labeled ([18F]1.55) (Figure 1-13).13,84,85 [11C]FMZ is used in imaging a 
Figure 1-12: PET tracers targeting the mu-opioid receptor. 
27 
 
broad range of diseases including AD, Schizophrenia, epilepsy and drug addiction.86 FMZ 
is discussed in more detail in Current GABA Imaging section.  
  
 General Production – Automated Synthesis  
Automated synthesis of radiopharmaceuticals has become necessary for any 
tracers with hopes of being translated into clinical use. This was not always the case, and 
the amount of radiation that was handled in the recent past by radiochemists could come 
as a shock as compared to current standards. In the early days of radiochemistry, 
experiments were carried out much like traditional organic chemistry experiments, using 
vials, syringes and, sometimes, fume hoods. As the field is becoming more regulated, 
laboratories are moving to shielding hoods and workspaces with lead bricks. This is a 
technique still used today when radiochemists are using small amounts (a few milliCuries) 
of radioactivity for methodology, proof of concept, or preliminary studies. In a busy 
research lab, doing lead brick shielded manual chemistry is necessary, as time in the hot 
cells can be hard to schedule between pre-clinical animal studies, and clinical studies that 
need to be completed for the hospital.  
Figure 1-13: Carbon-11 and fluorine-18 labeled flumazenil PET 
tracers. 
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All the radiotracers produced in the U of M Cyclotron and Radiochemistry facility 
are synthesized using fully automated, computer-controlled synthesis modules (Figure 1-
14) that are housed in lead-lined hot-cells. This ensures both the safety of the 
radiochemists as well as the safety of the patients as the radiotracers are synthesized 
according to cGMP. A typical production of a clinical dose begins with the cleaning of the 
hot-cell to remove residual reagents and solvents from previous production runs. After 
cleaning, the chemist will ensure the module is in the right configuration for the synthesis, 
double-checking lines, vials and valves are arranged correctly. For most clinical 
production runs, a cyclotron beam duration of 30 minutes is used, producing about 3 Ci 
[11C]CO2 or about 1.5 Ci of [18F]fluoride. Before the beam is started and while the beam 
is running, the chemist (and second chemist) will prepare and insert the proper reagents, 
filters, vials, and cartridges before closing the hot cell. When the module has been 
prepared and the hot-cell has been closed, the chemist can then deliver the radioactivity 
to the cell. Each radiotracer has a specific program on the computer controlling the 
Figure 1-14: An automated synthesis module for the preparation of 
radiotracers. 
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module. The program includes a time list that issues commands to the module: how to 
modify the cyclotron produced radionuclide into a reagent, how long to stir the reaction 
and at what temperature, when to add the vials of other reagents, and when to inject onto 
the self-contained semi-preparative HPLC. Although, prior to injection on the HPLC, the 
synthesis is mostly automated, chemists watch the synthesis, noting detector values and 
flow rates to ensure the synthesis is going smoothly. They then watch the HPLC trace for 
the elution of the purified product peak, which they collect into a dilution flask within the 
hot cell. If reformulation from the HPLC solvent is necessary, the fraction containing pure 
product is diluted so that further purification over a C18 (or other purification) cartridge is 
possible. After the diluted product is trapped on the purification cartridge, it can then be 
eluted with ethanol and saline into the product vial, resulting in an isotonic injectable dose. 
This reformulation procedure if the HPLC solvent is injectable (≤10% EtOH, in a ≤20 mL 
dose).87 This dose is then transferred to an aseptically assembled vial through a 0.22µm 
sterilizing filter before being removed from the hot-cell in a lead ‘pig’. A small portion of 
the dose (~0.5 mL) is removed and submitted for quality control (QC) testing, where 
standards such as radiochemical purity, pH, identity, residual solvent levels and endotoxin 
levels can be tested. Because of the short half-lives of the radionuclides used (carbon-
11, 20 minutes, fluorine-18, 110 minutes), every synthesis requires communication 
between the imaging suite and the radiochemistry facility to ensure proper delivery times.  
 General Production – Quality Control 
Each radiopharmaceutical is submitted to its own standard group of tests based 
on the IND, (A)NDA, or FDA approved syntheses. When the dose passes the necessary 
quality control (QC) checks, the dose can be sent to the hospital for patient scanning. 
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Radiopharmaceuticals produced using any amount of metals, for catalysis or present in 
the precursor, must undergo additional evaluation to confirm levels of the metal are below 
the threshold for an injectable compound. The thresholds acceptable for each of these 
tests is outlined by federal documents: United States Pharmacopeia (USP) 823, and title 
21 of Code of Federal Regulations part 212 (21 CFR 212). USP 823 outlines 
specifications for compounding or combining multiple base ingredients; the production of 
[68Ga]DOTATATE falls under this description as the [68Ga]gallium produced by the 
generator is simply combined and complexed with a precursor resulting in a final 
injectable dose. Manufacturing of PET radiopharmaceuticals is outlined in 21CFR212; 
including production of [11C]carbon and [18F]fluorine labeled tracers.  
Radiotracers produced in either method can be subjected to testing of pH, purity, 
identity of radionuclide via half-life measuring, residual solvents, residual metals and 
catalysts, as well as sterility and endotoxin tests. The pH of a dose is simply tested by 
placing a few drops on a pH test strip. Purity of a radiopharmaceutical can be measured 
by radioTLC (as in the case of [18F]FDG) or radioHPLC with comparison against a non-
radioactive reference standard. Half-life determination is necessary to ensure the correct 
radionuclide has been incorporated; this is done by measuring the radioactivity of a small 
sample of the dose at two separate times and calculating the half-life via Equation 1-1.  
t1
2⁄
=-ln2(
time difference
ln [
ending activity
starting activity
]
) 
Equation 1-1: Calculation of half-life. 
Residual solvent analysis is completed with gas chromatography (GC) analysis of 
a small sample as compared to a solvent standard. Residual catalysts and metals can be 
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tested for with a TLC plate with an appropriate stain for visualization. Endotoxin tests 
involve dispensing a diluted sample into a PTS cartridge in an endotoxin test machine. A 
more detailed discussion of how this pertains to production of [18F]FDG is in Chapter 4 of 
this thesis. 
Technology has steadily advanced in this field, including the automation and 
streamlining of quality control. Companies like LabLogic and Trace-Ability seek to make 
automated QC a mainstream technology in radiochemistry facilities. These instruments 
have the ability to test parameters such as pH, clarity, appearance, endotoxin, etc., and 
with a very small sample of the tracer itself.88 Researchers also are interested in 
downsizing the production of radiopharmaceuticals with microfluidic technology. 
Archibald and coworkers at the University of Hull are hoping to also implement the use of 
a microfluidic chip for the QC testing of commonly used radiotracers such as FDG.89 
These technologies are still in the prototype and development phase, nevertheless it is 
an exciting time to watch new developments in the technology surrounding PET.   
 Introduction to PET Scanners 
  Before a proper introduction to PET scanners can be described, it is necessary to 
understand how the recorded data originates. The radionuclide incorporated into a PET 
tracer is continually decaying from the moment the radionuclide is formed; the decay 
(transformation of a proton into a neutron in the radionuclide) releases a positron that 
collides with an adjacent electron in the tissue, in an event termed ‘annihilation’ (Figure 
1-2). The annihilation causes two gamma (γ) rays (photons) to be released 180° opposite 
each other; these photons are said to be in coincidence with one another, referring to the 
fact that they originated at the same time from the annihilation event. The photons are 
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then detected by scintillation crystals in the PET scanner, which provides information 
about where the probe resides in the patient or animal being scanned.1 Upon completion 
of the PET scan, a reconstructed image of the tissue or organ of interest is then produced 
by a computer that records each of these annihilation events, in a tomographic manner, 
collecting data on sections of the tissue.   
  The production of this image depends on the collection of data, correction of this 
data (detection of random (or false) coincident events, correction for photon attenuation 
and scatter in the body, and detector dead-time, etc.), and finally how the data is 
presented. PET imaging offers many advantages, but its main disadvantage lies in the 
technology used to collect the data and the algorithms and programs used to interpret it. 
The technology and algorithms have advanced impressively over the years, but it is still 
the human limit that is placed on this technology. As the technology has advanced over 
the past 50 years, resolution and sensitivity of PET images have increased. Originating 
with sodium iodide (NaI) crystals held by hand in the 1950s, today full ring PET scanners 
using bismuth germanate (BGO) or cerium-doped lutetium oxy-orthosilicate (LSO) 
Figure 1-15: A GE Discovery MI PET Scanner. Image courtesy of GE. 
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crystals offer high resolution images and much higher sensitivity for detection of the 
coincidence photons, hence yield images of higher signal-to-noise.90 
  A PET scanner is comprised of multiple elements (Figure 1-15). There is the bed 
where the subject (human patient or animal) lies, and the array or gantry that contains 
scintillation crystals connected to photomultiplier tubes (PMTs) which serve as the 
detectors for data collection. The scintillation crystals are what detect the incident photons 
emitted from the radionuclide of the radiotracer, they absorb energy from the photons, 
raising electrons to an excited state, then re-emit this energy in the form of light. The 
chemical makeup of these scintillation crystals is important as the detectors must stand 
the test of time, be simple and (relatively) inexpensive to manufacture, and have chemical 
properties that make them attractive for PET detection. Common types of crystals include 
NaI, bismuth germinate (BGO), lutetium oxyorthosilicate doped with cerium (LSO), yttrium 
oxyorthosilicate doped with cerium (YSO), gadolinium oxyorthosilicate doped with cerium 
(GSO) depending on the level (price, age) of scanner, and the energy level of the 
radionuclides that will be used in the scanner the most.39 The crystal choice is crucial in 
the determination of resolution and sensitivity. The size of the crystal is also important; 
too small of a crystal and the energy of the photon may not all be absorbed, too big of a 
crystal and spatial resolution is degraded.91 The size and chemical makeup of the crystal 
can affect how it detects and absorbs the photons/energy resulting from the annihilation 
events.42 The PMTs connected to these crystals generate an electrical signal in response 
to the light event (detection of the photon) in the scintillation crystal. This signal is 
recorded along with a time stamp and the height/level of the energy pulse. The energy of 
the pulses can be used to sort out pulses that are too low, resulting from Compton 
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scattering within the crystal, or too high, which could be the result of two or more photons 
detected by the crystal at the same time (this is one of the first steps where the data is 
‘cleaned up’ and sorted for true coincident events). A very small amount of the annihilation 
events are actually detected by the PET scanner (1-10% depending on the scanner itself 
and the type of scan being done). Collimators or shields can be used around detectors to 
limit the absorbance of false coincident events to help de-convolute data. Detection of 
coincident photons is determined by both spatial and temporal factors. They must be 
detected within a very brief time window to be considered coincident events. The location 
of detection within the detector block is determined by data collected by the photo 
multiplier tubes (PMTs); from this data it is possible to calculate the center of the 
scintillation (where the photon’s energy is dissipating from), and therefore the position of 
detection within the block.93 
  Raw data from a PET scan is acquired directly into what is known as a sinogram.  
This is done by recording the locations of the two detector crystals for each coincidence 
event, which then is recorded in a five-dimensional array of detected coincidences; four 
Figure 1-16: Examples of coincident events that occur during a PET scan. Image courtesy of Megan N. Stewart. 
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spatial measures plus time.  The four spatial measures include cylindrical coordinates in 
the x,y planes (r and θ), plus the location in the axial dimension (z), and finally the angle 
defined by the difference in the z-locations of the two detectors relative to the x-y plane 
(φ).  The reason for the term sinogram is that if one looks at a plot of the r and θ sinogram 
values for given z and φ coordinates, each point of radioactivity will trace out a sinusoidal 
path within the plot. 
A single point within the sinogram represents the number of coincidence events 
detected between any pair of detectors within the scanner.  The line connecting these two 
detectors is called a line-of-response, or LoR.  The complete sinogram for a scan is 
composed of the entire set of LORs within the scanner.  The LoRs are also often called 
“projection rays” and the set of all LORs or rays at a given angular orientation are called 
a projection.  Each LoR or projection ray is proportional (after corrections, see below) to 
the sum of radioactivity along that LoR. 
The raw sinogram data is then converted into an estimate of the 3-dimensional 
(x,y,z) distribution of radioactivity within the scanner’s field-of-view by the process called 
reconstruction from projections and yields the final images that are viewed and analyzed.  
The field of reconstruction from projections has a long history, as there have been many 
methods developed of the past 50 or more years, however, this is beyond the scope of 
this thesis 
  To better determine where along the LOR the annihilation event originated, time-
of-flight (TOF) PET imaging can be used. This technique compares the times the photons 
were detected on either side of the LOR and calculates the approximate distance along 
the LOR. In the past, this was not traditionally used, as the detection needed for it to 
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provide sensitive and accurate images requires use of specific scintillation crystals. 
Today, TOF is getting closer to being adopted across PET imaging as the production of 
faster crystals and electronics of the detectors (better time sensitivity and faster 
processing) improves.92  
  Multiple factors can degrade the quality of the data acquired during a PET scan. 
Working our way from the beginning, the first factor that can negatively impact the PET 
scan is excess energy in the positron. The resolution of the image is inherently limited by 
the distance which the emitted positron travels before it participates in an annihilation 
event. This is typically around 1 mm for [18F]fluorine .94 Once the events have occurred 
and light is detected by the scintillation crystals, the events can be sorted into true, 
scattered, random or multiple coincidences. Scattered coincidences are when both 
photons from the same annihilation event are detected but one (or both) of the photons 
was scattered, or deflected, before it reached the detector(s) (Fig 1-16). The LOR 
between these detectors is then not a true representation of where the event occurred. 
Another type of mispositioned event, called a random coincidence, occurs when two 
photons are detected in the appropriate time window but originate from different 
annihilation events. The corresponding photons for these events may not have been 
detected.92 Multiple coincidences occur when more than two photons are detected by the 
different detector crystals within the allotted time window; in this case it is impossible to 
determine which photon pair is the true coincidence, so the events are discarded.  
A very important correction is to account for attenuation of photons within the body. 
Attenuation in PET imaging refers to photons that are scattered or absorbed in the 
subject, so they are not part of a true coincidence event. Attenuation typically occurs in 
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more dense tissue, making images reconstructed without corrections appear to have 
more tracer uptake in less dense areas (e.g. lungs, less dense, vs. the membrane 
between the lungs, denser) and in areas closer to the bodies surface. This demonstrates 
the necessity of corrected images, as they not only give a false reading visually, but when 
quantified with the drawing of ROIs can lead to incorrect determination of tracer uptake. 
For PET scanners without anatomical imaging modality (CT, MR), technicians must run 
a transmission scan. This involves the use of an external photon source that is rotated 
around the patient, between the patient and the detectors. The data from this scan is used 
to determine the amount of attenuation in the patient. Because patients vary, a 
transmission scan must be done before each patient scan. Transmission/background 
scans are also run with phantom subjects (a stationary source of radioactivity) to test the 
detectors and serve as a daily quality maintenance check. For PET/CT scanners, the CT 
scan is used for attenuation corrections.  
  Random coincidences can be corrected using either an equation which accounts 
for all events detected by detectors on either side of an LOR along with the allowed time 
window (what’s the actual word for that?). Another method involved shifting the time 
window for one of the detectors but not the other. In this case there should be no true 
coincidences, and the number of false coincidences detected can be used as an estimate 
of the random coincidences that exist. This is sometimes translated into a sinogram for 
use in later processing.91  
  One problem in a ring type PET scanner is that the LORs can vary in length 
depending on which detectors are involved. If the LOR runs through the middle of the 
gantry the detectors on either side are the furthest apart as is possible for that scanner, 
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but an LOR that runs parallel to this in the periphery of the scanner will involve detectors 
that are closer together. The data acquisition will assume that all the LORs are the same 
length, and is corrected before image reconstruction with an ‘arc correction.’95 This 
correction becomes more important the smaller the diameter of the PET gantry (e.g. in 
small animal PET scanners, or dedicated brain scanners).  
  Different types of PET scanners can be separated first into their use: clinical 
human scans or pre-clinical animal studies (rodent, non-human primate, etc.). The best 
PET scanners are the full ring, but two- or three-plate as well as rotating partial rings are 
also available at a lower price and are used in smaller PET centers.  
  PET scanners are similar to instrumentation used for single photon imaging, 
although it is necessary to have detectors 180° apart from one another so that the incident 
photons can both be detected. The most obvious configuration to house the detectors is 
in a ring, although in early PET scanners the configuration consisted of two plates of 
detectors that were rotated around the subject. Having fewer detectors and needing to 
move them limits the events that can be detected and decreases the resolution of the 
images. One step towards increasing resolution was to add a third plate into the rotation. 
This presents another variability though as the three plates can be arranged differently: 
in a U-shape, spaced equally as a triangle, or varying throughout the scan. It has been 
found that the most desirable configuration for detectors in a PET scanner is a ‘stack’ of 
rings. This allows for a high detection of coincident photons and doesn’t require moving 
parts during the scan.  
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The progression of PET scanner technology over the last 40 years in PET 
scanners can be seen in Figure The first image is from the PET III scanner developed at 
Washington State University by Ter-Pogossian and coworkers. Comparing the images on 
the left with the PET/CT images acquired years later underlines the impact that 
advancement of not only the instrumentation itself, but also the advancement of data 
processing has on the sensitivity and resolution of these images. The images on the right 
were acquired using Hoffman phantom, a model used for regular testing of the 
instruments.  
  Co-registering (overlapping and aligning) functional and anatomical imaging is a 
widely used technique to ensure proper assignment of structures in the body. Both 
preclinical and clinical PET scanners exist with CT or MRI capabilities. These machines 
enable the layering of both anatomical and biological images; this can create a more 
comprehensive image and enhances the interpretation of the data from the PET scan. 
The CT image can also be used for attenuation corrections, eliminating the need for a 
Figure 1-17: Brain images showing the gradual increase of sensitivity and 
resolution of PET scans. (Image courtesy of Dr. Michael Phelps, David Geffen, 
School of Medicine at UCLA, and Dr. Robert Koeppe, University of Michigan.) 
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transmission scan, therefore decreasing the time of the patient in the scanner and the 
dose they are exposed to. Preclinical imaging scanners used for the imaging of animals 
(rodents, non-human primates, etc.) are smaller than clinical human PET scanners. This 
offers better resolution as the detectors are closer together because the bore doesn’t 
have to be as big. Preclinical scanners with an anatomical imaging modality (CT or MRI) 
are also available and allow for excellent evaluation of novel tracers. 
 An exciting, and very recent, development in PET scanners is a project based at 
University of California Davis called EXPLORER. Led by Simon Cherry, the goal of this 
multi-institution project is the development of a total-body PET scanner. This would 
enable the imaging of both brain and peripheral organs; this is both helpful for novel tracer 
evaluation, as well as staging and detection of cancer metastases. While it is currently 
possible to acquire a whole-body PET image, it requires multiple bed positions in the bore 
of the detector ring, and so data for each section of the body is acquired at a different 
time. The axial FOV of a traditional PET scanner is ~20 cm, meaning that 85-90% of the 
body is outside the FOV at any given point during a whole-body scan. A total-body PET 
scanner depends on a long axial FOV (~200 cm) so that the majority, if not all, of the body 
is inside the FOV for the entirety of the scan (Figure 1-18). This improves signal-to-noise 
ratios (SNR) greatly, increasing the effective sensitivity about 40 fold and enabling head 
to toe imaging.96 It is suggested that this increase in sensitivity could allow for detection 
of smaller and low-contrast lesions and structures. If current sensitivity levels are 
acceptable for an image, the increase in sensitivity of total body PET allows for the 
decrease of time needed to scan or dose of injected radiotracer, an attractive option for 
pediatric patients.  
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 A 40-fold increase in sensitivity also allows radiotracers to be followed twice as 
long as in traditional PET scanners (4-6 half-lives as compared to 3 half-lives on existing 
scanners). This is of use in the development of novel radiotracers, as the tracer can be 
observed at multiple time points, gaining more data about distribution, metabolism and 
excretion. In a clinical setting, this is incredibly useful, as it is suggested that [11C]carbon 
tracers could be imaged for as long as 3 hours post injection, possibly simplifying the 
timing coordination between the production of radiotracers in the radiochemistry lab, and 
delivery to the PET imaging suite. The increase in sensitivity also increases the feasibility 
of multi-tracer studies, whereas the second tracer could be injected at a fraction of the 
typical activity level, decreasing interference with the first radiotracer. The increased 
sensitivity, combined with the entire body being inside the FOV for the length of the study 
allows for more complete kinetic analysis of tracers as well as total-body dynamic 
imaging. Kinetic analysis will also be assisted by all chambers of the heart, and major 
blood vessels being within the FOV for the entirety of the scan, enabling the use of image-
derived input functions.  
 Initial reports and projections of this study state the need of the coupling of the 
total-body PET scanner with an anatomical imaging modality. MRI requires the movement 
of the bed from the MRI gantry and into the PET gantry, whereas CT and PET can be 
integrated into the same gantry. Due to the increased size of a total-body PET scanner it 
was decided that CT would be the most reasonable choice. After many years of planning, 
in mid-2017, the design of the first total-body PET/CT scanner was completed and parts 
were being manufactured.96 Although the bulk of the challenges stemmed from economic 
and engineering hurdles, careful planning was required in order to optimize use of current 
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technology. For example, because of the increase of the FOV, coincidence electronics 
(instrumentation involved in detection and sorting of coincident events) will need to 
process a higher volume of events from an increased number of detectors. While true 
events are determined in real-time for traditional PET scans, it is more feasible for all 
events to be collected during a total-body PET scan, for later deconvolution. In this same 
vein, it was necessary to assemble an appropriate computational system to handle the 
large bulk of data produced by these scans; it is suggested that the number of events 
detected and recorded could exceed a hundred billion events, or >1 TB of data.96 
  Progress towards the development of a clinical total-body PET scanner include the 
mock-up of the gantry, bore and patient system. Researchers are using this mock-up to 
determine how a patient interacts with the scanner, in terms of both movement and 
correction of that movement, and any claustrophobic reactions. The mock-up is also being 
used to model personnel needs, and workflow changes.96 Further development includes 
the design and building of a “mini EXPLORER” PET scanner, a long axial FOV PET 
scanner sized appropriately for total-body PET imaging of a mature Rhesus macaque 
monkey.96,97 Initial studies found that this mini EXPLORER scanner was able to image all 
the major organs of the Rhesus monkey simultaneously with the use of [18F]FDG. 
Included in this study was evaluation of the acceptance angle for the detectors. 
Acceptance angles are kept smaller (14° or 27°) in short axial FOV PET scanners to help 
correct for false or scattered events. In this evaluation of the mini EXPLORER, an 
acceptance angle of 46° was found to be well tolerated, trading higher sensitivity for a 
slight increase in scattered events.97 These recently published reports are promising and 
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interesting and give excellent examples of what can yet be accomplished using PET 
imaging. 
 
 
B. The GABAergic System:  
 GABA and the CNS 
  The balance of excitatory and inhibitory neurotransmitters is what regulates all 
activities of the brain, including learning, sleeping, memory, and consciousness. When 
this balance is disrupted it leads to physiological and psychological disorders such as 
epilepsy, dementia, schizophrenia, and cognitive impairment.98 Gamma(γ)-amino butyric 
acid (GABA, 1.55) is the principal inhibitory neurotransmitter in the CNS, which is 
balanced by the excitatory neurotransmitter glutamate (1.56). As the major 
neurotransmitters in the brain, the GABA/glutamate system has been and continues to 
be studied extensively.  
Figure 1-18: Comparison of traditional short axial FOV PET scanner (A), 
to a total-body long axial FOV PET scanner (B).Reprinted with 
permission from Elsevier Cherry, S. R.; Badawi, R. D.; Karp, J. S.; 
Moses, W. W.; Price, P.; Jones, T. Sci. Transl. Med. 2017, 9 (March 
2017), 1–4. 
Figure 1-19: The neurotransmitters GABA and glutamate. 
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First synthesized in 1883, GABA wasn’t confirmed to be found in brain tissue until 
1950, by three groups simultaneously.99–101 It was later identified as a neurotransmitter in 
1967 and 1968 by two groups of electrophysiologists.102,103 Research has been ongoing 
to determine the importance of this neurotransmitter, expanding even faster after the 
discovery of the first benzodiazepine, chlordiazepoxide (1.57, trade name Librium), in 
1957 by Sternbach and coworkers at Roche.104,105 This serendipitous discovery is said to 
have originated from a lab cleaning that found a forgotten compound which was 
successful when tested.  
Figure 1-21: A representative GABA synapse with the GABA metabolic cycle. 
Figure 1-20: Chlordiazepoxide, the 
first benzodiazepine. 
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  Benzodiazepines (BZ) are positive allosteric modulators of the GABAA receptor, 
an ionotropic ligand gated ion channel,  and now represent a large and lucrative drug 
class. 106  Binding of BZs alone to a GABAA receptor will not elicit an effect; the binding 
of endogenous GABA is necessary for the receptor’s ion channel to open.107–109 The late 
1970s and early 1980s found an increase in the development of GABAergic 
pharmaceutics, although the targets of these drugs may not have been immediately 
known. Towards this end, researchers used GABA as a lead and tested the effects of 
various GABA-related scaffolds, Figure 1-22.110 These studies sought to differentiate 
these conformationally restricted cyclic amino-acid-type molecules as GABA antagonists, 
agonists, uptake inhibitors or others.106 One such study evaluated methylated GABA 
analogs (1.58, 1.59) as well as compounds based on muscimol (1.60,1.61) and found the 
methylated GABA analogs to be much better GABA uptake inhibitors.110 It was known 
early on that GABA itself, as well as the more polar compounds being used in these 
studies, did not readily cross the blood brain barrier (BBB) when administered 
systemically. Effects of the drugs were observed when administered 
intracerebroventricularly.111 Preliminary investigation of the use of pro-drugs of these 
compounds found increased brain penetration, but also limited desired anticonvulsant 
Figure 1-22: A sample of GABA analogs evaluated for 
determination of antagonists or agonists. 
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activity and minor cholinergic toxicity.111 These findings discouraged the use of nipecotic 
acid-like pro-drugs in the development of anticonvulsant therapeutics, and researchers 
instead turned to increasing the lipophilicity of the drugs in other ways. Avoiding the active 
carboxylic acid moiety of nipecotic acid, the obvious and attractive route was to introduce 
lipophilicity in the form of N-alkyl side chains. 
  Before the mechanism of actions of psychoactive drugs were understood, the 
clinical approach to treating neurological and psychological disorders was to prescribe 
drugs based on presenting symptoms and observe the effect they had to determine 
efficacy. Then with the development of knockdowns, animal models and tissue work, 
scientific studies could be done to determine if the GABAergic system was affected in 
different diseases.104,106  
  Today, there are over 50 benzodiazepines alone and even more drugs that target 
the GABAergic system to attenuate and treat symptoms of a variety of diseases and 
disorders, both neurological and systemic.104 Inhibition of GABA uptake has been of 
interest in treating epilepsy for some time; research towards this end has also sought to 
differentiate between neuronal and glial uptake inhibition.106,112,113 Neuronal uptake 
inhibition initially was understood to increase the synaptic concentration of GABA, but it 
has also been found that neuronal GABA uptake inhibitors such as diaminobutyric acid 
(DABA, 1.62) and cis-3-aminocyclohexane carboxylic acid (ACHC, 1.63) are actually 
proconvulsant (causing seizures).112,114  It is thought that the inhibition of neuronal GABA 
Figure 1-23: GABA uptake inhibitors found 
to be pro-convulsant. 
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uptake depletes the neuronal source of GABA, because the synaptic GABA is instead 
taken up by glial transporters, and once in the glial cells is catabolized and must be 
transported back to the neuron as glutamine and synthesized into GABA once again.106  
  Biologically, GABA is synthesized from its counterpart glutamate, via a 
decarboxylase, GAD. The biosynthesis of GABA takes place in a pre-synaptic neuron, 
after which it is packaged into a vesicular GABA transporter (vGAT) to be released into 
the synaptic cleft. When released into the synaptic cleft, GABA acts on any of the GABA 
receptors, and is then taken up by any of the GABA transporters (GAT-1, -2, -3, or -4). 
When GABA is taken up through the neuronal GAT-1 it is recycled back into vGAT for 
release into the synapse. Conversely, if GABA is taken up by GAT-3 on an astrocyte, it 
is catabolized into glutamate. Concurrently, alpha-ketoglutarate is converted into succinic 
semialdehyde, and can be used in the citric acid cycle as a source of energy.115 The 
GABA shunt, the major metabolic pathway of GABA, is when the citric acid cycle is 
bypassed, and the α-ketoglutarate is converted to succinate via glutamate, GABA and 
succinic semi-aldehyde.107,115 
Table 1-2: Correlation of aspects of the GABAergic system with neurological disorders. 
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  Disorders involving the GABAergic system are widespread; Alzheimer’s Disease 
(AD), Parkinson’s Disease (PD) and epilepsy combined affect nearly 10 million people in 
the US alone.116,117 Dysfunction in the GABAergic system also affects the serotonergic 
and dopaminergic systems, and excess GABA was found to suppress the release of both 
dopamine and serotonin, leading to anxiety and depression related disorders.108 As such, 
knowledge of the distribution of GABA receptors and transporters is necessary to better 
understand the physiology of the CNS and to develop more effective treatments and 
therapies for the diseases outlined in Table 1-2.118–124  
 
 GABA Physiology   
  From the time that GABA was understood as a neurotransmitter in 1967,102 there 
has been much interest in the pharmacology of the GABAergic system (see recent 
reviews).104,106,125 These therapeutics target receptors, transporters and enzymes in the 
GABAergic system. For example, the target of the first class of GABAergic drugs, 
benzodiazepines, is a subtype of the GABA receptors, GABAA.104 Each GABAA receptor 
Figure 1-24: Top view of the pentamer of the most 
common isoform of GABAA receptors 2α12β2γ2. 
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is comprised of five subunits which form heteroligomeric ligand gated ion channel. There 
are eight classes of these subunits, some with multiple variants (α1-6, β1-3, γ1-3, δ, ε, π, θ, 
and ρ1-3);126 the most common combination of these subtypes found in the mammalian 
brain is 2α12β2γ2, Figure 1-24.108 GABA acts allosterically on these receptors, binding to 
a specific GABA binding site, which activates the ion channel of the receptor. The 
ionotropic GABAA receptors are located post-synaptically in the GABAergic synapse and 
are responsible for the modulation of the membrane potential of the neuron is reside on, 
via the flow of chloride ions. As an inhibitory neurotransmitter, the binding of GABA to its 
receptors causes the hyperpolarization of the neuronal membrane, decreasing the 
excitability of the cell. Therapeutics targeting GABAA receptors either enhance (e.g. 
benzodiazepines, agonists) or decrease (e.g. flumazenil, an antagonist) the inhibitory 
action of the endogenous GABA.104  
  Sometimes referred to as GABAC receptor subtypes, GABAA-rho receptors are 
comprised of entirely rho (ρ) subunits and are expressed mainly in the mammalian 
retina.127 It is still argued that these receptors are their own subtype as agonists and 
antagonists of both GABAA and GABAB receptors have no effect on the GABAA-rho/C 
receptors; however these receptors are also ionotropic, and mediate membrane potential 
through a chloride channel.128  
Figure 1-25: Drugs that act on the GABAB receptor subtype. 
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  GABAB receptors are metabotropic GPCRs located both pre- and post-
synaptically, and also induce hyperpolarization of the membrane of their cells, albeit 
slower than their GABAA counterparts.108 GABAB receptors are comprised of two 
subunits, GABAB1 which contains the GABA binding site and GABAB2 which is responsible 
for the binding of the G-coupled messenger proteins.129 The activation of pre-synaptic 
GABAB receptors has the ability to regulate the release of neurotransmitters, like GABA 
and glutamate, serving as a feedback mechanism for the GABAergic system. This makes 
GABAB receptors an interesting therapeutic target; compounds targeting GABAB 
receptors include those for spasticity (baclofen, 1.64), anxiety ((R,S)-5,7-di-tert-butyl-3-
hydroxy-3-trifluoromethyl-3H-benzofuran-2-one, BHFF, 1.65),130 and autism.131  
 Enzymes necessary for the metabolism and catabolism of GABA include GABA 
transaminase (GABA-T, also known as GABA aminotransferase or GABA-AT) and 
glutamic acid decarboxylase (GAD). GABA-T, assisted by pyridoxal 5’-phosphate, is key 
in the degradation of GABA to succinic semialdehyde before its entrance into the citric 
acid cycle, and it is present in both glial and neuronal cells.104,108,115 GABA-T is 
therapeutically targeted by drugs such as vigabatrin, which inhibit the breakdown of 
GABA for the treatment of epilepsy.104 GAD exists in two isoforms, GAD65 and GAD67, 
which both participate in the synthesis of GABA from glutamic acid, but in separate 
metabolic pathways.132 These enzymes are expressed in all GABAergic neurons making 
these enzymes a therapeutic target for neurological diseases such as epilepsy. In 
Silverman and coworkers’ search for a GABA-T inhibitor, pregabalin (Lyrica), was 
discovered.133 Although the exact action of this drug is yet unknown, a dose dependent 
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increase in the activity of GAD can be observed, and it is regularly used in the treatment 
of disorders such as epilepsy and neuropathic pain.134  
  The action of GABA is mediated by its removal from the synapse by GABA 
transporters. There are four transmembrane transporter subtypes (GAT-1, -2, -3, and -4) 
which remove GABA from the synaptic cleft and one vesicular GABA transporter (VGAT) 
which is responsible for release of GABA into the synaptic cleft. All GABA transporters 
are members of the solute carrier 6 (SLC6) family.135  GAT-4, also referred to as the 
betaine-GABA transporter 1 (BGT-1), is a peripheral GABA transporter that can also 
transport betaine and has been shown to be expressed mainly in the liver, with lower 
expression levels in other tissues such as hepatocytes and the leptomeninges.136 GAT-
2, like BGT-1, has found to be expressed in both the brain as well as peripheral tissues. 
In the brain, it has been found to be expressed in low levels in the meninges, and to a 
lesser extent on astrocytic cells.112,135 GAT-3 is known to be located on glial cells and 
extrasynaptically, expressed at lower levels than GAT-1. GAT-2 and -3 are expressed at 
higher levels than GAT-1 systemically. In the CNS, GAT-3 is located mainly in the retina, 
olfactory bulb, and brainstem.137 GAT-1, the most abundantly expressed GABA 
transporter, is located pre-synaptically and almost exclusively in the CNS. This 
transporter is discussed in more detail below.  
 Respective levels of the GABA transporter subtypes have been determined thus 
far using post-mortem tissue with fluorescent staining as well as observations of mRNA 
levels.138,139 These methods are difficult to quantify reliably as staining can give 
inconsistent results, and mRNA levels are not always representative of expression of 
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protein in tissue.140 This work seeks to offer a quantifiable, in vivo method for the 
observation of GAT-1 through the use of PET imaging.  
 The importance of GAT-1   
  GABA transporter 1 (GAT-1) is one of four GABA transporters, GAT-1, GAT-2, 
GAT-3 and GAT-4/BGT-1. Of these four transporters, GAT-1, located on pre-synaptic 
GABA neurons, is the most abundant with levels higher in the cortex, and hippocampus 
(among other regions). In addition, it has been shown that the GABA receptor dysfunction 
is a result of the malfunction of GABA transporter 1 (GAT-1) in epileptic mice.141  The 
binding capacity (Bmax) of GAT-1 in control subjects has been determined via a brain 
homongenate assay method using [3H]tiagabine giving a Bmax in the frontal cortex of 3400 
fmol/g protein.142  
It was demonstrated that GABA could accumulate in incubated brain slices by Elliot 
and van Gelder in 1958143  ten years before Iversen and Neal proved the existence of  
GABA uptake transporters in 1968.144  First cloned and expressed in 1990 by Guastella 
and coworkers,145 GAT-1 has been of interest as a pharmacological target for over 30 
years. As Andersen and coworkers pointed out, inhibiting GABA uptake offers the 
potential for less side effects than a GABA agonist, as it is only enhancing the activity of 
endogenous GABA in synapses where it has been physiologically released.146 The only 
Figure 1-26: The only FDA approved 
GAT-1 inhibitor, tiagabine (Gabitril). 
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FDA-approved GABA uptake inhibitor (GAT-1 selective) is the anti-convulsant tiagabine 
(Figure 1-26, 1.66).147  
  Approved by the FDA in 1997, tiagabine is used as adjunctive therapy to attenuate 
epileptic seizures and has been the basis of many structure-activity relationship (SAR) 
and PET studies. To broaden the understanding and further the pharmacological 
relevance of GAT-1, many studies have been conducted to determine how GAT-1 is 
involved in the pathophysiology of different neurological diseases. For example, post-
mortem studies on schizophrenic brains have shown an increase in [3H]-tiagabine 
binding, indicating an increase in GAT-1 in these circumstances.122 Additional work 
showed an inverse correlation between a [3H]-tiagabine binding and the subject’s age, 
demonstrating a decrease in GAT-1 expression in the aging brain.123 Alzheimer’s disease 
(AD) has a somewhat contradictory history with the GABAergic system. Some studies 
claim that GAT-1 levels are left unaffected by the disease,121 while other reports argue 
that the GABAergic system is being glanced over in the efforts to understand the 
mechanisms underlying AD.148 These studies, done either in post-mortem tissue or 
animal models, lack in vivo confirmation of their findings.   
   Previous studies have also sought to provide an initial map of distribution of the 
pre-synaptic GAT-1 via fluorescent labeling or observations of levels of GAT-1 mRNA; 
however, fluorescent staining can be inconsistent and levels of mRNA do not always 
directly represent levels of expressed protein.140 In contrast to these in vitro and ex vivo 
techniques, PET imaging offers an advanced, non-invasive, in vivo technique that is used 
to determine the distribution and function of endogenous targets, particularly those that 
are over- or under-expressed in patients with a given disease when compared to healthy 
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subjects. This technique also acts as a companion diagnostic to help monitor patient 
response to therapy and stratify patients for a more personalized approach to 
medicine.149–152 
    
 Current approaches for imaging of the GABAergic System 
Currently multiple techniques for imaging of the GABAergic system exist. Magnetic 
resonance spectroscopy (MRS) has been used to determine concentration of GABA itself 
in vivo.153 Although this method allows for the quantification of neurotransmitters in vivo, 
MRS is only capable of measuring total concentration in a limited region and is not able 
to distinguish between pools of neurotransmitters (e.g. is the neurotransmitter in a pre- or 
post- synaptic neuron, or in the synaptic cleft). Because of these limitations, more specific 
imaging modalities are necessary to draw relationships between neurotransmitter, 
receptor and transporter levels and various neurological disorders. PET imaging offers 
one such modality.  
Initially, there were attempts to image the GABAergic system using simple 11C-
labeled GABA ([11C]1.56) , but since GABA is not BBB permeable, this approach is not 
suitable for neuroimaging.154 Currently in the clinic, studies with [11C]flumazenil 
Figure 1-27: Synthesis of [11C]GABA for use in PET imaging. 
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([11C]FMZ, [11C]1.55, Figure 1-28) image the post-synaptic GABAA receptor. Researchers 
have sought to improve [11C]FMZ, either by introducing a 18F-label instead to lengthen 
scan time, and make the tracer available in areas without a cyclotron,13,85 or by altering 
the molecule to enhance selectivity of the radiotracer for certain subtypes of the GABAA 
receptor.13,155 Both [11C]- and [18F]- labeled FMZ have been used extensively in the 
exploration of the GABAergic system. A study using [11C]FMZ disclosed that the 
administration of the GAT-1 inhibitor tiagabine (1.66) led to an increase in [11C]FMZ 
binding, demonstrating how FMZ can be used to image changes in synaptic GABA 
concentration; this effect was later shown to be dose-dependent.156,157 FMZ has also been 
found to have decreased binding in epileptic foci, assisting in pre-surgical preparations 
and evaluation of epileptic patients.85,158 Yet another utility of FMZ is the stratification of 
stroke patients to better develop treatment for those with acute ischemic deficits as well 
as predict any subsequent stroke events.159 Analysis of the studies above is possible due 
to FMZs excellent tracer properties: metabolites are non-BBB permeable, metabolism 
does not occur in the brain, it has low non-specific binding in the brain, and it has fast 
reversible kinetics.160  
Many other studies have been done to image the GABAergic system, mainly 
targeting the GABAA receptor and its benzodiazepine binding complex.161  A promising 
Figure 1-28: [11C]FMZ and its azide analog [11C]Ro 15-4513 for 
PET imaging of GABAA receptors. 
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tracer is [11C]Ro 15-4513, an azide derivative of FMZ; preliminary studies of this [11C]-
labeled partial inverse agonist have indicated selectivity to the GABAA receptor α5 
subunit.162 This same research group used [11C]Ro 15-4513 to compare alcohol-
dependent men with healthy controls and found decreased binding in the alcohol-
dependent subjects, specifically in the nucleus accumbens and hippocampus. Previous 
studies of alcohol-dependent subjects with [11C]FMZ have also found a decrease in 
binding, however in the frontal cortex, as [11C]FMZ binds preferentially to the α1 subtype 
GABA receptor found there.163 A more recent study also found a decrease in [11C]Ro 15-
4513 in the nucleus accumbens in a group of opiate-dependent subjects, suggesting that 
the α5 subunit has reduced levels in addiction in general.162  
  Currently, there are no specific radiotracers for pre-synaptic GAT-1 in clinical use. 
Development of a novel CNS tracer specific to GAT-1 will provide information on the 
concentration, location, and changes in GABAergic neurons that is currently impossible 
Figure 1-29: Previous efforts towards molecular imaging of GABA transporters. 
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to obtain due to lack of suitable in vivo imaging agent. Although work is being done to find 
an inhibitor of GAT-1 more potent than tiagabine, these studies are focused on developing 
a high-affinity, highly selective inhibitor for therapeutic use.164,165 Previous work 
developing imaging agents targeting GABA transporters has involved radiolabeling of 
tiagabine (targeting GAT-1) or similar scaffolds selective for targeting other GABA 
transporters (GAT-2/3). For example, in 1990, Kilbourn and coworkers successfully 
radiolabeled an analogue of CI-966 (1.71), a compound developed by Parke-Davis;166 
this work was promising with in vivo evaluations indicating uptake of the radiotracer into 
the brain, albeit at fairly low levels.167 More recent efforts include a study in which 
tiagabine was successfully labeled with iodine-123 for single photon emission computed 
tomography (SPECT) imaging, [123I]1.72, Figure 1-29. However, in vivo testing showed 
that although the tracer passed through the BBB, it was quickly circulated and at 3 hours 
post injection was found in nasal mucosa and Hadrian glands and no longer in the brain 
(Figure 1-30).168  
Schirrmacher et al. developed a PET ligand specific to GAT-3, (±)-(2-((4- 
([18F]fluoroethoxy)phenyl)bis(4-methoxyphenyl)methoxy)ethyl)piperidine-3-carboxylic 
Figure 1-30: SPECT/CT Images using [123I]1.72. Reproduced with permission from Ref 
{Schijns 2013}. 
58 
 
acid, [18F]1.73. GAT-3 is largely expressed in glial cells, especially in the hypothalamus, 
and imaging of this transporter could offer an interesting and regionally specific 
perspective; however, targeting GAT-3 does not offer a complete comprehension of pre-
synaptic irregularities throughout the brain.169 These studies have been successful in 
radiolabeling but the novel radiopharmaceuticals are lacking in BBB permeability. Some 
cite the position of the radiolabel (e.g. 123I on the olefin, Schijns 2013) for their lack of 
uptake,168 while others targeted GABA transporters with low comparative expression in 
the brain (such as GAT-3) and demonstrated successful radiosynthesis with limited 
evaluation of the radioligand itself.169  
  A GAT-1 specific in vivo imaging agent has the potential to improve our 
understanding of the pathology of epilepsy, schizophrenia, and other diseases and, 
therefore, could positively impact the lives of numerous patients. The radiotracer(s) 
developed as a result of this research will provide new information about the role of GAT-
1 in the pathophysiology of these disorders, which is currently limited to the data obtained 
mainly by pathologists during post-mortem studies. With in vivo imaging, more conclusive 
diagnostic techniques and more directed drug development is a real possibility that can 
lead to personalized treatment and better patient outcome.150 
 GABA Uptake Inhibitors 
  Even before the approval of tiagabine in 1997,147 many studies had been 
conducted to develop molecules with potency and selectivity for GABA uptake 
inhibitors,170,171 and efforts in this space continue today. The majority of these include a 
cyclic amino acid such as nipecotic acid (1.74) or guvacine (1.75), Figure 1-31; both of 
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which can be considered as conformationally restricted forms of GABA and thus essential 
for the activity of typical GABA uptake inhibitors. These amino acids are not BBB 
permeable themselves, and therefore they are typically connected to a diaryl moiety via 
an alkyl linker, Figure 1-32. The linker chain can be saturated or unsaturated, with or 
without heteroatoms such as O or N, and is 3-5 atoms long in most cases. The aryl 
residue the linker leads to could be two or three substituted phenyls, thiophenes, or a 
tricyclic group. Comparing these studies, it seems that selectivity between the GABA 
transporter subtypes (GAT-1 to -4) is achieved by altering these side chains and aryl 
groups.146,170,171 For example, SNAP-5114 (1.78), with a triphenyl pendant shows 
Figure 1-31: Cyclic amino acids used as 
GABA analogs. 
Figure 1-32: Examples of how differing aryl pendants can build selectivity between 
GAT subtypes. 
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selectivity for GAT-3, as opposed to NO-711 (1.77) or SK&F-89976-A (1.76) which show 
selectivity for GAT-1, Figure 1-32. 
  Some studies have also sought to determine the binding mode of these scaffolds 
by aligning GAT-1’s gene sequence with the only transporter in the solute carrier family 
to be crystallized: a bacterial leucine transporter, LeuT.172 These studies have mostly 
suggested that the carboxylic acid moiety on the nipecotic acid is necessary for inhibition 
of the transporter,173,174 although one study suggested that it was in fact the piperidinyl 
amine that turns into the active site and participates in binding, at least for N-unsubstituted 
inhibitors.175 Additionally, the aryl groups can participate in pi-pi stacking outside the 
binding pocket.176  
  Although most of the GABA uptake inhibition SAR studies have been focused on 
inhibition of neuronal GAT-1, a small number of studies have sought to inhibit the other 
subtypes of GABA transporters. A small library was synthesized targeting GATs 2 and 3. 
The researchers used amino-methyl tetrazoles as a bioisostere for the nipecotic acid 
moiety and experimented with size and composition of side chains to create selectivity 
for GAT subtypes.177 This led to the development of inhibitors of GAT-2 (1.79) as well as 
GAT-4/BGT-1 (1.80, 1.81) , Figure 1-33. GAT-3 has also been the subject of an inhibitor 
search,178 although GAT-1 still attracts the most attention as the most promising of the 
Figure 1-33:Non-classical GABA uptake inhibitors with selectivity to GAT-2 and -4. 
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GABA transporters therapeutically and pharmacologically. By targeting this GABA 
transporter with PET imaging, we hope to learn more about the target engagement of the 
radiolabeled tracers, and about the distribution and activity of the transporter itself.  
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Chapter 2  
GAT-1: Inhibitors and their adaptation into PET tracers 
A. Introduction 
i.   Development of GAT-1 inhibitors 
  As discussed in Chapter 1, GAT-1 has been shown to be an interesting and 
promising target in the treatment of many neurological diseases and disorders, especially 
epilepsy. After the discovery and approval of the anticonvulsant tiagabine (GabitrilTM, 2.1), 
many structure-activity relationship studies for GAT-1 specific inhibitors have been 
published encouraging further exploration of this target. Improvements from earlier 
molecules, such as 2.2 and 2.3, include lengthening the alkenyl chain, incorporating 
heteroatoms in the linker, use of both hetero- and carbonyl-aryl rings, and substitution at 
Figure 2-1: Tiagabine, the only FDA approved GAT-1 
inhibitor. Ki values as reported by Knutsen et al. 
Figure 2-2: Comparison of GABA uptake inhibitors synthesized by Knutsen et al.  (Ki values are as 
reported by Knutsen et al.) 
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the various positions on the aryl rings. The lengthening of the alkenyl chain shows 
enhanced binding, while substitution at the ortho position of the aryl rings is believed to 
be more tolerant of bulk,1 leading to a wider range of possible substituents. 
 Andersen, Braestrup and coworkers have performed considerable work in this 
space, including the development of tiagabine as a GABA uptake inhibitor.1–7 This work 
included the design of molecules that showed increased potency inhibiting GABA uptake 
compared to tiagabine (up to 50% increase in inhibition), which are of particular interest 
(Figure 2-2). This group also reported the superior inhibitory concentration of the vinyl 
ether (e.g. 2.2 and 2.4) as opposed to other alkyl or hetero-atom containing linkers such 
as oximes (2.3).1 Knutsen and coworkers suggest the increased electronegativity of the 
oxime containing molecules for their improved activity.1 This series of papers (Synthesis 
of Novel GABA Uptake Inhibitiors, Parts 1-61–3,5–7) has been instrumental in the further 
investigation of GABA uptake inhibition as a therapeutic strategy.  
Even recent work concentrates on N-alkylated analogues of nipecotic acid. One 
example synthesized Schiff base analogs of nipecotic acid, and reported a molecule (2.5) 
with similar epilepsy prevention as tiagabine with slightly improved permeability as 
demonstrated by a PAMPA-BBB assay.8 Unfortunately no cell based assays were 
reported with this molecule, making comparaison of 2.5 to the previosly mentioned 
compounds (2.2-2.4) difficult. Although these PAMPA assays give a very good estimate 
of permeability, it is no subtitution for an in vivo evaluation as can be done with PET.  
Figure 2-3: Schiff base derived GABA uptake inhibitor. 
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ii.   Unsymmetrical GAT-1 inhibitors 
  A study by Wanner and coworkers in 2013 demonstrated the successful use of an 
unsymmetrical lipophilic aryl moiety in the development of highly selective and potent 
GAT-1 inhibitors.9 The library produced in the 2013 study expanded on work done by 
Andersen and coworkers5 which had investigated the potency of an unsymmetrical 
lipophilic side chain, as opposed to the hitherto reported symmetrical GABA uptake 
inhibitors such as tiagabine. In previous studies by the same group,1 they had discovered 
that unsymmetrically substituted aryl groups were well tolerated and were encouraged to 
synthesize and test a new series of unsymmetrical analogues. In Andersen’s series, the 
position of attachment to the ether linker was situated on one side of the pendant (2.6). 
In some cases, one of the aryl groups was omitted entirely (2.7), and while the activity 
was significantly decreased it could be rescued by replacing the aryl residue with some 
other bulky residue (2.8). Wanner and coworkers also hoped to improve on the selectivity 
and affinity of these series of molecules by combining the unsymmetrical bis-aromatic 
residue (as shown in 2.6) with the ether or vinyl ether linker previously demonstrated by 
Andersen and coworkers to have enhanced GABA uptake inhibition properties (as shown 
in 2.2, 2.6).1 In order to fully evaluate this novel scaffold, the researchers also chose to 
variously substitute the aromatic residues with fluorine; as the most electronegative atom, 
it can both alter the electronics of the molecules for better protein-ligand interactions, and 
Figure 2-4: Unsymmetrical, and singly substituted GABA uptake 
inhibitors synthesized by Knutsen, Andersen, and coworkers. 
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is often employed to protect metabolically labile sites. Through the substitution with 
fluorine, they sought not only to improve the selectivity and affinity of these molecules but 
also further probe and understand the protein-ligand interaction of the GABA uptake 
inhibitors with the GABA transporters. This fluorine substitution also made for a decent 
selection of molecules that appeared amenable to radiolabeling, as the fluorine 
substituent could easily be replaced by a [18F] substitution without altering the molecules 
properties. Three selected molecules from this library are shown in Figure 2-5. Comparing 
these molecules, it can be seen that the addition of aryl-fluorine substituents indeed does 
improve affinity of these molecules for GAT-1: 2.9 compared with 2.11, pIC50 4.60 and 
5.73 respectively for the E isomers. Whereas, omission of the carbonyl in favor of a 
methylene linker in the diaryl moiety causes a decrease in affinity: 2.10 compared with 
2.11, pIC50 5.34 and 5.73 respectively for the E isomers. 
The lead compound produced by this study, 2.11, has shown excellent potency for 
GAT-1 (1.86 µM and 339 nM for E and Z respectively, calculated from reported pIC50 
Figure 2-5: Lead compounds and pIC50 values as reported by 
Wanner and colleagues. 
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values) and 15 to 17 fold selectivity over the other GABA transporters (mGAT-2, -3, and 
-4).9 Additionally, the c log P (calculated by ChemDraw) of the molecule is 1.9, an ideal 
number for CNS drugs. Encouraged by the success of this molecule in vitro it was chosen 
for adaptation into a GAT-1 selective PET radiotracer. This work commenced with efforts 
to label 2.11 with fluorine-18. It has been shown that R-nipecotic acid has better affinity 
than either S- or racemic nipecotic acid,10 and so R-nipecotic acid was used for the 
synthesis of these molecules to boost affinity. 
B.   Results and Discussion 
i.   Synthesis of Reference Standards and Precursors 
Development of a novel PET tracer requires the development of both a reference 
standard for quality control analysis, and a precursor molecule. This precursor molecule 
is the starting material that ideally requires a few simple steps, including radiolabeling, to 
produce the radiotracer. Precursor molecules should be able to be produced in large 
amounts, and be shelf stable, especially for translation to a clinically useful PET tracer.  
Adaptation of these unsymmetrical, fluorinated GAT-1 inhibitors from potential 
therapeutic ligand to radiopharmaceutical was straightforward and successful.11 The 
unsymmetrical diaryl ketone on compound 2.11 appeared attractive as a site where SNAr 
radiofluorination could be employed to produce a radiotracer from a chlorinated (or nitro, 
or trimethylamino) precursor. The convergent synthesis of the molecules was designed 
by Wanner and coworkers via retrosynthetic analysis and involved alkylation of ethyl 
nipecotate 2.21 with the vinyl ether linker (2.20), in preparation for a Heck coupling with 
the aryl triflate bis-aromatic residue (2.14a or b).9 Synthesis of the standard and precursor 
followed this published scheme, with minor additions, and resulted in good yield. This 
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synthesis (Scheme 2-1) began with the coupling of 4-fluorophenol 2.12 and either 4-fluoro 
or 4-chloro- benzoyl chloride (X = F, 2.13a; X = Cl, 2.13b) to form the esters 2.18a and 
2.18b. Treating these intermediate esters with aluminum trichloride promoted a Fries 
rearrangement to give the ortho-acylated phenols 2.19a and 2.19b. The free alcohol was 
activated by conversion to the corresponding triflates 2.14a and 2.14b for use in a Heck 
coupling.  
The nipecotate linker was formed by the tosylation of commercially available ethylene 
glycol vinyl ether 2.15 with tosyl chloride, and then alkylation of ethyl nipecotate ester 
2.21 with this tosylated ether to give 2.16. The Heck coupling of triflate, 2.14a or 2.14b, 
with the nipecotate linker 2.16 yielded (R, E/Z)-2.17a or (R, E/Z)-2.17b as a 72:28 mixture 
of E and Z isomers for both fluorinated and chlorinated molecules. While the reference 
paper reported successful separation of these isomers, this current work found that the 
separation was challenging, and was not optimized due to the negative preliminary in vivo 
evaluation of this compound.    
  Small changes made to the published route include the addition of triethylamine 
(TEA, Et3N) to encourage the alkylation of the nipecotate ester, as well as the addition of 
triphenyl phosphine (PPh3) as a ligand to assist in the Heck coupling to link the 
intermediates.  Pre-stirring of the nipecotate ester (2.21) with TEA, before the addition of 
the tosylate (2.20), appears to assist in the deprotonation and therefore activation of the 
piperidinyl nitrogen as a stronger nucleophile to attack the electrophilic tosylate (2.20). 
The Heck coupling reaction was attempted ligand free, as reported in the reference 
literature,9 but was unsuccessful. Addition of the triphenyl phosphine ligand resulted in 
successful Heck coupling to give (R, E/Z)-2.17a or (R, E/Z)-2.17b in yields of 20-48%. 
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The chlorinated ester is the desired precursor for radiolabeling, (R, E/Z)-2.17b), while 
saponification of the fluorinated ester, (R, E/Z)-2.17a was necessary to generate 
unlabeled reference standard (R, E/Z)-2.11. The hydrolysis of the ester was first 
attempted with 12 M sodium hydroxide leading to incomplete conversion (<50% yield). 
Thus, the hydrolysis was then optimized with the use of 5M lithium hydroxide. Reaction 
times are also noted as what was found to be successful by the author and not necessarily 
what was reported by the literature. The substitution of 2.13b for 2.13a for production of 
the chlorinated precursor did not affect the yields of the reactions and in many cases the 
precursor intermediates were produced in better yields than the fluorinated standard. Both 
chloro-precursor, (R, E/Z)-2.17a, and fluoro-reference standard, (R, E/Z)-2.11, were 
characterized by NMR and mass spectrometry. 
Scheme 2-1: Synthesis of precursor (R,E/Z)-2.17b and reference standard (R,E/Z)-2.11. Reagents 
and conditions: i) Et3N, CH2Cl2, reflux, 1 h (X = F, 77% X=Cl, 83%); ii) AlCl3, 200 °C, 30-40 min (X= 
F, 54%, X=Cl, 59%); iii) Tf2O, 2,6-lutidine, CH2Cl2, 0 °C – rt, 36 h (X= F, 59% X=Cl, 61% ); iv) TsCl, 
Et3N, DMAP, CH2Cl2, 48 h (65%); v) Et3N, (R)-2.21, rt, 16 h (50%); vi) Pd(OAc)2, Et3N, PPh3, DMF, 
80 °C, 48 h (X= F, 20%, X=Cl, 48%); vii) 2M LiOH, EtOH, 0 °C – rt, 0.5 h (X = F, 46%).  
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ii.   [18F]-Radiofluorination of Novel GAT-1 PET Tracers 
  Prior to the radiolabeling of precursors, reverse phase HPLC methods were 
developed for both semi-preparative purification and final product analysis that give 
elution of the standard at a reasonable retention time and separation from the precursor. 
The semi-preparative HPLC method is used in the hot cell for initial purification of the 
product from the reaction mixture. The analytical method served as the means for 
confirming the identity of the radiolabeled compound. Oftentimes, when chlorinated 
precursors are utilized for [18F]fluorinations, there is difficulty achieving acceptable 
baseline separation between the precursor and the standard or final radiolabeled product. 
As (R, E/Z)-2.11 and (R, E/Z)-2.17b are lipophilic molecules, Luna C18 columns were 
chosen for both purification and analysis. It is typical to use an HPLC solvent that is 
acetonitrile (MeCN) based, with a moderate concentration of ammonium acetate as buffer 
(NH3OAc, 5-50 mM) with these columns. As the reference paper did not utilize HPLC 
purification of these compounds it was necessary to develop a new HPLC method for 
both semi-preparative purification as well as analytical evaluation. To first determine the 
Table 2-1: HPLC conditions for 2.11 and 2.17a radiochemistry with retention times. 
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appropriate concentration of MeCN in the HPLC solvent, a gradient method was run from 
5 to 95% MeCN (Solvent B: water + 0.5% trifluoroacetic acid (TFA)). An overlay of the 
chromatogram with the gradient method gave an approximation of what concentration of 
MeCN will elute the compounds efficiently; for compound (R,E/Z)-2.11 this gave an 
estimation of 50% MeCN, which was then adjusted to 35% after 50% gave elution of the 
standard with the solvent front. Slight acidification of the eluent ensured the protonation 
state of the carboxylic acid and gave a sharp peak (Figure 2-21). A quick but clean 
separation is necessary for the quality control of radioactive products, working within the 
constraints of a continually decaying product. Analytical HPLC methods for the ester, 
(R,E/Z)-2.17a, were developed in much the same way, without the need for additional 
acidification.  
 Semi-preparative HPLC conditions were first evaluated on HPLC instruments 
outside of the hot cell using reference standard and precursor to ensure efficient and 
clean separation. As any free [18F]fluoride elutes within 5-6 minutes it is desired that the 
product elutes at 10-20 minutes with excellent separation from the precursor. For this 
purpose, oftentimes, longer (250 mm vs 150 mm) columns are used for semi-preparative 
HPLC, using the same type of column (e.g. C18) and solvent as the analytical method. A 
mixture of precursor and reference standard (coinjection) is injected on the HPLC system 
Scheme 2-2: Optimized radiochemical synthesis of (R,E/Z)-[18F]2.11. 
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to test its suitability. When an acceptable system is developed, it can then be moved to 
the hot-cell for a validation run before any in vitro or in vivo studies are scheduled.  
Radiolabeling of chlorinated precursor (R,E/Z)-2.17b (Scheme 2-2) was performed 
using high-specific activity fluorine-18 prepared as [18F]KF∙K2,2,2 for use in SNAr 
radiofluorination of the chlorinated precursor. Initial radiolabeling of the unsymmetrical 
precursor (R, E/Z)-2.17b was tested via a small manual reaction (10 mCi of [18F]fluoride) 
using standard SNAr conditions ([18F]KF and kryptofix-2.2.2 (K2.2.2) in DMF, 130°C, 30 
min), and successfully gave 13% radiochemical conversion (RCC) to (R,E/Z)-[18F]2.17a 
(fluorinated ester) as determined by crude radio TLC (Figure 2-6, Scheme 2-3). Crude 
reaction mixture was spotted onto a silica TLC plate and ran in 20% EtOAc in hexanes 
TLC eluent.  
We were confident in the radiolabeling of this precursor based upon this 
preliminary data, and next scaled up the radiolabeling for initial preclinical evaluation. 
Using higher amounts of 18F (1.5 Ci) necessitated transferring the radiolabeling to a GE 
TRACERLab FXFN automated synthesis module (Figure 2-7) in a lead-shielded hot-cell. 
Figure 2-6: RadioTLC results of preliminary radiolabeling of [18F]-(R, 
E/Z)-2.17b. Large peak near the baseline represents free 
[18F]fluoride, and small peak at ~100mm represents product. 
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Analysis of the crude reaction mixture confirmed formation of ester (R,E/Z)-[18F]2.17a by 
comparing the radiochemical peak in HPLC with the UV peak of the unlabeled reference 
standard. Thus, we next moved forward to automating saponification of the ester with 
LiOH, and purification of the radiotracer using the synthesis module. The final step in 
developing a radiosynthesis procedure for a new PET tracer is to confirm that it can be 
reformulated into an injectable dose. This can either be accomplished by using an 
injectable mobile phase (usually ethanol / aqueous buffer), or by reformulating a non-
injectable mobile phase. As stated above, the method developed for purifying (R,E/Z)-
[18F]2.11 utilized 30% MeCN, and so the fraction collected from the semi-preparative 
HPLC (~2 min collection at 4 mL/min = 8 mL) contained 2.4 mL of MeCN. This fraction 
was diluted in ~50 mL of milliQ water so that the sample could be passed over a C18 
cartridge and the organic molecule trapped on the cartridge. Once the molecule is trapped 
Figure 2-7: Picture of a TRACERLabFX-N installed in a lead lined hot-cell for [18F]radiochemical 
syntheses. 
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on the cartridge, it is washed with sterile water to remove any residual MeCN and the 
product is then eluted with 0.5 mL ethanol and 4.5 mL 0.9% sterile saline into the product 
vial, resulting in an injectable dose formulated in 10% ethanol. This final dose is stirred 
for a short period of time before it is transferred into the final sterile dose vial. Sometimes 
this transfer happens through a 0.22 µm sterile filter if, for example, it will be employed in 
pre-clinical animal studies. Table 2-2 shows the reagents and materials used in the 
production of (R,E/Z)-[18F]2.11 and (R,E/Z)-[18F]2.17a. In the final automated synthesis, 
the fluorine-18 labeled compound ((R,E/Z)-[18F]2.11) was accomplished by subjecting 
chloro-precursor 2.17b to standard SNAr conditions ([18F]KF and kryptofix-2.2.2 (K2.2.2) in 
DMF, 130°C, 30 min) and saponification of the ester with LiOH (Scheme 2-2). Purification 
(semi-preparative HPLC, typical trace shown in Figure 2-8) and reformulation (C18 
cartridge) provided 9.3±3.3 mCi of (R,E/Z)-[18F]2.11 (1% non-corrected RCY, 100% 
radiochemical purity and specific activity = 1702 Ci/mmol, n = 4). Synthesis of the ester 
radiotracer (R,E/Z)-[18F]2.17a, followed the same procedure with the omittance of the 
final saponification step. The final automated procedure for synthesis of (R,E/Z)-[18F]2.11 
and (R,E/Z)-[18F]2.17a can be found in the experimental section of this chapter.   
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Figure 2-8: Computer controls for TRACERLabFX-N synthesis module. (A) 
Reagent vials. (B) QMA Sep-pak. (C) Reactor vial. (D) Product vial with final 
dose before sterile filtering. (E) Semi-preparative HPLC. 
Table 2-2:Checklist for setup of radiochemical synthesis of [18F]2.11 and [18F]2.17a. 
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iii.   In vivo Evaluation of Novel PET Tracers 
Moving to in vivo evaluation at this point may seem a bit premature, however, because 
of how the radiotracer was designed (replacing a fluorine atom with a [18F]fluorine atom), 
minimal chemical changes were made to the lead compound. The previously reported in 
vitro results of these molecules are encouraging in both the affinity and selectivity of this 
molecule for GAT-1 (5.73 pIC50 with no affinity for GAT-2, -3 or -4), and after successful 
radiolabeling and purification of the compound, in vivo evaluation is a logical step to 
development of a GAT-1 selective radiotracer. Brain uptake in vivo of these 
unsymmetrical radiotracers was first evaluated in Sprague-Dawley rats. Rats are typically 
used for the evaluation of novel imaging agents for the CNS as the brains are larger than 
mice and regions of interest can be adequately assigned and evaluated for distribution of 
the ligand. In initial evaluation of (R,E/Z)-[18F]2.11 in rat, a female Sprague-Dawley rat 
(289 g) was injected with (R,E/Z)-[18F]2.11 (0.479 mCi) i.v. via tail vein injection.  The rat 
was scanned for 90 min post-injection of the radiotracer (see experimental section for 
Figure 2-9: Representative semi-preparative HPLC trace for preparation of (R,E/Z)-[18F]2.11 
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detailed scanning procedure) but unfortunately the PET scan revealed no brain uptake of 
the radiotracer (Figure 2-10).  
 
As rats have fast metabolism and much more active efflux transporters than non-human 
primates (NHP),12 we were not discouraged by this initial result and tracer (R,E/Z)-
[18F]2.11 was also evaluated in a mature female Rhesus Macaque monkey (n=2). 
Imaging studies were performed in a young, mature female rhesus monkey and 
radiotracer (R,E/Z)-[18F]2.11 (4.40 ± 0.20mCi) was injected i.v. via a venous catheter 
inserted into one hind limb of the monkey. The monkey was scanned for 90 min but these 
Figure 2-10: Results of in vivo evaluation of (R,E/Z)-[18F]2.11 in rodent demonstrating 
no brain uptake. 
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studies also demonstrated no significant brain uptake of the tracer in the monkey brain 
(Figure 2-12).  
To test if the lack of brain uptake was due to the actions of P-glycoprotein (P-gp), 
an efflux transporter at the blood-brain barrier, we repeated imaging of a rat with (R,E/Z)-
[18F]2.11  (0.422 mCi) following pre-treatment with 50 mg/kg cyclosporine A, as we have 
done previously for other radiotracers.13 Even with blocking the P-gp efflux transporter, 
BBB permeability of (R,E/Z)-[18F]2.11 was limited (Figure 2-14).   
Figure 2-12: Results of in vivo evaluation of (R,E/Z)-[18F]2.11 in NHP. 
Figure 2-13: Time activity curve (TAC) of (R,E/Z)-[18F]2.11 in NHP. 
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With the hypothesis that 2.11 possesses properties consistent with BBB 
permeability (Table 2-3), the lack of brain uptake into the rat and monkey brain was 
unexpected. Curious if the carboxylic acid played a role in the BBB permeability of this 
Table 2-3: Comparison of lead compound 2.11 with typical values for successful radiotracers. 
Scheme 2-3: Radiochemical synthesis of (R,E/Z)-[18F]2.17a. 
Figure 2-14: Image and SUV as a result of Pgp blocking of 
Cyclosporine A before administration of (R,E/Z)-[18F]2.11. 
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molecule, the saponification of the ester was forgone to produce (R,E/Z)-[18F]2.17a for 
additional in vivo evaluation (Scheme 2-3). This radiotracer was again initially evaluated 
in rat. A female Sprague-Dawley rat (289 g) was injected with (R,E/Z)-[18F]2.17a  (0.413 
mCi) i.v. via tail vein injection and scanned for 90 min post-injection as before. However, 
PET studies again showed no brain uptake in rodent (Figure 2-15). In contrast to the 
result in rats, administration of the ester (R,E/Z)-[18F]2.17a (3.20 ± 0.70 mCi, n = 2) gave 
significant brain uptake of radioactivity in cortex, thalamus, striatum and cerebellum 
(Figure 2-16, 2-17). The species differences between rodents and primates could be due 
to differences in esterase expression, as the hydrolysis of certain esters is known to be 
much faster in rat than monkey. This PET tracer may be behaving like a traditional pro- 
drug. This requires the ester to remain intact before crossing the BBB as the parent 
Figure 2-15: Image and SUV as a result of administration of (R,E/Z)-[18F]2.17a. 
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molecule, and then be immediately cleaved to the acid form in order to bind to the GAT-
1. Although prodrugs have been used previously in PET tracers,14 in the case of (R,E/Z)-
[18F]2.11, while ester derivative (R,E/Z)-[18F]2.17a  crosses the BBB, a prodrug approach 
is not compatible with brain PET as it does not (easily) allow kinetic modelling of the 
imaging data (Figure 2-18). The levels of (R,E/Z)-[18F]2.17a  entering and leaving the 
brain will allow estimation of K1 and k2, but since (R,E/Z)-[18F]2.11 cannot cross the BBB 
(Figures 2-10 and 2-12 above), it will be trapped in the brain following any hydrolysis. As 
(R,E/Z)-[18F]2.11  cannot leave the brain, it will be extremely challenging (perhaps even 
impossible) to estimate separate values for rate of hydrolysis of (R,E/Z)-[18F]2.17a  into 
(R,E/Z)-[18F]2.11 (k3), and the association of (R,E/Z)-[18F]2.11 to (k4) or dissociation from 
Figure 2-16: Results of in vivo evaluation of (R,E/Z)-[18F]2.17a. 
Figure 2-17: Regional time activity curves for (R,E/Z)-[18F]2.17a in NHP. 
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(k5) the GAT-1 transporter. In an attempt to address this issue, the focus of this project 
was turned to analogs of nipecotic acid that contain a carboxylic acid bioisostere. 
Bioisosteres are alternative elements or functional groups that have similar size, volume, 
electronic and physicochemical properties to those they are intended to replace and 
which, when substituted into a drug molecule, generate a new derivative with similar 
biological properties to the original. Efforts to introduce a bioisostere to a GAT-1 tracer 
will be discussed in the next chapter. 
C. Experimental Methods 
i.   Chemistry methods 
Reference standards (R,E/Z)-2.11  and (R,E/Z)-2.17a, as well as precursor (R,E/Z)-
2.17b, were synthesized through adaption of literature procedures.9  
Compound 2.18 
4-Fluorophenol (2.12, 141.5 mg, 1.26 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (3.15 
mL) in a flame dried flask, under argon. To this was added Et3N (152.8 mg, 0.21 mL, 1.52 
mmol, 1.2 equiv.), followed by dropwise addition of benzoyl chloride (2.13, 1.26 mmol, 
Figure 2-18:Difficulties with Pharmacokinetic Modeling of GAT-1 PET Radiotracers. 
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1.0 equiv.). This mixture was then heated to reflux and stirred for 1 h. After this time, the 
reaction mixture was cooled, diluted with CH2Cl2, and washed with saturated NaHCO3, 
water, and brine. The organic layer was dried (Na2SO4), concentrated and purified by 
flash chromatography (0-15% gradient of EtOAc in Hexanes) to give the title compounds. 
 
4-Fluorophenyl 4-fluorobenzoate (2.18a) 
 
Yield: 228.4 mg (77%) as a white solid. 
 
1H NMR (500 MHz, CDCl3) δ 8.33 – 8.14 (m, 2H), 7.23 – 7.15 (m, 4H), 7.14 – 6.93 (m, 
2H). 
 
13C NMR (126 MHz, CDCl3) δ 198.94 (d, J = 2.5 Hz), 165.20 (d, J = 254.5 Hz), 159.27 (d, 
J = 1.6 Hz), 154.54 (d, J = 238.9 Hz), 133.48 (d, J = 3.3 Hz), 131.76 (d, J = 9.1 Hz, 2C), 
123.93 (d, J = 23.5 Hz), 119.86 (d, J = 7.2 Hz), 118.53 (d, J = 6.3 Hz), 117.93 (d, J = 23.8 
Hz), 115.81 (d, J = 22.2 Hz, 2C). 
 
19F NMR (470 MHz, CDCl3) δ -108.89 (s), -120.50 (s). 
 
HRMS: M+ predicted m/z = 234.0492, actual m/z = 234.0500 
 
4-Fluorophenyl 4-Chlorobenzoate (2.18b) 
Yield: 207.8 mg (73 %) as a white solid. 
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1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.115-
7.169 (m, 4H). 
 
13C NMR (126 MHz, CDCl3) δ 164.33, 160.35 (d, J = 244.6 Hz), 146.55 (d, J = 2.9 Hz), 
140.28, 131.52 , 128.99, 127.73, 123.01 (d, J = 8.6 Hz, 2C), 116.19 (d, J = 23.7 Hz, 4C). 
 
19F NMR (470 MHz, CDCl3) δ -116.68. 
 
HRMS: M+ predicted m/z = 250.0197, actual m/z = 250.0190. 
 
Compound 2.19 
2.18 (2.13 mmol, 1.0 equiv.) was liquefied via heating and stirred in a 200°C sandbath. 
Aluminum trichloride (340.97 mg, 2.56 mmol, 1.2 equiv.) was added through the reflux 
condenser and the mixture was allowed to stir for 30-40 minutes. The reaction mixture 
was cooled to room temperature and the glass like product was crushed to a powder 
before being added to a mixture of ice water and 12 M HCl (20:1 H2O:12 M HCl). This 
mixture was extracted several times with diethylether (Et2O). The combined organic 
layers were then washed with water. The organic layer was dried (sodium sulfate), 
concentrated and purified via flash column chromatography (0- 15% gradient of EtOAc in 
Hexanes) to give the title compounds. 
 
(5-Fluoro-2-hydroxyphenyl)(4-fluorophenyl)methanone (2.19a) 
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Yield: 370.2 mg (74%) as an off-white solid. 
 
1H NMR (400 MHz, CDCl3) δ 11.59 (s, 1H), 8.21 (dd, J = 8.6, 5.4 Hz, 1H), 7.73 (dd, J = 
8.6, 5.3 Hz, 1H), 7.25 – 6.99 (m, 5H). 
 
13C NMR (126 MHz, CDCl3) δ 198.94 (d, J = 2.5 Hz), 165.20 (d, J = 254.5 Hz), 159.27 (d, 
J = 1.6 Hz), 154.54 (d, J = 238.9 Hz), 133.48 (d, J = 3.3 Hz), 131.76 (d, J = 9.1 Hz, 2C), 
123.93 (d, J = 23.5 Hz), 119.86 (d, J = 7.2 Hz), 118.53 (d, J = 6.3 Hz), 117.93 (d, J = 23.8 
Hz), 115.81 (d, J = 22.2 Hz, 2C). 
 
19F NMR (470 MHz, CDCl3) δ -98.73 – -110.75 (m), -123.80 (td, J = 8.2, 4.2 Hz). 
 
HRMS: Predicted (M-H)- = 233.042, actual = 233.0417. 
 
(4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methanone (2.19b) 
 
Yield: 315.9 mg (63%) as an off-white solid. 
 
1H NMR (400 MHz, CDCl3) δ 11.60 (s, 1H), 8.13 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 
1H), 7.50 (dd, J = 9.2, 7.5 Hz, 2H), 7.20 – 7.02 (m, 3H). 
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13C NMR (101 MHz, CDCl3) δ 199.11 (d, J = 2.6 Hz), 162.90 (d, J = 277.0 Hz), 159.30 (d, 
J = 1.5 Hz), 154.50 (d, J = 238.9 Hz), 138.82, 135.50, 131.50 (d, J = 2.6 Hz), 130.56 (d, 
J = 21.2 Hz), 128.87 (d, J = 23.9 Hz), 124.21 (d, J = 24.1 Hz), 120.31 – 119.69 (m), 118.35 
(d, J = 6.4 Hz), 117.86 (t, J = 23.2 Hz). 
 
19F NMR (470 MHz, CDCl3) δ -122.60 – -124.08 (m). 
 
HRMS: Predicted (M-H)- = 249.0124, actual = 249.0120. 
 
4-Fluoro-2-(4-fluorobenzoyl)phenyl trifluoromethanesulfonate (2.14a) 
2.19a (300 mg, 1.28 mmol, 1.0 eq) was dissolved in CH2Cl2 (3.2 mL). Collidine (631.35 
mg, 0.69 mL, 5.21 mmol, 4.1 equiv) was added and the reaction mixture was stirred at 
0°C for 15 min to equilibrate. Triflic anhydride (722.25 mg, 0.43 mL, 2.56 mmol, 2.0 equiv.) 
was added dropwise at 0°C and the reaction was warmed to rt and stirred for 48 hrs. After 
this time the reaction was diluted with ether and wash twice with water. The aqueous 
layer was extracted with further ether, and the organic layers were combined, washed 
with copper (II) sulfate solution, dried (MgSO4) and concentrated. The product was 
purified by flash column chromatography (0-10% gradient of EtOAc in Hexanes) to give 
triflate 2.14a. 
. 
Yield: 357.2 mg (76 %) as a white solid. 
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1H NMR (400 MHz, CDCl3) δ 8.02 – 7.71 (m, 2H), 7.41 (dd, J = 9.1, 4.2 Hz, 1H), 7.32 (m, 
1H), 7.30 – 7.21 (m, 1H), 7.24 – 7.12 (m, 2H). 
 
13C NMR (126 MHz, CDCl3) δ 189.59, 166.36 (d, J = 257.5 Hz), 160.84 (d, J = 252.6 Hz), 
142.20, 132.86 (d, J = 9.6 Hz, 2C), 132.22, 124.44 (d, J = 8.5 Hz), 119.45 (d, J = 23.9 Hz, 
2C), 117.94, 117.74, 116.07 (d, J = 22.0 Hz, 2C). 
 
19F NMR (470 MHz, CDCl3) δ -73.36, -100.33 – -105.21 (m), -110.69 (td, J = 7.5, 4.2 Hz). 
 
HRMS: Predicted m/z (M+Na)+ = 388.9877, actual = 388.9874. 
  
2-(4-Chlorobenzoyl)-4-fluorophenyl trifluoromethanesulfonate (2.14b) 
2.19b (546.5 mg, 2.18 mmol, 1.0 eq) was dissolved in CH2Cl2 (8.7 mL). Collidine (961.7 
mg, 1.04 mL, 8.94 mmol, 4.1 equiv) was added and the reaction mixture was stirred at 
0°C for 15 min to equilibrate. Triflic anhydride (1046.7 mg, 0.6 mL, 3.71 mmol, 1.7 equiv.) 
was added dropwise at 0°C and the reaction was warmed to rt and stirred for 48 hrs. After 
this time the reaction was diluted with ether and wash twice with water. The aqueous 
layer was extracted with further ether, and the organic layers were combined, washed 
with copper (II) sulfate solution, dried (MgSO4) and concentrated. The product was 
purified by flash column chromatography (0-10% gradient of EtOAc in Hexanes) to give 
triflate 2.14b. 
 
Yield: 654.1mg (78%) as a white solid. 
103 
 
 
1H NMR (500 MHz, CDCl3) δ 7.80 – 7.71 (m, 2H), 7.50 – 7.45 (m, 2H), 7.42 (dd, J = 9.1, 
4.2 Hz, 1H), 7.33 (ddd, J = 9.1, 7.2, 3.1 Hz, 1H), 7.26 (dd, J = 7.6, 3.1 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 189.95 (d, J = 1.6 Hz), 160.83 (d, J = 252.4 Hz), 142.27 (d, 
J = 3.3 Hz), 134.17, 133.84 (d, J = 6.9 Hz, 2C), 131.42, 129.10, 124.51 (d, J = 8.6 Hz), 
119.61 (d, J = 23.9 Hz), 117.86 (d, J = 25.0 Hz, 2C), 117.10. 
 
19F NMR (470 MHz, CDCl3) δ -73.36, -110.60 (td, J = 7.5, 4.2 Hz). 
 
HRMS: Predicted m/z (M+Na)+ = 404.9582, actual = 404.9579. 
 
2-(Vinyloxy)ethyl 4-methylbenzenesulfonate (2.20) 
Ether 2.15 (500 mg, 0.51 mL, 5.67 mmol, 1.0 eq) was dissolved in CH2Cl2 (5.5 mL). Et3N 
(900.87 mg, 1.25 mL, 8.90 mmol, 1.57 equiv.) and DMAP (2.77 mg, 0.023 mmol, 0.004 
equiv.) were added and the reaction mixture stirred at 0°C. A solution of TsCl (1297.2 mg, 
6.80 mmol, 1.2 equiv.) in CH2Cl2 (9.0 mL) was added dropwise to the reaction mixture at 
0°C. The reaction was allowed to warm to room temperature and stirred overnight. After 
this time the reaction mixture was diluted with CH2Cl2 and washed with water. The organic 
layer was dried (Na2SO4) and concentrated to give tosylate 2.20 which was used without 
further purification. 
 
Yield: 1373.8 mg (quantitative) as a clear colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 7.77 (m, 2H), 7.32 (m, 2H), 6.33 (dd, J = 14.3, 6.8 Hz, 1H), 
4.24 – 4.18 (m, 2H), 4.10 (dd, J = 14.3, 2.4 Hz, 1H), 3.98 (m, 1H), 3.84 (dd, J = 5.4, 4.0 
Hz, 2H), 2.42 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 150.72, 145.05, 132.51, 130.44 – 128.19 (m, 2C), 126.84 
(d J = 195.8zz, 2C), 88.49 – 86.59 (m), 68.27, 65.26, 21.52. 
 
HRMS: Predicted m/z (M+Na)+ = 265.0505, actual = 265.0509. 
 
Ethyl (R)-1-(2-(vinyloxy)ethyl)piperidine-3-carboxylate ((R)-2.16) 
Tosylate 2.20 (500 mg, 2.06 mmol, 1.0 eq) was weighed into flame dried flask and then 
purged with argon. (R)-Nipecotate, 2.21, (647.7 mg, 0.64 mL, 4.12 mmol, 2.0 equiv.) was 
diluted in Et3N (1042.36 mg, 1.45 mL, 10.3 mmol, 5.0 equiv.) and added dropwise to 
tosylate 2.20. The reaction mixture was allowed to stir at room temperature for 7 hrs. After 
this time, the reaction was quenched with water and extracted with pentanes several 
times. The organic layers were combined, dried (K2CO3) and concentrated. The residue 
was purified by flash chromatography (Hexanes/EtOAc + 0.5% Et3N) to yield (R)-2.16. 
 
Yield: 326.5 mg (70%) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 6.48 (dd, J = 14.4, 6.8 Hz, 1H), 4.16 (dd, J = 14.4, 2.1 Hz, 
1H), 4.11 (q, J = 7.1 Hz, 2H), 3.99 (dd, J = 6.8, 2.1 Hz, 1H), 3.79 (t, J = 5.8 Hz, 2H), 3.06 
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– 2.99 (m, 1H), 2.82 (d, J = 11.2 Hz, 1H), 2.68 (td, J = 5.7, 2.9 Hz, 2H), 2.62 – 2.53 (m, 
1H), 2.21 (t, J = 10.8 Hz, 1H), 2.05 (td, J = 11.2, 2.9 Hz, 1H), 1.97 – 1.90 (m, 1H), 1.71 
(m, 1H), 1.65 – 1.54 (m, 1H), 1.42 (qd, J = 11.7, 4.2 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 173.96, 151.62, 86.26, 65.05, 60.18, 57.24, 55.67, 53.96, 
41.67, 26.77, 24.44, 14.13. 
 
HRMS: Predicted m/z (M+H)+ = 228.1594, actual = 228.1593. 
 
(R,E/Z)-Ethyl-1-(2-((4-fluoro-2-(4-fluorobenzoyl)styryl)oxy)ethyl)piperidine-3-
carboxylate, (R,E/Z)-2.17a 
Palladium (II) acetate (21.8 mg, 0.10 mmol, 0.21 eq) and triphenyl phosphine (59.1 mg, 
0.22 mmol, 0.49 eq) were dissolved in DMF (2.0 mL). A solution of 2.14a (170.0 mg, 0.46 
mmol, 1.0 eq) in DMF (0.5 mL) was added dropwise, followed by Et3N (104.7 mg, 0.14 
mL, 1.03 mmol, 2.25 eq). A solution of nipecotate linker (R)-2.16 (185.8mg, 0.67 mmol, 
1.54 eq) in DMF (0.5 mL) was then added and the reaction mixture which was stirred at 
80°C for 48 h. After this time the reaction mixture was cooled, diluted with CH2Cl2 (7 mL), 
and washed with water (2x) and brine (2x). The organic fraction was dried (K2CO3) and 
concentrated. Purification by flash chromatography (Hex/EtOAc + 0.5% Et3N) gave the 
title compound. 
 
Yield: 78.2 mg (38 %) as a yellow oil. 
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1H NMR (500 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 7.38 (dd, J = 8.7, 5.2 Hz, 1H), 7.16 – 
7.12 (m, 2H), 7.11 (dd, J = 5.2, 3.3 Hz, 1H), 6.99 (ddd, J = 21.4, 8.6, 2.8 Hz, 1H), 6.83 (d, 
J = 12.9 Hz, 1H), 6.10 (d, J = 7.2 Hz, 1H), 5.77 (d, J = 12.9 Hz, 1H), 5.14 (d, J = 7.1 Hz, 
1H), 4.12 (q, J = 7.1 Hz, 2H), 3.75 (t, J = 5.7 Hz, 2H), 2.99 – 2.94 (m, 1H), 2.74 (d, J = 
11.2 Hz, 1H), 2.66 – 2.58 (m, 2H), 2.55 (m, 1H), 2.17 (m, 1H), 2.01 (td, J = 11.1, 3.0 Hz, 
1H), 1.96 – 1.89 (m, 1H), 1.72 – 1.66 (m, 1H), 1.62 – 1.51 (m, 1H), 1.47 – 1.36 (m, 1H), 
1.24 (m, 3H). 
[Protons presenting at 5.14 and 6.10 ppm represent the Z-isomer, while protons at 5.77 
and 6.83 ppm represent the E-isomer. The reaction yielded 32% of the Z isomer and 68% 
of the E isomer.] 
 
13C NMR (126 MHz, CDCl3) δ 195.49, 174.02, 165.96 (d, J = 255.9 Hz), 160.38 (d, J = 
247.3 Hz), 149.57, 147.41, 137.86 (d, J = 6.0 Hz), 133.44, 132.87 (d, J = 9.4 Hz, 2C), 
131.42, 127.25, 117.34 (d, J = 21.1 Hz), 115.72 (d, J = 21.9 Hz, 2C), 114.95 (d, J = 23.0 
Hz), 102.33, 101.29, 66.99, 60.31, 57.26, 55.71, 53.93, 41.74, 26.81, 24.49, 14.19. 
 [Carbons presenting at 101.29 and 147.41 pmm represent the Z-isomer, while carbons 
at 102.25 and 149.56 represent the E-isomer]. 
 
19F NMR (470 MHz, CDCl3) δ -104.12, -116.46 (d, J = 5.5 Hz). 
 
HRMS: Predicted m/z (M+H)+ = 444.1981, actual = 444.1988. 
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(R,E/Z)- Ethyl-1-(2-((2-(4-chlorobenzoyl)-4-fluorostyryl)oxy)ethyl)piperidine-3-
carboxylate (R, E/Z)-2.17b 
Palladium (II) acetate (29.1 mg, 0.13 mmol, 0.21 eq) and triphenyl phosphine (78.7 mg, 
0.30 mmol, 0.49 eq) were dissolved in DMF (1.6 mL). A solution of 2.14b (233.4 mg, 0.61 
mmol, 1.0 eq) in DMF (1.0 mL) was added dropwise, followed by Et3N (135.6 mg, 0.19 
mL, 1.34 mmol, 2.25 eq). A solution of nipecotate linker (R)-2.16 (200.0 mg, 0.88 mmol, 
1.54 eq) in DMF (1.0 mL) was then added and the reaction mixture which was stirred at 
80°C for 48 h. After this time the reaction mixture was cooled, diluted with CH2Cl2 (7 mL), 
and washed with water (2x) and brine (2x). The organic fraction was dried (K2CO3) and 
concentrated. Purification by flash chromatography (Hex/EtOAc + 0.5% Et3N) gave the 
title compound. 
 
Yield: 159.1 mg (57 %) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 7.79 – 7.69 (m, 2H), 7.44 – 7.36 (m, 3H), 7.19 – 7.06 (m, 
1H), 6.98 (ddd, J = 21.4, 8.6, 2.8 Hz, 1H), 6.82 (d, J = 12.9 Hz, 1H), 6.09 (d, J = 7.2 Hz, 
1H), 5.77 (d, J = 12.9 Hz, 1H), 5.13 (d, J = 7.1 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.75 (t, 
J = 5.7 Hz, 2H), 2.96 (dd, J = 10.7, 3.9 Hz, 1H), 2.74 (d, J = 11.3 Hz, 1H), 2.64 – 2.57 (m, 
2H), 2.57 – 2.49 (m, 1H), 2.18 (t, J = 10.7 Hz, 1H), 2.01 (td, J = 11.1, 3.0 Hz, 1H), 1.96 – 
1.91 (m, 1H), 1.74 – 1.66 (m, 1H), 1.62 – 1.51 (m, 1H), 1.46 – 1.37 (m, 1H), 1.24 (t, J = 
7.1 Hz, 3H).  
[Protons presenting at 5.13 and 6.09 ppm represent the Z-isomer, while protons at 5.77 
and 6.82 ppm represent the E-isomer. The reaction ratio was 72:28, E:Z.] 
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13C NMR (126 MHz, CDCl3) δ 195.81, 173.99, 160.38 (d, J = 247.4 Hz), 149.65, 147.43, 
139.99 (d, J = 7.5 Hz), 137.59 (d, J = 6.2 Hz), 135.06 (d, J = 88.8 Hz), 131.75 – 131.11 
(m, 2C), 128.87 (d, J = 12.0 Hz), 127.89, 127.33 (d, J = 7.5 Hz), 117.49 (dd, J = 85.7, 
21.2 Hz), 115.41 (d, 2 C, J = 22.9 Hz), 114.71 (d, J = 22.9 Hz), 102.33, 101.34, 71.37, 
60.32, 57.26, 55.72, 53.92, 41.74, 26.81, 24.49, 14.20. 
[Carbons presenting at 101.34 and 147.43 pmm represent the Z-isomer, while carbons 
at 102.33 and 149.65 represent the E-isomer]. 
 
19F NMR (376 MHz, CDCl3) δ -116.37. 
 
HRMS: Predicted m/z (M+H)+ = 460.1685, actual 460.1685. 
 
(R,E)-1-(2-((4-Fluoro-2-(4-fluorobenzoyl)styryl)oxy)ethyl)piperidine-3-carboxylic 
Acid  (Reference Standard (R,E/Z)-2.11) 
Ester (R,E/Z)-2.17a(50.0mg, 0.1 mmol, 1.0 eq) was dissolved in ethanol (1.0 mL). Aq. 
LiOH (10M, 0.3 mL) was added dropwise and the reaction was stirred at room 
temperature for 3 h. Upon completion, the reaction was concentrated, and the resulting 
residue was dissolved in water and cooled to 0°C. The pH was adjusted to 2 with 1N HCl 
while keeping the temperature below 5°C, and the product was extracted from the aq. 
layer with CH2Cl2 (2 x 25 mL). The organic fraction was dried (MgSO4), concentrated and 
purified by flash chromatography (Hex:EtOAC + 0.05% Et3N) to give reference standard 
(R,E/Z)-2.11. 
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Yield: 21.4 mg (46%) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 7.78 (dt, J = 8.8, 4.7 Hz, 2H), 7.42 (dd, J = 8.7, 5.2 Hz, 1H), 
7.16 – 7.09 (m, 3H), 6.97 (dd, J = 8.4, 2.7 Hz, 1H), 6.79 (d, J = 12.7 Hz, 1H), 6.06 (d, J = 
7.2 Hz, 1H), 5.87 (d, J = 12.8 Hz, 1H), 5.22 (d, J = 7.1 Hz, 1H), 4.18 (dd, J = 30.3, 7.6 Hz, 
2H), 3.05 (m, 4H), 2.20 – 1.98 (m, 3H), 1.88 (s, 2H), 1.74 – 1.34 (m, 2H). 
[Protons presenting at 5.22 and 6.06 ppm represent the Z-isomer, while protons at 5.87 
and 6.79 ppm represent the E-isomer. This standard contained both isomers, 28% Z and 
72% E]. 
 
13C NMR (126 MHz, CDCl3) δ 195.36, 174.37, 166.02 (d, J = 256.2 Hz), 160.50 (d, J = 
48.6 Hz), 148.01, 145.87, 137.81 (d, J = 5.9 Hz), 133.25, 132.97 (d, J = 9.2 Hz, 2C), 
130.45 (d, J = 3.5 Hz), 129.30, 118.18 – 117.20 (m), 115.90 (d, J = 21.9 Hz, 2C), 115.53 
(d, J = 22.7 Hz), 104.44, 103.31, 64.32, 56.15, 54.20, 53.22, 39.05, 24.91, 21.92. 
[Carbons presenting at 103.31 and 145.87 ppm represent the Z-isomer, while carbons at 
104.44 and 148.01 represent the E-isomer.] 
 
19F NMR (376 MHz, CDCl3) δ -103.77, -115.64. 
 
HRMS: Predicted m/z (M+H)+ = 416.1668, actual 416.1668. 
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ii.   Radiochemistry methods 
 
General Considerations. 
Unless otherwise stated, reagents and solvents were commercially available and used 
without further purification: sodium chloride, 0.9% USP, and sterile water for injection, 
USP, were purchased from Hospira; ethanol was purchased from American Regent; 
HPLC grade acetonitrile was purchased from Fisher Scientific. Other synthesis 
components were obtained as follows: sterile filters were obtained from Millipore; sterile 
product vials were purchased from Hollister-Stier; QMA-light and C18-light Sep-Paks 
were purchased from Waters Corporation. QMA-light Sep-Paks were flushed with 10 mL 
each, ethanol, water, 0.5 M NaHCO3, and further water prior to use. C18 Sep-Paks were 
flushed with 10 mL of ethanol followed by 10 mL of sterile water prior to use. Analytical 
HPLC was performed using a Shimadzu LC-2010A HT system equipped with a Bioscan 
B-FC-1000 radiation detector and a UV detector. 
 
Radiosynthesis of (R,E/Z)-[18F]2.11 
  [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction using a GE 
PETTrace cyclotron (40 μA beam for 30 min generated ~1500 mCi of [18F]fluoride). The 
[18F]fluoride was delivered to a GE TRACERLab FXFN synthesis module (in a 1.5 mL 
bolus of [18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. 
[18F]Fluoride was eluted into the reaction vessel using K2CO3 (3.5 mg in 0.5 mL of water). 
A solution of K2.2.2 (15 mg in 1 mL of acetonitrile) was added to the reaction vessel, and 
the resulting solution was azeotropically dried by heating the reaction vessel to 100 °C 
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and drawing vacuum for 4 min. After this time, the reaction vessel was subjected to an 
argon stream and simultaneous vacuum draw for an additional 4 min. 
  Chlorinated precursor ((R,E/Z)-2.17b) (2.5 mg dissolved in 1.0 mL of DMF) was 
delivered to the reaction vessel, and the reaction was stirred for 30 min at 130°C to give 
(R,E/Z)-[18F]2.17a. After this time the reactor was cooled to 100°C, 5 M LiOH (1 mL) was 
added, and the hydrolysis reaction was stirred for 15 min. After this time the reactor was 
cooled to 50°C and neutralized by addition of glacial AcOH (0.3 mL). The mixture was 
stirred for 1-2 minutes and then diluted with semi-preparative HPLC solvent (2 mL). The 
reaction mixture was purified by semipreparative HPLC (column: Phenomenex Luna C18, 
250 mm x 10 mm; mobile phase: 50 mM NH4OAc in 30% MeCN, pH 6.0 adjusted with 
AcOH, flow rate = 4.0 mL/min). The product peak (retention time ~18-19, Figure 2-19) 
was collected and diluted into a round bottom flask containing milliQ water (50 mL). The 
resulting solution was passed through a 1 cc vac C18 Sep-Pak to remove organic solvent 
while trapping (R,E/Z)-[18F]2.11. The Sep-Pak was washed with sterile water (6 mL), and 
(R,E/Z)-[18F]2.11 was eluted with 0.5 mL EtOH, followed by 4.5 mL saline. The final 
formulated dose was passed through a 0.22 μm sterile filter into a sterile dose vial to give 
9.3 ± 3.3 mCi (344.1 ± 122.1 MBq) of (R,E/Z)-[18F]2.11 (1.0% non-corrected RCY, 100% 
RCP (column: Phenomenex Luna C18 5μ150 x 4.6 mm; mobile phase: 35% MeCN 
10mM, NH4OAc, pH 4.5, flow rate = 2.0 mL/min, UV: 254 nm; Figure 2-21), high specific 
activity (1702 Ci/mmol) and pH = 5.5, n = 4). 
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Figure 2-19: Representative semi-preparative HPLC trace from preparation of (R,E/Z)-
[18F]2.11. “Cut peak” depicts volume collected for dose. 
Figure 2-20: Representative quality control HPLC trace of prepared dose (R,E/Z)-[18F]2.11. 
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Radiosynthesis of (R,E/Z)-[18F]2.17a 
(R,E/Z)-[18F]2.17a was produced as described for (R,E/Z)-[18F]2.11. After 
radiofluorination, the reaction vessel was cooled to 50°C and semi-preparative HPLC 
mobile phase was added (2 mL). The reaction mixture was then purified by semi-
preparative HPLC (column: Phenomenex Luna C18, 250 mm x 10 mm; mobile phase: 10 
mM NH4OAc in 70% MeCN, flow rate = 4.0 mL/min). The product peak (retention time 
~14-15 minutes, Figure 2-22) was collected and reformulated in the same way as (R,E/Z)-
[18F]2.11. The final formulated dose was passed through a 0.22 μm sterile filter into a 
Figure 2-21: Representative coinjection HPLC trace of prepared dose of (R,E/Z)-[18F]2.11 with 
standard (R,E/Z)-2.11 
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sterile dose vial to give 7.7 ± 3.5 mCi (284.9 ± 129.5 MBq) of (R,E/Z)-[18F]2.17a (1.3% 
non-corrected RCY, 100% RCP (column: Phenomenex Luna C18 5μ150 x 4.6 mm; 
mobile phase: 70% MeCN 10mM NH4OAc, flow rate = 1.5 mL/min, UV: 254 nm; Figure 
2.23), moderate effective specific activity (250 Ci/mmol), and pH = 5.5, n = 4). 
 
Figure 2-22: Representative semi-preparative HPLC trace from preparation of (R,E/Z)-
[18F]2.17a. “Cut peak” depicts volume collected for dose. 
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Figure 2-23: Representative quality control HPLC trace of prepared dose (R,E/Z)-[18F]2.17a. 
Figure 2-24: Representative coinjection HPLC trace of prepared dose of (R,E/Z)-[18F]2.17a with 
standard (R,E/Z)-2.17a. 
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iii. In vivo methods 
MicroPET imaging was done in a microPET R4 or microPET P4 for 60-90 minutes 
following injection of each radiotracer. Images were reconstructed using 3D maximum a 
priori (3D MAP) program.  
 
General considerations 
All animal PET imaging experiments were conducted under the supervision of the 
University of Michigan and its Institutional Animal Care and Use Committee (IACUC) 
according to approved protocols and all applicable federal, state, local and institutional 
laws or guidelines governing animal research. Imaging studies were conducted using a 
Concorde Microsystems P4 PET scanner as described below. 
 
Rodents 
Anesthesia was induced in healthy, female Sprague-Dawley rats (279-369 g) using 
isoflurane/O2, and anesthesia was maintained with 2-4% isoflurane/O2 throughout the 
imaging studies. Body temperature was maintained by a heating pad. Following a 
transmission scan for attenuation correction, the animals were injected (i.v. via 
intravenous tail vein) with the radiotracer as a bolus over 1 min (Table 2-4), and the brain 
imaged for 90 minutes. 
 
Primate Imaging 
Imaging studies were performed in a young, mature female rhesus monkey. The animal 
was anesthetized in the home cage with ketamine and transported to the PET imaging 
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suite. The monkey was intubated for mechanical ventilation, and anesthesia was 
continued with isoflurane. Anesthesia was maintained throughout the duration of the PET 
scan. A venous catheter was inserted into one hind limb and the monkey was placed on 
the PET gantry with its head secured to prevent motion artifacts. Following a transmission 
scan, radiotracers were administered in a bolus dose over 1 minute (Table 2-4). Emission 
data were collected beginning with the injection and continued for 90 minutes. 
 
Image Analysis 
Upon completion of the PET scans, emission data were corrected for decay, dead time 
and random coincidences before reconstruction using an iterative ordered subset 
expectation maximization–maximum a posteriori (MAP) method to generate 
Table 2-4:Collected data for all in vivo studies completed with(R,E/Z)-[18F]2.11 and (R,E/Z)-[18F]2.17a. 
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reconstructed images. Frames were summed, smoothed, and regions-of-interest (ROIs) 
were defined manually for the whole brain over multiple adjacent frames in the sagittal 
projection. The volumetric ROIs were then applied to the full dynamic data sets to obtain 
regional tissue time-radioactivity data. Standardized uptake values (SUVs) were 
calculated for each region of interest. 
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Chapter 3  
Investigation of Bioisosteres for Improved BBB Permeability 
A. Introduction 
i. Use of Bioisosteres in Medicinal Chemistry  
  Bioisosteres have long been a strategy in the enhancement or diminution of 
different characteristics of a drug candidate when developing new therapeutics. First 
described as ‘isosteres’ by Langmuir in 1919, the word was used to describe categories 
of different functional groups, atoms and molecules sorted according to their 
physicochemical properties.1 Six years after the publication of Langmuir’s paper, Grimm’s 
Hydride Displacement Law was presented (Table 3-1). This law stated that any atom up 
to four places to the right of a noble gas on the periodic table could bond one to four 
hydrogen atoms to form an isostere of the atom that many places to the left or right of 
itself.2 An example of this still used today is the bioisterism of an -OH group for a fluorine 
atom, as can be seen in the development of dual inhibitors of epithelial neutral 
endopeptidase (NEP) and  endothelial angiotensin-converting enzyme (ACE) for the 
treatment of hypertension (Figure 3-1).2,3 Replacing the hydroxyl group on 3.1, with a 
Figure 3-1: A fluorine (3.2) for hydroxy (3.1) replacement 
in the development of dual ACE & NEP inhibitors. 
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fluorine atom (3.2), slightly improves the potency of this molecule (Figure 3-1). Oxygen is 
one place to the left of fluorine, a noble gas; oxygen bonded to one hydrogen can then 
serve as an isostere to fluorine. Erlenmyer aimed to expand Grimm’s and Langmuir’s 
definition of ‘isostere’ in 1932, when he proposed that the term be applied to elements, 
ions or molecules which have the same valence electrons.4 This led to elements within 
the same columns of the periodic table being grouped as isosteres among themselves, 
as well as the grouping of electronically similar rings as ring isosteres.  When these 
properties began to be used to modify and enhance molecules with biological activity the 
term ‘bioisostere’ was used; the term being coined in the early 1950s by Friedman5 and 
later reevaluated by Thornber.6 As with most terms in the scientific community, definitions 
of bioisostere can vary slightly depending on who is defining it, and Thornber argues that 
the term ‘isostere’ has become loosely defined, even as soon as 1979.6 Friedman’s 
original definition of ‘bioisostere’ was any “compounds [that]…fit the broadest definition 
for isosteres and have the same type of biological activity”5. In medicinal chemistry, it is 
generally understood that bioisosteres are a group of atoms or functional groups that have 
similar properties and when employed in a scaffold elicit a similar effect on the same 
biological target. These isosteres or bioisosteres can be sorted into classical and non-
classical families.2,6 Isosteres considered to be classical adhere to the original description 
Table 3-1: Each column depicts a family of isosteres 
according to Grimm’s Hydride Displacement Law. 
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of isosteres and are similar both electronically and sterically (Table 3-2). When 
isosteres/bioisosteres stray from this definition, it is considered non-classical 
bioisosterism. Bioisosteres in a non-classical family could differ in electronic behavior, 
shape, size, or even number of atoms.  When bioisosteres are used for drug development 
it seems as though they are mostly non-classical, as some property of the molecule needs 
adjusting (e.g. lipophilicity, pKa, size, etc.) and therefore some property of the isosteric 
replacement must change as well. This is demonstrated in Figure 3-2. In the search for a 
more potent and less toxic muscarinic antagonist, researchers explored non-classical 
bioisosterism in using cyclic moieties in replacement of a non-cyclic moiety (the methyl 
ester on arecoline, 3.3). Both the fused ring systems (3.4, 3.5) and replacement of the 
ester with a heterocycle (3.6-3.9) resulted in compounds with affinity for muscarinic 
receptors (although the R values affected this in some cases).2,7 Thornber also outlines 
that it is important to consider the roles which parts of molecules may have (structural, 
receptor interactions, pharmacokinetics, or metabolism); he points out that usually the 
role that a certain part of a molecule plays in its activity is unknown. Today, 40 years later, 
it is possible, through molecular modeling or evaluation of crystal structures, to determine 
Table 3-2: Classical bioisosteric replacements. 
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not only the role a certain part of a molecule plays in its biological activity, but also how 
much that certain moiety can change before interactions and therefore activity is lost. 
Whereas Langmuir was concerned with finding isosteres that behaved more or less the 
same, the best bioisosteres are those that remain almost the same, fine tuning specific 
characteristics for a pharmacological need.1,6 The use of bioisosteres is common in the 
development of novel drugs and in improving existing drugs. They can be used to block 
metabolically labile sites, encourage solubility, or limit toxicity.   
  As would be expected, the most commonly used bioisosteres correspond to 
functional groups that are found often in biologically relevant molecules. These include 
carboxylic acids, alcohols, aryl and hetero rings, carbonyls, and even hydrogen itself. As 
a functional group present in a plethora of endogenous and exogenous substrates, 
carboxylic acid is of particular interest in drug design and therefore bioisosteric 
replacement. Many studies and reviews have been completed to better understand what 
affects bioisosteres have the molecules compared with a carboxylic acid. One such study 
sought to provide a more comprehensive data set for carboxylic acid bioisosteres.8 In this 
research, Ballatore and coworkers chose a simple molecule, phenylpropionic acid, and 
exchanged the carboxylic acid for various bioisosteres, recording chemical characteristics 
Figure 3-2: Non-classic bioisosteres in the development of a more potent muscarinic agent. 
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of each one, either calculated or experimental, enabling the reader to make informed 
decisions on which bioisostere fits their need. The comparison of over 30 bioisosteres on 
a single scaffold is incredibly helpful to evaluate the specific effect each of these 
bioisosteres has on the molecule as a whole. Another of the same group’s papers is more 
traditional in its review and includes specific examples of where bioisosterism was 
employed successfully.9 Of note are the angiotensin II type 1 (AT1) receptor antagonists, 
the development of which used bioisosterism to both increase potency, but also to 
increase oral bioavailability, as seen in Figure 3-3. Replacement of the carboxylic acid 
moiety on 3.10, with a tetrazole group (3.11) shows a 10-fold increase in potency (0.23 
μM to 0.019 μM) and a drastic improvement of oral bioavailability (dosing decreased from 
11 mg/kg to 0.59 mg/kg). 
 
ii. Use of Bioisosteres in PET 
Bioisosteres are also highly important in the development of PET radiotracers as 
the design of radiotracers, although very similar to the design of therapeutics, 
necessitates very specific parameters. Firstly, it is important that the biological half-life of 
Figure 3-3: AT1 receptor antagonists and their respective inhibition and dosing. 
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the bioactive molecule matches with the half-life of the radionuclide on the radiotracer. 
Secondly, it is best for both physician and patient if the molecule reaches its target in a 
short amount of time, is biologically available at a microdose, and it is necessary that the 
tracer can achieve these goals without the need for titration of doses. Regulations require 
small amounts of radiotracer be used for PET imaging, so it is very important that the 
drug is highly specific and selective for its target. It is also necessary to be able to 
radiolabel the molecule without altering its biological properties; this is where bioisosteric 
replacement is used the most.  
One of the most common bioisosteric replacements in PET is to substitute a group 
(or atom) for a fluorine, specifically [18F]fluorine; this is due to the ideal half-life (110 
minutes) and availability of [18F]fluorine (can be produced on site, or delivered to 
radiochemistry facilities) as previously described.10 Fluorine can be used to replace 
another halogen, such as chlorine, or hydrogen or hydroxyl groups. Notably however, it 
is important to evaluate the biological activity of the radiolabeled molecule, as the fluorine 
may alter it. In some cases, bioisosterism can make the radiochemical synthesis of a 
Figure 3-4: FMZ and related radiotracers. 
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radiotracer more straight forward, as well as improve the properties of the radiotracer. 
Consider the flumazenil (3.12) derivatives shown in figure 3-4.  The fluorinated derivative, 
[18F]FFMZ ([18F]3.14 ) was developed with the belief that the fluorine could be placed on 
the ester as a bioisostere. Unfortunately, both [18F]FFMZ and [18F]FEFMZ ([18F]3.13) did 
not display satisfactory characteristics in vivo when compared to [11C]FMZ.11,12 At this 
point [18F]FMZ ([18F]3.12), an isotopolog of FMZ had been developed, but reported 
syntheses gave yields below 10%.13  With the desire for another [18F]fluorine labeled 
benzodiazepine related PET tracer,  AH114726 was adapted for radiolabeling by Rodnick 
and coworkers.12 It can be said that the relocation of the aryl fluorine substituent to the 
ortho position relative to the carbonyl gives a bioisosteric structural isomer. This allows a 
simplified SNAr [18F]fluorination of a precursor, increases the yield up to 24%, and the 
radiotracer exhibits similar activity to [11C]FMZ.12 In this case, a bioisostere in the right 
location on the molecule helped to preserve characteristics of the parent molecule as well 
as allow for translation of the scaffold into PET imaging. This speaks both to the necessity 
of re-evaluation of a tracer after bioisosterism, as well as suggests that protons on an 
aromatic ring are tolerant of substitution with fluorine.   
B. Evaluation of [11C]-labeled GABA Analogs 
i. Radiochemical Syntheses of [11C]-Nipecotic Acid and Ester 
  In the development of a GAT-1 selective radioligand, thus far, the candidates have 
not been found to be BBB permeable. It is known that the lipophilic side chain of tiagabine 
Figure 3-5: Small molecule [11C]-labeled radiotracers, [11C]PMP, [11C]3.17, and [11C]3.18. 
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and related molecules assists in brain penetration at high doses titrated over weeks,14 
however, as found in Chapter 2, these molecules lack the brain penetration to be 
successful CNS PET tracers. To test our hypothesis that the carboxylic acid moiety is 
inhibiting the BBB penetration, both nipecotic acid (3.20) and ethyl nipecotate ester (3.19) 
were N-methyl-[11C]-methylated (Scheme 3-1) to generate [11C]3.18 and [11C]3.17, 
respectively, for evaluation in vivo. The simple molecule nipecotic acid was chosen to be 
evaluated as it is both the active moiety of the GAT-1 inhibitors, but also contains the 
potentially problematic carboxylic acid functional group. It was expected that N-methyl 
nipecotic acid should not cross the BBB while the N-methyl ethyl nipecotate ester should 
be BBB permeable due to increased lipophilicity. Previous work done in this area includes 
the N-[11C]-methylation of nipecotic acid in the search for an appropriate radiotracer for 
acetylcholinesterase (AChE);15,16 this work ultimately led to the selection of 1-
[11C]methylpiperidin-4-yl propionate ([11C]PMP, [11C]3.16) for the imaging of AChE.  
  The precursor for both the acid and ester radiotracers [11C]3.17 and [11C]3.18 was 
the commercially available ethyl ester nipecotate, 3.19. Reference standard N-methyl 
nipecotic acid (3.18) was also purchased, and the N-methyl ether ester nipecotate (3.17) 
was prepared in 20% yield by simple N-methylation with methyl iodide (Scheme 3-1). The 
Scheme 3-2: Radiochemistry for the preparation of [11C]3.17 and [11C]3.18. 
Scheme 3-1: Synthesis of the reference standard 3.17. 
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poor UV absorbance of these molecules (at typical HPLC wavelengths, 220, 254, 280 
nm) required additional development of HPLC methods and the use of an ion 
chromatography system equipped with an electrochemical detector for analysis. The 
ester precursor and standard were visible at 220 nm (Figure 3-16), and an HPLC 
equipped with an ion-detector was used for the analysis of the N-methyl nipecotic acid as 
it was not visible by the HPLC UV lamp (Figure 3-19). Both molecules (ester, [11C]3.17 
and acid, [11C]3.18) were produced successfully using [11C]MeOTf prepared in a 
TracerLab FXC-Pro synthesis module (Scheme 3-2). In the production of [11C]3.18, 
hydrolysis took place immediately after methylation with 5M LiOH at 100°C. Purification 
on a semi-preparative HPLC in ethanolic buffer gave an injectable dose.  
ii. In vivo evaluation of [11C]-N-Methyl Nipecotic Acid and Ethyl Ester   
These radiotracers were evaluated in Sprague-Dawley rats (n=2 for each 
molecule) to observe the effects in vivo. In initial evaluation of (R/S)-[11C]3.18 in rat, a 
female Sprague-Dawley rat (369 g) was injected with (R/S)-[11C]3.18 (0.489 mCi) i.v. via 
tail vein injection.  After the rat was scanned for 60 min post-injection of the radiotracer 
(see experimental section for detailed scanning procedure) [11C]N-methyl nipecotic acid 
([11C]3.18), which has been studied previously,16 demonstrated no brain uptake as 
expected (Figure 3-6). Following our hypothesis that the carboxylic acid was inhibiting 
Figure 3-6: Results from in vivo evaluation of (R/S)-[11C]3.18 in rodent. 
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brain uptake of (R/S)-[11C]3.18, the ester form, (R/S)-[11C]3.17 was then isolated and 
evaluated in rodent (287 g, 0.505 mCi dose i.v. via tail vein injection). We were surprised 
to also observe lack of brain uptake for ester (R/S)-[11C]3.17 (Figure 3-6). This was 
surprising not just because of the increased lipophilicity but also because of the fact that 
it is identical in molecular weight and has a similar structure to [11C]PMP (3.16), which is 
brain penetrant. These results along with the comparison of the N-methyl nipecotic acid 
to the normally accepted parameters for a successful CNS drug candidate (Table 3-3) led 
us to investigate whether the use of a carboxylic bioisostere may increase BBB 
permeability of these GAT-1 inhibitors.  
Figure 3-7: Results from in vivo evaluation of (R/S)-[11C]3.17 in rodent. 
Table 3-3: Comparison of properties of N-methyl nipecotic 
acid and nipecotate ester. 
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C. BIOISOSTERISM OF NIPECOTIC ACID 
  As a large neuronal network with a wide range of therapeutic possibilities, it is 
unsurprising that the GABAergic system has been the subject of a number of 
bioisosterism studies.17–22 Some of these molecules incorporate bicyclic systems based 
on natural products such as muscimol.23 Others remain closer to more classical 
bioisosteres, mainly for a carboxylic acid, such as sulfonamides and hydroxamic acids.9,19 
To move forward with the development of a brain-permeable GAT-1 radiotracer, a number 
of carboxylic acid bioisosteres were considered. A common bioisostere for carboxylic 
acids, hydroxamic acid was briefly considered, but the acidity and susceptibility of the 
moiety to be charged at physiological pH made its qualities too alike to a carboxylic acid 
and we reasoned hydroxamic derivatives could have difficulties crossing the BBB. 
Sulfonamides offer another option for the replacement of a carboxylic acid (Table 3-4, 
entry 4, 3.22). They were one of the first employed in the improvement in drug design as 
demonstrated by their use in a class of antibacterial agents.9 The isomeric ß-alanine 
Table 3-4: Select bioisosteres of nipecotic acid. 
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analogue 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol (THPO, Table 3-4, entry 5, 3.23), 
one of the bicyclic systems based on the natural product muscimol, was also a viable 
option displaying both the planar shape of a carboxylic acid and containing the necessary 
hydrogen bond donor in the hydroxy group.19,24,25 Tetrazoles, such as 3.24, entry 6 in 
Table 3-4, are one of the most commonly used bioisosteres for carboxylic acid, given the 
acidic proton and planar shape of the moiety. They are slightly larger than the carboxylic 
acid group, but also have an increased lipophilicity desirable for BBB penetration.9 
Another bioisostere, not commercially available, but which has been claimed to be made 
in a patent,26 is the trifluromethyl ketone of nipecotic acid (Table 3-4, entry 3, 3.21). The 
trifluoromethyl ketone offers higher lipophilicity with weak acidic character that could 
helpful in the development of a BBB permeable molecule. A variety of routes were 
attempted to obtain this bioisostere, but unfortunately these were unsuccessful.27–29  
Table 3-5: Results from [3H]GABA uptake 
inhibition assay using rat brain homogenate. 
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  Three commercially available bioisosteres (sulfonamide, THPO, and tetrazole, 
entries 4, 5 and 6 in Table 3-4) were chosen for evaluation in an assay run by Cerep 
PanLabs. In this uptake inhibition assay the compounds were tested for their ability to 
inhibit uptake of [3H]GABA in rat brain homogenate. The three bioisosteres were 
submitted alongside tiagabine, the unsymmetrical molecules discussed in Chapter 2 as 
well as ethyl nipecotate ester. For preliminary data, only one concentration of each 
sample was run in duplicate. This assay returned interesting results (Table 3-5). 
Normalizing the inhibition concentrations to the value reported to tiagabine (the internal 
positive standard), it is found that the tetrazole gives the best inhibition in this assay 
encouraging further investigation of this bioisostere. Moving forward, various routes were 
attempted for the synthesis of a precursor and standard of the tetrazole containing 
molecule. While commercially available, development of a radiochemical synthesis, 
including in vitro validation required a larger amount of material, and, assuming it is 
synthetically accessible via an in-house synthesis, this would be the more economical 
route. While 13C-carbon NMR did confirm the production of the tetrazole (Scheme 3-3, 
Figure 3-8), the separation of the tetrazole from the cyano-piperidine proved difficult due 
to the delicate balance of pKas of the tetrazole (~5.0) and piperidine (~9.0). Purification 
Scheme 3-3:Multiple methods for production of tetrazoles from a cyano starting material. 
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efforts ranges from attempted flash column chromatography with varied solvent systems 
(Hex:EtOAc, Hex:EtOAc+ 0.5% TEA, DCM:MeOH, EtOAc:MeOH), as well as pH 
manipulation during work up of the reaction. Both acidification and basification of the 
aqueous layer of the reaction resulted in the extraction of a mixture of starting material 
and product in the organic layer, as evident by crud TLC as well as 13C-NMR (Figure 3-
8). Synthesis attempts of this and other bioisosteres can be found in the experimental 
section of this chapter.  
Figure 3-8: 13C-NMR spectra of a inseparable mixture of cyano (120 ppm) and tetrazole (160 ppm). 
Figure 3-9: Example of thiazolyl bioisosterism in 
the development of 5-HT3 receptor antagonists. 
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Stemming from the assay success (and elusive promise) of the tetrazole, another 
heterocycle, thiazole, was investigated. Thiazolyls have been successfully incorporated 
into CNS agents, including those targeting dopamine receptors.30 They have also been 
used as bioisostere for a carbonyl group in serotonin receptor subtype 3 (5-HT3) 
antagonists.31 Rosen and colleagues were able to replace a carbonyl moiety, which 
participates in binding to 5-HT3 receptors, with a thiazolyl linker, and maintained activity 
and selectivity over other serotonin receptors, as well as other receptors and binding sites 
in the brain (Figure 3-9). These reported results led to the investigation of a thiazolyl 
piperidine as a possible bioisostere for the acid functionality of nipecotic acid in the 
development of a GAT-1 selective radiotracer. 
 
D. Thiazole For Use as a Bioisostere of Nipecotic Acid 
i. Radiochemical Synthesis 
  The precursor 3-(1,3-thiazol-2-yl)piperidine (3.30) is commercially available and 
was purchased from Enamine. This bioisostere was then evaluated in vivo similar to the 
evaluation of N-methyl nipecotic acid and ester described earlier. To do this, the reference 
standard was synthesized via a simple N-methylation (Scheme 3-4). An HPLC method 
was developed for the semi-preparative purification of the product, and then the analysis 
of the identity of that product in the final dose form. Initially, an ethanolic buffer system 
was used for both semi-preparative and analytical HPLC. Although successful in 
Scheme 3-4: Methylation for formation of thiazolyl reference 
standard. 
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separating the product, the peaks were broad, and the radiochemical yields were low 
using this system. Switching to an acetonitrile eluent, buffered with ammonia, the peaks 
were much sharper (Figure 3-21) and yields >100 mCi in the final, injectable dose were 
obtained (HPLC parameters can be found in the experimental section of this chapter).  
  The piperidinyl thiazole precursor was labeled with [11C]MeOTf prepared in a 
TracerLab FXC-Pro as described previously. After methylation the reaction mixture was 
diluted with semi-preparative HPLC buffer and injected onto a semi-preparative Gemini 
NX C18 250 x 10 mm HPLC column. The product peak was collected and diluted in 50 
mL milliQ water. The product was then trapped on a 1cc Vac C18 cartridge; the cartridge 
was rinsed with further milliQ water, and the product eluted with ethanol followed by 
saline. This purified and reformulated dose was then transferred to a sterile 10 mL vial 
(assembled aseptically, and with a sterile filter for NHP studies). RCYs of [11C]3.31 were 
131 ± 62 mCi at EOS, corresponding to 15% non-corrected radiochemical yield (n = 6). 
Radiochemical purity was >99%, produced in high specific activity (>2500 Ci/µmol).  
 
Scheme 3-5: [11C]Methylation of the commercially available thiazole to 
produce [11C]N-methyl piperidinyl thiazole. 
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ii. In Vivo Evaluation of [11C]-N-methyl Thiazolyl Piperidine  
This novel radiotracer ([11C]3.31) was first evaluated in vivo to determine whether 
the substitution of the carboxylic acid with a thiazole resulted in a BBB permeable 
molecule. As with the other radiotracers discussed within, the tracer was first evaluated 
in Sprague-Dawley rats. A female Sprague-Dawley rat (425 g) was injected with [11C]3.31 
(0.50 ± 0.04 mCi) i.v. via tail vein injection.  The rat was scanned for 60 min post-injection 
of the radiotracer (see experimental section for detailed scanning procedure). Compared 
to the rat images produced with [11C]-N-methyl nipecotic acid 3.18 and ester 3.17, the 
thiazole displayed excellent brain uptake (Figure 3-10). Whole brain time-radioactivity 
curves (Figure 3-11) revealed a peak standardized uptake value (SUV) of 4. Encouraged 
by this success the radiotracer was also evaluated in non-human primates. Imaging 
studies were performed in a young, mature female rhesus monkey and radiotracer 
Figure 3-10: Results of in vivo evaluation of [11C]3.31 in 
rodent. 
Figure 3-11: Average time activity curve for 2 rodent 
studies with standard deviation bars. 
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[11C]3.31 (4.56 ± 0.44 mCi) was injected i.v. via a venous catheter inserted into one hind 
limb of the monkey. The monkey was scanned for 60 min and the images also revealed 
high brain uptake of the radiotracer (Figure 3-12). Time-radioactivity curves (Figure 3-13) 
revealed a whole brain SUV of 4, and the patterns displayed in the brain suggest uptake 
of the tracer in the cortex and striatum, where GABA neurons are known to be highly 
expressed.32 
 
iii. In vitro Evaluation of [11C]-N-methyl Thiazolyl Piperidine  
  Radiotracer 11C]3.31 displayed excellent brain uptake and appeared to be 
localizing to areas of higher GAT-1 expression. Thus, we undertook in vitro studies to 
Figure 3-12: Results of in vivo evaluation of [11C]3.31 in NHP. 
Figure 3-13: Regional and whole brain TACs showing 
enhanced uptake in the striatum of [11C]3.31. 
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confirm affinity of 3.31 for the GAT-1 target. This was investigated through a series of in 
vitro experiments: immunohistochemistry (IHC) with GAT-1 specific antibodies to confirm 
presence of the target in the tissue samples, and autoradiography with [11C]3.31 to 
confirm colocalization of radiotracer binding with IHC. Frozen rat brain was sliced into 20 
μm slices on a microtome and mounted onto slides and placed into a -80°C freezer until 
the time of the assay. Radiotracer [11C]3.31 was prepared as described above and diluted 
to proper concentration, 25 nM, for the assay at hand.  
These studies commenced with staining brain slices (human and rat) with anti-
GAT-1 antibodies to confirm the presence of GAT-1 in the tissue type (rat vs human) and 
area of brain being used. Once the target (GAT-1 in this case) was confirmed in the tissue, 
adjacent slices of tissue were employed for autoradiography studies using both the 
labeled radiotracer and the cold reference standard. The first study was to determine the 
time needed to get saturation of the tissue/target with the radiotracer. Tissue slices (on 
slides, but not fixed) were incubated in a solution containing 25 nM concentration of the 
of the tracer along with a smaller dilution (10 μM) of cold standard, and a separate set of 
slides are incubated in a solution with radiotracer and a 1000x fold (10 mM) reference 
standard. The tissues incubated for different amounts of time (2, 5, 10, 15, and 30 
minutes) before the slide is rinsed/washed, and the tissue is wiped off the slide and placed 
into a vial for measurement with a scintillation/gamma counter. The cold reference 
standard is included in this study to determine (roughly) any amount of non-specific 
binding. This will give the equilibration/saturation time of the tissue with the radiotracer so 
that subsequent studies can be timed accordingly.  
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  This study is then repeated again for determination of KD and Bmax, only this time, 
slides were incubated for 15 minutes in an increasing concentration of cold reference 
standard with 25 nM tracer. The slides were then removed from solution, rinsed with 
additional PBS, and dried on a hot plate at for 5 minutes. The slides were then placed in 
an autoradiograph developing cassette for 5 minutes, before imaging with a Fujifilm BAS-
1800 Bioimaging Analyzer System. Scatchard analysis of the resulting data allows for the 
calculation of dissociation constant (KD) and binding potential (Bmax) (Figure 3-14, inset). 
This initial study gives a KD of 2.26±0.46 nM and a Bmax of 0.34± 0.03 fmol/μg protein. 
 
 
 
Figure 3-14: Saturation binding curve resulting from preliminary in vitro studies, and Scatchard analysis 
(inset) to determine KD and Bmax of [11C]3.31. 
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E. Experimental Methods 
i.  Chemistry Methods 
Ethyl 1-methylpiperidine-3-carboxylate (3.17, reference standard, Scheme 3-1) 
A 1.0 M solution of nipecotate (R,S)-3.21 (500.0 mg, 3.18 mmol, 1.0 equiv.) in THF 
(0.7 mL) was prepared in a flame-dried flask. Iodomethane (541.6 mg, 0.24 mL, 3.81 
mmol, 1.2 equiv) was added dropwise and the reaction was allowed to stir for 3-4 hours 
at room temperature. Upon completion, the reaction was quenched with aq. NaHCO3, 
and extracted with diethyl ether. The organic layer was dried (MgSO4), filtered and 
concentrated to give the title compound.  
 
Yield: 98.5 mg (18 %) as a clear oil. 
 
1H NMR (400 MHz, CDCl3) δ 4.06 (q, J = 7.1 Hz, 2H), 2.93 – 2.80 (m, 1H), 2.65 (m, 1H), 
2.52 (ddt, J = 11.1, 10.3, 3.9 Hz, 1H), 2.22 (s, 3H), 2.05 (t, J = 10.8 Hz, 1H), 1.89 (m, 2H), 
1.71 – 1.62 (m, 1H), 1.62 – 1.46 (m, 1H), 1.35 (m, 1H), 1.18 (t, J = 7.2 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 174.08, 60.33, 57.37, 55.62, 46.54, 41.88, 26.37, 24.63, 
14.18. 
 
HRMS: M+ predicted m/z = 171.1259, actual m/z = 171.1332. 
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Thiazole chemistry: 
Cold reference standard (3.31) was synthesized by N-methylation of commercially 
available 3-(1,3-Thiazol-2-yl)piperidine (3.30).  
 
2-(1-methylpiperidin-3-yl)thiazole (3.31, Scheme 3-4) 
Method A: 3-(1,3-Thiazol-2-yl)piperidine (3.30, 163.5 mg, 0.97 mmol, 1.0 equiv) was 
dissolved in THF (1.35 mL). To it, methyl iodide (0.07 mL, 165.5 mg, 1.16 mmol, 1.2 
equiv) was added dropwise. The reaction was stirred at room temperature until starting 
material was consumed. Upon completion, the reaction was quenched with aq. NaHCO3, 
and extracted with diethyl ether. The organic layer was dried (MgSO4), filtered and 
concentrated. Crude product contained side products and starting material. Purification 
attempts via flash column chromatography were not successful.  
 
Method B: 3-(1,3-Thiazol-2-yl)piperidine (3.30, 100.0 mg, 0.59 mmol, 1.0 equiv) was 
dissolved in MeOH (0.6 mL) and cooled to 0°C. To it was added formaldehyde (0.22 mL 
of 30% aqueous solution, 1.78 mmol, 3.0 equiv). Keeping the reaction at 0°C, NaBH4CN 
(73.7 mg, 1.17 mmol, 2.0 equiv) was added portion wise. The reaction was allowed to 
come to room temperature and stir overnight. Upon consumption of starting material, the 
reaction was rotovapped to dryness, and the residue dissolved in an ethyl acetate: water 
mixture (1:1). The aqueous layer was extracted with ethyl acetate, and the combined 
organic layers were washed with water and brine. The organic layer was dried over 
Na2SO4, filtered and rotovapped giving the title compound.  
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Yield: 97.2 mg, 90% as yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 3.4 Hz, 1H), 7.17 (d, J = 3.2 Hz, 1H), 3.28 (tt, J 
= 10.7, 3.9 Hz, 1H), 3.13 (d, J = 11.6 Hz, 1H), 2.79 (dd, J = 11.9, 5.1 Hz, 2H), 2.29 (s, 
3H), 2.17 (t, J = 10.8 Hz, 1H), 2.10 (m, 2H), 2.01 (td, J = 11.4, 3.3 Hz, 1H), 1.82 – 1.63 
(m, 2H), 1.52 (qd, J = 11.8, 4.4 Hz, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 173.35, 141.98 (d, J = 30.0 Hz), 117.87 (d, J = 35.8 Hz), 
61.14, 55.55 (d, J = 27.5 Hz), 46.36 (d, J = 19.8 Hz), 40.76, 30.70, 24.88. 
 
HRMS: M+ predicted m/z = 183.0950, actual m/z = 183.0950. 
 
Other Investigated Bioisosteres 
The following are experimental data for both attempted and successful chemical 
syntheses done towards the development of a bioisosteric replacement for nipecotic acid.  
 
1-benzylpiperidine-3-carboxylic acid, 3.32 
Method A: Nipecotic acid (500 mg, 3.87 mmol, 1.5 equiv) and benzaldehyde (0.27 mL, 
273.8 mg, 2.58 mmol, 1.0 equiv) were added to a flame dried flask and diluted in MeOH 
(12 mL). To the flask was added NaBH3CN (2431.9 mg, 38.7 mmol, 15.0 equiv) 
portionwise, and acetic acid (0.3 mL). The reaction was stirred for 2 hours at room 
temperature before being neutralized to pH 7 with saturated aqueous NaHCO3. The 
reaction was diluted in ethyl acetate, and the layers separated. The organic layer was 
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washed with brine before being dried over Na2SO4 and concentrated via rotovap. No 
product was formed.  
 
Method B: In a flame dried flask, nipecotic acid (250.0 mg, 1.94 mmol, 1.0 equiv), K2CO3 
(1340.6 mg, 9.70 mmol, 5.0 equiv), benzyl bromide (0.69 mL, 995.5 mg, 5.82 mmol, 3.0 
equiv), and DMF (2.52 mL) were combined. The reaction was heated at 70°C for 22 hours. 
TLC of the reaction showed remaining starting material; additional K2CO3 (300 mg) was 
added and the reaction was stirred an additional 4 hours. The reaction was cooled to 
room temperature and diluted in ethyl acetate and water. The layers were separated, and 
the organic layer washed with 1.0 M HCl, water and brine. The organic layer was then 
dried over Na2SO4, filtered and rotovapped. Product could not be confirmed, and so the 
second step of the reaction (deprotection of the carboxylic acid) was forgone. 
 
Ethyl 1-benzylpiperidine-3-carboxylate, 3.33 
Ethyl nipecotate ester (0.30 mL, 300.0 mg, 1.91 mmol, 1.5 equiv) and benzaldehyde (0.13 
mL, 134.7 mg, 1.27 mmol, 1.0 equiv) were added to a flame dried flask in THF (9.0 mL). 
To the flask was added NaBH(OAc)3 (3.36 mL, 403.78 mg, 19.05 mmol, 15.0 equiv) 
portionwise, followed by Na2SO4 (100 mg, 0.7 mmol, 0.55 equiv). Glacial acetic acid 
(17M, 0.15 mL, 2.54 mmol, 2.0 equiv) was added dropwise. The reaction was stirred at 
room temperature for 2 hours before progress was checked by TLC. Additional THF (1.0 
mL), and Na2SO4 (50 mg) were added after 2 hours and the reaction was allowed to stir 
for 2 days. The reaction was then diluted in water, neutralized to pH 7 with saturate 
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aqueous NaHCO3, and extracted 2x with ethyl acetate. The organic layer was separated, 
washed with brine, dried over Na2SO4 and then rotovapped to give product.  
 
Yield: 295.5 mg, 94% as an oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.16 (m, 5H), 4.09 (qd, J = 7.1, 0.8 Hz, 2H), 3.51 (q, 
J = 13.2 Hz, 2H), 2.99 – 2.89 (m, 1H), 2.72 (d, J = 11.4 Hz, 1H), 2.58 (tt, J = 10.3, 3.8 Hz, 
1H), 2.21 (t, J = 10.6 Hz, 1H), 2.12 – 1.98 (m, 1H), 1.94 – 1.85 (m, 1H), 1.74 – 1.65 (m, 
1H), 1.63 – 1.51 (m, 1H), 1.42 (s, 1H), 1.21 (t, J = 7.1 Hz, 3H). 
 
Ethyl 1-tritylpiperidine-3-carboxylate, 3.34 
Triphenylmethyl chloride (Ph3CCl, 389.5 mg, 1.4 mmol, 1.1 equiv), and ethyl nipecotate 
ester (0.2 mL, 200.0 mg, 1.27 mmol, 1.0 equiv) were dissolved in DCM (0.53 mL) in a 
flame dried flask and stirred for 5 minutes. To this mixture, Et3N (0.62 mL, 450.3 mg, 4.45 
mmol, 3.5 equiv) was added dropwise, and the reaction stirred for 1 hour at room 
temperature. The reaction was then diluted in ethyl acetate, and the layers separated. 
The organic layer was washed 5x with water, before the organic layer was concentrated 
via rotovap. Flash column chromatography (gradient, Hexanes: Ethyl Acetate) gave the 
title compound.  
 
Yield: 147.8 mg, 29% as white solid.  
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1H NMR (400 MHz, CDCl3) δ 7.64 – 7.43 (m, 6H), 7.30 (ddd, J = 15.3, 8.3, 6.5 Hz, 8H), 
7.20 (d, J = 7.4 Hz, 1H), 4.18 – 3.95 (m, 2H), 3.42 (s, 1H), 3.16 (q, J = 7.0 Hz, 1H), 2.87 
(s, 1H), 2.08 (s, 1H), 1.79 (d, J = 37.8 Hz, 1H), 1.52 (d, J = 24.3 Hz, 1H), 1.28 (m, 5H). 
 
1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid, 3.35 
Method A: Nipecotic acid (250.0 mg, 1.94 mmol, 1.0 equiv) was dissolved in DCM (~1.425 
mL) in a flame dried flask. To it was added Et3N (0.7 mL, 510.4 mg, 5.04 mmol, 2.6 equiv). 
In another flask or vial, Boc2O (464.9 mg, 2.13 mmol, 1.1 equiv) was dissolved in DCM 
(~1.0 mL) and added portion wise to nipecotic acid. The reaction was stirred at room 
temperature for 12 hours. The reaction was diluted in DCM and washed with water. The 
organic layer was dried over Na2SO4, filtered and concentrated via rotovap. Product was 
not confirmed by NMR. 
 
Method B: Nipecotic acid (600 mg, 4.65 mmol, 1.0 equiv) and MeOH (23.25 mL) were 
combined in a flame dried flask under argon. To the reaction, Et3N (18.5 mL, 25.482 g, 
251.8 mmol, 54.1 equiv) was added in two parts, 5 minutes apart. The reaction was then 
cooled to 0°C before the addition of Boc2O (1217.9 mg, 5.58 mmol, 1.2 equiv). The 
reaction is allowed to come to room temperature while it stirs for 48 hours. Confirming 
consumption of starting material by TLC, the reaction is diluted in a mixture of DCM:water 
(50 mL:10 mL). This mixture is cooled to 0°C and the pH adjusted to 3.5 (done carefully, 
adding acid (HCl) dropwise). The organic layer was then separated, and the aqueous 
layer was extracted with DCM. The combined organic layers were dried over MgSO4, 
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filtered and concentrated via rotovap. Purification by flash column chromatography gave 
the title compound.  
 
Yield: 727.7 mg, 68% as white solid.  
 
1H NMR (400 MHz, CDCl3) δ 11.65 (s, 1H), 4.01 (s, 1H), 3.82 (d, J = 13.4 Hz, 1H), 2.99 
(s, 1H), 2.78 (t, J = 11.6 Hz, 1H), 2.40 (ddd, J = 10.3, 6.3, 3.9 Hz, 1H), 2.00 (dd, J = 13.0, 
4.6 Hz, 1H), 1.72 – 1.49 (m, 2H), 1.38 (s, 9H). 
 
N-hydroxypiperidine-3-carboxamide, 3.36 
Method A:33 Ethyl nipecotate ester (0.25 mL, 250.0 mg, 1.59 mmol, 1.0 equiv) was 
dissolved in methanol (2.0 mL) in a flame dried flask. In a separate flask, a slurry was 
made from KOH (711.2 mg, 9.54 mmol, 6.0 equiv), HONH2·HCl (331.5 mg, 4.77 mmol, 
3.0 equiv), and methanol (2.0 mL). This slurry was added portionwise to the ester mixture, 
and the reaction was stirred at room temperature, monitoring by TLC. After 18h a small 
product spot emerged, and the reaction was heated at 50°C for an additional 2 hours. 
The reaction was then acidified to pH 4 with 3 M HCl before removing organic solvent via 
rotovap. The residue was diluted in water, and this mixture was extracted with ethyl 
acetate until TLC confirmed no product was left in the aqueous layer. The organic layer 
was dried over Na2SO4, filtered and rotovapped. Product formation could not be 
confirmed by NMR. 
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Method B:33 Ethyl nipecotate ester (0.03 mL, 31.4 mg, 0.2 mmol, 1.0 equiv), HONH2·HCl 
(41.7 mg, 0.6 mmol, 3.0 equiv), KOH (89.46 mg, 1.2 mmol, 6.0 equiv), and methanol (1.0 
mL) were all added to a 10 mL microwave reaction tube. The reaction was irradiated in a 
microwave at 150 W, 80°C for 6 minutes. After the microwaving, the reaction was acidified 
to pH 4 with 3 M HCl and concentrated via rotovap. The residue was diluted in water and 
extracted with ethyl acetate. The organic layer was concentrated via rotovap. Product 
formation not confirmed by NMR.  
 
Tert-butyl 3-((diethoxymethyl)(ethoxy)phosphoryl)-3-hydroxypiperidine-1-
carboxylate17, 3.37 
N-boc piperidone (200.0 mg, 1.01 mmol, 1.0 equiv), ethyl (2,2-diethoxyethyl)phosphinate 
(198.1 mg, 1.01 mmol, 1.0 equiv), and Et3N (0.14 mL, 102.2 mg, 1.01 mmol, 1.0 equiv) 
were combined in a flame dried flask under argon. The reaction was heated at 100°C for 
3 hours before being cooled to room temperature. The reaction was diluted in 100 mL 
DCM, and this organic mixture was washed with each ice cold 4M HCl, saturated NaHCO3 
and brine. The organic layer was then dried over Na2SO4, filtered, and rotovapped. TLC 
showed conversion, but NMR could not confirm product formation. 
 
tert-butyl 3-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate, 3.38 
Method A:27 N-Boc Nipecotic acid (300 mg, 1.31 mmol, 1.0 equiv) was suspended in 
toluene (3.3 mL) in a flame dried flask under argon. Trifluoroacetic acid was added at 
room temperature, and then the reaction was cooled to 0°C. Pyridine (0.63 mL, 621.7 mg, 
7.86 mmol, 6.0 equiv) was added dropwise. The reaction was then heated to 60°C and 
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stirred overnight. The reaction was checked by TLC, and when starting material was 
consumed, the reaction was cooled to 0°C. Water (2.62 mL) was added slowly to the 
reaction, before heating to 45°C for 2 hours. The reaction was then cooled to room 
temperature and the layers separated. The aqueous layer was extracted with MTBE 
which was combined with the organic layer. This organic layer was washed with 1 N 
NaOH before drying over MgSO4, filtering and rotovapping. No product was recovered.  
 
2,2,2-trifluoro-1-(piperidin-3-yl)ethan-1-one, 3.21 
Method A:27 Nipecotic acid (500 mg, 3.87 mmol, 1.0 equiv) was suspended in toluene 
(1.5 mL) in a flame dried flask under argon. Trifluoroacetic acid (1.29 mL, 1951.2 mg, 
9.29 mmol, 2.4 equiv) was added to the flask dropwise at room temperature. The reaction 
was then cooled to 0°C in an ice water bath. Pyridine (2.59 mL, 2540.7 mg, 32.12 mmol, 
8.3 equiv) was then added slowly to the reaction at 0°C. The reaction was then heated to 
50°C and stirred for 24 hours. After this time, the reaction was again cooled to 0°C, and 
water (~500 mL) was added slowly to quench the reaction. The aqueous reaction mixture 
was then heated to 45°C and stirred for 2 hours, after which the reaction was diluted with 
ethyl acetate. The layers were separated, and the organic washed with water followed by 
saturate aqueous NaHCO3. The organic layer was then dried over Na2SO4, filtered and 
concentrated via rotovap. No product was recovered. 
 
Method B:27 Nipecotic acid (500 mg, 3.87 mmol, 1.0 equiv) was suspended in toluene 
(9.67 mL) in a flame dried flask under argon. Trifluoroacetic acid (2.42 mL, 3658.7 mg, 
17.42 mmol, 4.5 equiv) was added to the flask dropwise at 0°C in an ice water bath. 
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Pyridine (1.87 mL, 1836.7 mg, 23.22 mmol, 6.0 equiv) was then added slowly to the 
reaction at 0°C. The reaction was then heated to 60°C and stirred for 4 hours before 
checking by TLC. After starting material was consumed, the reaction was cooled to room 
temperature, and water (7.74 mL) was added slowly over 5 minutes, keeping the reaction 
temperature below 40°C. The aqueous reaction mixture was then heated to 60°C and 
stirred for 1 hour and then cooled to room temperature. The reaction was diluted with 
hexanes and water. The layers were separated, and the aqueous extracted with hexanes. 
The combined organic layers were then washed with water, and then dried over Na2SO4, 
filtered and concentrated via rotovap. No product was recovered. 
 
Method C:27 Nipecotic acid (300 mg, 2.32 mmol, 1.0 equiv) was suspended in toluene 
(5.8 mL) at room temperature. Trifluoroacetic acid (TFAA, 1.45 mL, 2192.7 mg, 10.44 
mmol, 4.5 equiv) was then added to the reaction before cooling to 0°C. Pyridine (1.12 mL, 
1101.1 mg, 13.92 mmol, 6.0 equiv) was then added dropwise. The reaction was stirred 
overnight, allowing it to come to room temperature. The reaction was then cooled to 0°C 
once again before adding 5.0 mL water. The reaction was then stirred for 24 hours. There 
was no formation of product.  
 
Method D:27 Nipecotic acid (300 mg, 2.32 mmol, 1.0 equiv) was dissolved in DCM (4.54 
mL) at room temperature in a flame dried flask. Trifluoroacetic acid (1.45 mL, 2192.7 mg, 
10.44 mmol, 4.5 equiv) was added before cooling the reaction to 0°C. Pyridine (1.12 mL, 
1101.1 mg, 13.92 mmol, 6.0 equiv) was then added dropwise in two parts. The reaction 
was stirred, allowing to come to room temperature while being monitored by TLC. Upon 
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consumption of starting material, the reaction was cooled to 0°C, and 5.0 mL of water 
was added slowly. The reaction was again allowed to come to room temperature while 
stirring, and the progress monitored by TLC. The crude reaction mixture did not show 
product. The crude reaction was then diluted in hexanes and water. The aqueous layer 
was extracted with hexanes; the combined organic layers were dried over Na2SO4 and 
rotovapped (Sample A). The aqueous layer was neutralized with NaOH, and again 
extracted with hexanes; this organic layer was kept separate (sample B). The aqueous 
layer was then made basic with NaOH and extracted with ethyl acetate (Sample C).  
Samples A and C had promising NMR spectra (1H and 19F), and nominal mass 
spectroscopy showed product in sample C. However, attempting purification of sample C 
resulted in loss of product.  
 
1-(1-benzylpiperidin-3-yl)-2,2,2-trifluoroethan-1-one, 3.39 
Ethyl 1-benzylpiperidine-3-carboxylate (295.5 mg, 1.19 mmol, 1.0 equiv) and TMS∙CF3 
(0.19 mL, 186.28 mg, 1.31 mmol, 1.1 equiv) were added to a flame dried flask in DME 
(0.32 mL). To the flask was added cesium fluoride (CsF, 3.6 mg, 0.02 mmol, 0.02 equiv). 
The reaction was stirred at room temperature for 2 hours, monitoring by TLC. Starting 
material consumption was slow, and so the reaction was allowed to stir for 4 days. Upon 
starting material consumption, HCl (2mL, 4 M) was added to the reaction and it was 
allowed to stir at least 2 hours. The reaction was then extracted with diethyl ether. The 
organic layers were combined, dried over Na2SO4, filtered, and rotovapped. Formation of 
product could not be confirmed by NMR.  
 
151 
 
2,2,2-trifluoro-1-(1-tritylpiperidin-3-yl)ethan-1-one, 3.40 
Method A:28,29 Ethyl 1-tritylpiperidine-3-carboxylate (3.36, 148.0 mg, 0.37 mmol, 1.0 
equiv.) was added to a flame dried flask under argon with TMS·CF3 (0.06 mL, 58.3 mg, 
0.41 mmol, 1.1 equiv) and DME (0.10 mL). To it was added CsF (1.1 mg, 0.007 mmol, 
0.02 equiv), and the reaction was allowed to stir at room temperature for 2 hours. 
Checking by TLC showed no product forming, and so the reaction was heated at 35°C 
overnight. The reaction was acidified with 4 N HCl (1 mL) and stirred for 2 additional 
hours. TLC showed emergence of new spot. The reaction was extracted with diethyl ether 
(Et2O), dried over Na2SO4, and rotovapped. NMR could not confirm product and showed 
remaining starting material.  
 
 2,2,2-trifluoro-1-(1-methylpiperidin-3-yl)ethan-1-one, 3.41 
Method A: N-methyl nipecotic acid (143.2 mg, 1.0 mmol, 1.0 equiv) and TMS∙CF3 (0.16 
mL, 156.42 mg, 1.1 mmol, 1.1 equiv) were added in DME (0.3 mL) to a flame dried flask. 
To the flask was added CsF (31.04 mg, 0.02 mmol, 0.02 equiv) and the reaction was 
allowed to stir until consumption of starting material as monitored by TLC (about 45 
hours). The reaction was acidified with 4 N HCl (1 mL) and stirred for 1 hour. The reaction 
was rotovapped to dryness, and no product was recovered as observed by TLC and NMR.  
Method B: N-methyl nipecotic acid (143.2 mg, 1.0 mmol, 1.0 equiv) and TMS∙CF3 (0.18 
mL, 177.75 mg, 1.25 mmol, 1.25 equiv) were added in DME (0.3 mL) to a flame dried 
flask cooled to -78°C. To the flask was added TBAF (0.03 mL of a 1 M solution, 0.025 
mmol, 2.5 mol %), and the reaction was allowed to come to room temperature, stirring 
until consumption of starting material as monitored by TLC (about 45 hours). The reaction 
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was acidified with 4 N HCl (1 mL) and stirred for 1 hour. The reaction was rotovapped to 
dryness, and no product was recovered as observed by TLC and NMR. 
 
Tetrazole Chemistry: 
For the synthesis of both compound 3.24 (intended precursor) and 3.44 (reference 
standard) multiple reagents were investigated for the formation of a tetrazole from a 
cyanopiperidine. While under some conditions, formation of the tetrazole was observed 
via 13C-NMR, it was not possible to separate the product from the cyano-starting material.  
 
1-methylpiperidine-3-carbonitrile, 3.43 
Piperdine-3-carbonitrile, 3.44, (0.13 mL, 124.18 mg, 1 mmol, 1.0 equiv) was added to a 
flame dried flask with THF (1.4 mL) under argon. Methyl iodide (0.15mL, 340.66 mg, 2.4 
mmol, 2.4 equiv) was added dropwise at room temperature. The reaction was stirred at 
room temperature for 3 hours. When a precipitate formed, 5% NaOH (1.5 mL) was added 
to re-dissolve it.  The reaction was extracted with ethyl acetate, and the organic layer 
dried over MgSO4, filtered and concentrated. TLC showed complete consumption of 
starting material. Product was used without further purification. 
 
Scheme 3-6: Attempted syntheses of intended tetrazole 
precursor from piperidine-3-carbonitrile. 
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Yield: 89.4 mg, 72% as oil. 
 
1H NMR (400 MHz, CDCl3) δ 2.99 (dd, J = 8.3, 4.2 Hz, 1H), 2.76 (td, J = 8.3, 3.9 Hz, 2H), 
2.54 – 2.35 (m, 2H), 2.26 (s, 3H), 1.94 – 1.70 (m, 2H), 1.68 – 1.40 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ 121.13, 57.08, 55.09, 46.21, 27.38 (d, J = 69.1 Hz, 2C), 
23.56. 
 
HRMS: M+ predicted m/z = 124.1000, actual m/z = 124.0997. 
 
1-methyl-3-(2H-tetrazol-5-yl)piperidine, 3.44 
Method A: 3-(2H-tetrazol-5-yl)piperidine hydrochloride (50 mg, 0.326 mmol, 1.0 equiv) 
was diluted in THF (0.5 mL) in a flame dried flask. To the flask was added Et3N (0.1 mL, 
65.97 mg, 0.652 mmol, 2.0 equiv), and the mixture was allowed to stir ~5 minutes. Methyl 
iodide (0.024 mL, 55.6 mg, 0.392 mmol, 1.2 equiv) was added dropwise, and the reaction 
was stirred at room temperature, monitoring by TLC. When starting material appeared 
consumed, the reaction was quenched with excess saturated aqueous NaHCO3. The 
aqueous reaction mixture was then extracted with diethyl ether. The organic layers were 
combined, dried over MgSO4, filtered and concentrated. Product formation could not be 
confirmed by NMR. 
 
Method B: 1-methylpiperidine-3-carbonitrile (3.43, 89.4 mg, 0.72 mmol, 1.0 equiv), NaN3 
(70.2 mg, 1.08 mmol, 1.5 equiv), and DMF (1.8 mL) were added to a flame dried flask 
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under argon. To the flask was added I2 (42.02 mg, 0.166 mmol, 0.23 equiv), and the 
reaction was heated to 120°C and stirred overnight. TLC showed conversion of starting 
material, and so the reaction was cooled to room temperature and diluted in water. The 
pH was adjusted to 4 with 1 M HCl. The reaction was extracted with ethyl acetate, and 
the combined organic layers washed with brine. The organic layers were dried over 
MgSO4, filtered and concentrated. Analysis with 13C-NMR shows conversion to the 
desired product, with remaining starting material. 
 
3-(2H-tetrazol-5-yl)piperidine, 3.24 
Method A:34 Piperidine-3-carbonitrile, 3.42, (0.21 mL, 200 mg, 1.61 mmol, 1.0 equiv) was 
diluted in DMF (3.2 mL) in a flame dried flask under argon. To the flask was added NaN3 
(314.0 mg, 4.83 mmol, 3.0 equiv), and TEA∙HCl (664.85 mg, 4.83 mmol, 3.0 equiv). The 
flask was heated to 100°C overnight. TLC showed consumption of starting material. The 
reaction was cooled to 0°C, and EtOAc:4 M HCl (10 mL: 2 mL) was added to the flask. 
This was allowed to stir ~15 minutes. The layers were then separated, and the organic 
layer washed with 2 N HCl 5x. The organic layer was dried over Na2SO4, filtered and 
rotovapped. No product was formed according to NMR. 
 
Method B:34 Piperidine-3-carbonitrile, 3.42, (0.1 mL, 100.0 mg, 0.81 mmol, 1.0 equiv), 
NaN3 (157.97 mg, 2.43 mmol, 3.0 equiv), TEA∙HCl  (334. 5 mg, 2.43 mmol, 3.0 equiv), 
and DMF (1.6 mL) were all combined in a 10 mL microwave reaction tube. The reaction 
was run in a microwave at 130°C, 150 W, 250 psi for 2 hours. The reaction was cooled 
and a mixture of EtOAc:4 N HCl (20 mL: 5 mL) was added to the reaction at 0°C. This 
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was allowed to stir ~5 minutes. The layers were then separated, and the organic layer 
washed with 1 N HCl x 5 times. The organic layer was dried over Na2SO4, filtered and 
concentrated. This product, when placed under house vacuum, decomposed. No product 
was recovered. 
 
Method C:35 Piperidine-3-carbonitrile, 3.42, (0.05 mL, 50 mg, 0.4 mmol. 1.0 equiv), NaN3 
(39.01 mg, 0.6 mmol, 1.5 equiv), and DMF (1.0 mL) were added to a flame dried flask 
under argon. To the flask was added iodide (I2, 18.0 mg, 0.071 mmol, 0.18 equiv). The 
reaction was heated to 120°C and stirred overnight. Upon consumption of starting 
material, the reaction was diluted in ethyl acetate and 4 M HCl. The aqueous layer was 
separated and extracted twice with ethyl acetate. The combined organic layers were 
washed twice with each saturated aqueous Na2S2O3 and water. NMR of the crude 
reaction mixture showed formation of product with remaining starting material. Purification 
of product was attempting using flash column chromatography (silica, hexanes:ethyl 
acetate gradient), but no separation was achieved. 
 
Tert-butyl 3-(2H-tetrazol-5-yl)piperidine-1-carboxylate, 3.27  
Scheme 3-7: Attempted methods for the production of a tetrazolyl 
piperidine. 
156 
 
Method A:35 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.26, (135 mg, 0.64 mmol. 1.0 
equiv), NaN3 (62.6 mg, 0.96 mmol, 1.5 equiv), and DMF (1.0 mL) were added to a flame 
dried flask under argon. To the flask was added iodide (I2, 29.0 mg, 0.115 mmol, 0.18 
equiv). The reaction was heated to 120°C and stirred overnight. Upon consumption of 
starting material, the reaction was diluted in ethyl acetate and 4 M HCl. The aqueous 
layer was separated and extracted twice with ethyl acetate. The combined organic layers 
were washed twice with each saturated aqueous Na2S2O3 and water. NMR of the crude 
reaction mixture showed formation of product with remaining starting material. Purification 
of product was attempting using flash column chromatography (silica, hexanes:ethyl 
acetate gradient), but no separation was achieved. 
 
Method B:36 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.26,  (100.0 mg, 0.47 mmol, 1.0 
equiv), and NaN3 (30.0 mg, 0.47 mmol, 1.0 equiv) were added to a flame dried flask with 
DMF (1.0 mL). This flask was purged with argon and allowed to stir at room temperature 
for 10 minutes. To the flask was added ZnCl2 (0.67 mL of 0.7M solution in THF, 0.47 
mmol, 1.0 equiv), and this was allowed to stir an additional 5 minutes at room 
temperature. The reaction was then equipped with a reflux condenser and heated to 
70°C. The reaction was allowed to reflux at 70°C for 4 hours, and the reaction cooled to 
room temperature. The reaction was concentrated, and the crude residue analyzed by 
NMR, which did not show formation of product.  
 
Method C:37 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.26,  (200.0 mg, 0.95 mmol, 1.0 
equiv) and NaN3 (123.57 mg, 1.9 mmol, 2.0 equiv) were added to a flask with a 1:2 mixture 
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IPA:H2O (1.5 mL: 3.0 mL). To the flask was added ZnCl2 (0.67 mL 0.7M Solution in THF, 
0.47 mmol, 0.5 equiv). The reaction was heated to reflux (80°C), and stirred for 16 hours, 
after which it was cooled to room temperature. To the reaction was added 4 N HCl (0.5 
mL) and ethyl acetate (3 mL), and the reaction was stirred until all the solids were 
dissolved, adding more ethyl acetate if necessary. The layers were separated, and the 
aqueous layer was extracted twice with ethyl acetate. The combined organic layers were 
dried over Na2SO4, filtered and rotovapped. NMR did not confirm formation of product.  
Method D:38 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.28,  (200.0 mg, 0.95 mmol, 1.0 
equiv), NaN3 (185.3 mg, 2.85 mmol, 3.0 equiv), and TEA·HCl (196.15 mg, 1.425 mmol, 
1.5 equiv) were all combined with NMP (7.6 mL) and stirred for 2 minutes at room 
temperature. The flask was equipped with a reflux condenser, heated to 140°C, and 
refluxed for 6 hours. The reaction was monitored by TLC, and when reaction slowed or 
stopped it was cooled to room temperature. The reaction was diluted with water before 
adjusting the pH to 4 with 1 N HCl. The aqueous mixture was extracted three times with 
ethyl acetate. The combined organic layers were washed with NH4Cl and brine, dried over 
MgSO4, filtered and rotovapped. NMR showed a mixture of product and starting material, 
but purification via flash column chromatography was not successful.  
 
Method E:39 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.26, (105.14 mg, 0.5 mmol, 1.0 
equiv) and DMF (2.5 mL) were added to a flame dried flask under argon. To the flask was 
added NaN3 (97.515 mg, 1.5 mmol, 3.0 equiv); this was allowed to stir for 2 minutes. The 
reaction was then heated to 100°C and allowed to stir for 48 hours, checking reaction 
progression by TLC. The reaction was then cooled to room temperature, diluted with 50 
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mL ethyl acetate, and washed with brine three times. The combined organic layers were 
dried over Na2SO4, filtered, and rotovapped. Crude NMR showed formation of product. 
Purification via flash column chromatography (DCM:MeOH gradient on silica) was not 
able to separate the starting material from the product.  
 
Method F:7 Tert-butyl 3-cyanopiperidine-1-carboxylate, 3.26,  (200.0 mg, 0.95 mmol, 1.0 
equiv), and Bu2SnO (34.9 mg, 0.14 mmol, 0.15 equiv) were added to a flame dried flask 
under argon. To these reagents was added toluene (1.9 mL), and TMS·N3 (0.25 mL, 
218.9 mg, 1.9 mmol, 2.0 equiv) at room temperature. The reaction was then heated to 
95°C overnight (15 hours). Up to 4 more equivalents of TMS·N3 was added, and the 
reaction was stirred for another 6 hours at 95°C. When starting material was consumed, 
the reaction was allowed to cool to room temperature before being rotovapped to dryness. 
The product should precipitate when the residue is triturated with cold hexanes. NMR 
analysis of the resulting precipitate did not confirm product formation. 
 
i. Radiochemistry methods 
  Unless otherwise stated, reagents and solvents were commercially available and 
used without further purification: sodium chloride, 0.9% USP, and sterile water for 
injection, USP, were purchased from Hospira; ethanol was purchased from American 
Regent; HPLC grade acetonitrile was purchased from Fisher Scientific. Other synthesis 
components were obtained as follows: sterile filters were obtained from Millipore; sterile 
product vials were purchased from Hollister-Stier; C18-light Sep-Paks were purchased 
from Waters Corporation. C18 Sep-Paks were flushed with 10 mL of ethanol followed by 
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10 mL of sterile water prior to use. Analytical HPLC was performed using a Shimadzu LC-
2010A HT system equipped with a Bioscan B-FC-1000 radiation detector and either a UV 
detector ([11C]3.17 and [11C]3.31) or CDD-10Avp conductivity detector with temperature-
controlled cell ([11C]3.18). 
 
Radiosynthesis of [11C]3.17 
Carbon-11 was produced via the 14N(p,α)11C nuclear reaction using a GE PETTrace 
cyclotron (40 μA, 30 min beam provided ~3 Ci of carbon-11 as [11C]CO2). [11C]CO2 was 
transferred to a TracerLab FXC-Pro automated radiochemistry synthesis module and 
converted to [11C]CH3OTf via [11C]CH3I (~400 or 850 mCi, based on a 15 or 30 minute 
beam time) as previously described.40 [11C]CH3OTf was bubbled through the reaction 
charged with a solution of nipecotate precursor 3.19(1 mg in 0.1 mL DMF) for 3 min at 
room temperature. The reaction mixture diluted with semi-preparative HPLC solvent (0.5 
mL) and purified by semi-preparative HPLC (column: Phenomenex Luna C18 (2), 250 
mm x 10 mm; mobile phase: 20 mM NH4OAc in 10% EtOH, flow rate: 4 mL/min, UV: 220 
nm). The product was collected (retention time ~18-19 min, Figure 3-15) and, given the 
injectable mobile phase, the dose was passed directly through a 0.22 μm sterile filter into 
a sterile dose vial to give 52 ± 12 mCi (1924 ± 444 MBq) of [11C]3.17, 2% non-corrected 
RCY based upon [11C]CO2, 100% radiochemical purity (RCP) (column: Phenomenex 
Omega Polar RP; mobile phase: Gradient (0-50%) MeCN in water + 0.5% TFA, flow rate 
= 1.5 mL/min, UV: 220 nm; figure 3-16), high specific activity (>2500 Ci/mmol), and pH = 
5.5, n = 2. 
 
160 
 
 
 
 
 
 
Figure 3-15 : Representative semi-preparative HPLC trace from preparation of [11C]3.17. 
“Cut peak” depicts volume collected for dose. 
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Figure 3-16: Representative Quality Control HPLC trace of prepared dose of [11C]3.17. 
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Figure 3-17: Representative coinjection HPLC trace of prepared dose of [11C]3.17 with 
standard ester. 
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Radiosynthesis of [11C]3.18 
Ester [11C]3.17 was prepared as described above. After the methylation, the reaction 
vessel was heated to 100°C and 5 M LiOH (0.5 mL) was added. The reaction was stirred 
for 5 min to generate [11C]3.18, cooled to 40°C and diluted with semi-preparative HPLC 
solvent (0.5 mL). The reaction mixture was purified by semi-preparative HPLC (column: 
Gemini-NX C18, 250 mm x 10 mm; mobile phase 20 mM NH4OAc in 5% EtOH, flow rate 
= 2 mL/min for 5 min and then then 1 mL/min, UV: 220 nm). The product was collected 
(retention time ~7-8 min, Figure 3-18) and, given the injectable mobile phase, the dose 
was passed directly through a 0.22 μm sterile filter into a sterile dose vial to give 113± 17 
mCi (4181± 629 MBq) of [11C]3.18, 4% non-corrected RCY based upon [11C]CO2, >98% 
RCP (column: Phenomenex IP-Pak Cation M/D 150 x 3.9 mm; mobile phase: 5 mM HCl, 
flow rate = 2.0 mL/min, UV: 220 nm + CDD electrochemical detector; Figure 3-19), high 
specific activity (>2500 Ci/mmol), pH = 5.5, n = 2. 
Figure 3-18: Representative semi-preparative HPLC trace from preparation of [11C]3.18. 
“Cut peak” depicts volume collected for dose. 
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Figure 3-19: Representative quality control HPLC trace of prepared dose [11C]3.18 This molecule, lacking 
appreciable UV detection, was monitored by a Shimadzu CDD-10Avp. 
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Radiosynthesis of [11C]3.31 
Carbon-11 was produced via the 14N(p,α)11C nuclear reaction using a GE PETTrace 
cyclotron (40 μA, 30 min beam provided ~3 Ci of carbon-11 as [11C]CO2). [11C]CO2 was 
transferred to a TracerLab FXC-Pro automated radiochemistry synthesis module and 
converted to [11C]CH3OTf via [11C]CH3I (~400 or 850 mCi, based on a 15 or 30 minute 
beam time) as previously described.40 [11C]CH3OTf was bubbled through the reaction 
charged with a solution of 3-(1,3-Thiazol-2-yl)piperidine precursor 3.30 (0.8 mg in 0.2 mL 
Figure 3-20: Representative coinjection HPLC trace of prepared dose of [11C]3.18 with reference 
standard acid. This molecule, lacking appreciable UV detection, was monitored by a Shimadzu CDD-
10Avp. 
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DMF) for 3 min at room temperature. The reaction mixture diluted with semi-preparative 
HPLC solvent (0.5 mL) and purified by semi-preparative HPLC (column: Gemini NX, 250 
mm x 10 mm; mobile phase: 30% MeCN, 50mM NH4OAc, pH 10 (adjusted with NH4OH), 
flow rate: 4 mL/min, UV: 220 nm). The product was collected (retention time ~8-9 min, 
Figure 3-21) and diluted in 50 mL milliQ water. The diluted product was then trapped on 
a 1cc Vac C18 cartridge. The cartridge was rinsed with an additional 6 mL of MilliQ water 
before the product was eluted with 0.5 mL ethanol and 4.5 mL saline solution. The dose 
was then passed through a 0.22 μm sterile filter into a sterile dose vial to give131±62 mCi 
(4900±2300 MBq) of [11C]3.31, 15% non-corrected RCY based upon [11C]CO2, 100% 
radiochemical purity (RCP) (column: Kinetix Evo 250 x 4.6 mm; mobile phase: 20% 
MeCN, 50 mM NH4HCO3, pH 10 (adjusted with NH4OH), flow rate = 2.0 mL/min, UV: 254 
nm; figure 3-22), high specific activity (>2500 Ci/mmol), and pH = 6.0, n = 6. 
 
Figure 3-21: Representative semi-preparative HPLC trace from preparation 
of [11C]3.31. “Cut peak” depicts volume collected for dose. 
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Figure 3-22: Representative Quality Control HPLC trace of prepared dose of [11C]3.31. 
Figure 3-23: Representative coinjection HPLC trace of prepared dose of [11C]3.31 with 3.31 reference standard. 
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ii. In vivo Methods 
General Considerations 
Images were reconstructed using 3D maximum a priori (3D MAP) program. All animal 
PET imaging experiments were conducted under the supervision of the University of 
Michigan and its Institutional Animal Care and Use Committee (IACUC) according to 
approved protocols and all applicable federal, state, local and institutional laws or 
guidelines governing animal research. Imaging studies were conducted using a Concorde 
Microsystems P4 PET scanner as described below. 
 
Rodents  
Anesthesia was induced in healthy, female Sprague-Dawley rats (279-369 g) using 
isoflurane/O2, and anesthesia was maintained with 2-4% isoflurane/O2 throughout the 
imaging studies. Body temperature was maintained by a heating pad. Following a 
transmission scan for attenuation correction, the animals were injected (i.v. via 
intravenous tail vein) with the radiotracer as a bolus over 1 min (Table 3-6), and the brain 
imaged for 90 minutes. 
 
Primates (NHP) 
Imaging studies were performed in a young, mature female rhesus monkey. The animal 
was anesthetized in the home cage with ketamine (acid and ester compounds) or telazol 
(thiazole compound) and transported to the PET imaging suite. The monkey was 
intubated for mechanical ventilation, and anesthesia was continued with isoflurane. 
Anesthesia was maintained throughout the duration of the PET scan. A venous catheter 
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was inserted into one hind limb and the monkey was placed on the PET gantry with its 
head secured to prevent motion artifacts. Following a transmission scan, radiotracers 
were administered in a bolus dose over 1 minute (Table 3-6). Emission data were 
collected beginning with the injection and continued for 90 minutes.  
 
Image Analysis 
Upon completion of the PET scans, emission data were corrected for decay, dead time 
and random coincidences before reconstruction using an iterative ordered subset 
expectation maximization–maximum a posteriori (MAP) method to generate 
reconstructed images. Frames were summed, smoothed, and regions-of-interest (ROIs) 
were defined manually for the whole brain over multiple adjacent frames in the sagittal 
projection. The volumetric ROIs were then applied to the full dynamic data sets to obtain 
regional tissue time-radioactivity data. Standardized uptake values (SUVs) were 
calculated for each region of interest. 
 
 
 
 
Table 3-6: Compiled in vivo evaluation data. 
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Chapter 4  
[18F]Fludeoxyglucose (FDG): Use and Production 
A. Introduction 
PET radiochemistry exists at the intersection between organic chemistry and nuclear 
medicine. The short-lived radionuclides used make the synthesis of PET 
radiopharmaceuticals for clinical care quite unique. They are made on demand, and 
frequently used within minutes to a few hours after end-of-synthesis. Since PET 
radiopharmaceuticals are used in clinical care, they need to be manufactured according 
to current Good Manufacturing Practice (cGMP), and there are strict quality control testing 
requirements before a dose can be released to the clinic. In addition to understanding the 
synthesis and pre-clinical evaluation of new PET radiopharmaceuticals as outlined in the 
earlier Chapters of this thesis, appreciation of how PET radiopharmaceuticals are 
synthesized for clinical use has also been an essential part of my graduate student 
training. Thus, during my tenure as a graduate student, I was trained in the production of 
[18F]FDG for clinical use at the University of Michigan hospital. As FDG is an important 
PET tracer for molecular imaging, this chapter describes the history of FDG, updates to 
the production of FDG that I was involved in and uses of the radiotracer.  
[18F]FDG is by far the most produced and used radiotracer. This fluorinated glucose 
derivative is a non-specific trapped metabolite that images increase (or decrease) of 
metabolic activity. First evaluated in humans at Brookhaven National Laboratory in 
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1976,1,2 FDG was the first commonly used PET radiopharmaceutical, and it is still widely 
used to this day. 
i. Development and use of [18F]FDG as a radiotracer  
  The development of [18F]FDG began in 1969 with the synthesis of the non-
radioactive isotopolog 2-deoxy-2-fluoro-D-glucose by Pacák and coworkers.3 Almost 10 
years later, a collaboration between researchers at Brookhaven National Laboratory 
(BNL) and the University of Pennsylvania culminated in the first reported synthesis of 
[18F]fludeoxyglucose, known today as [18F]FDG.1 Using nucleophilic [18F]F2 gas 
(produced by the 20Ne(d,α)18F nuclear reaction), researchers were able to fluorinate 3,4,6-
tri-O-acetyl-D-glucal (Scheme 4-1). Interestingly, Ido and coworkers reported a dual 
radiofluorination across the double bond in the glucal precursor. It could be argued today 
that the intermediates formed were only radiofluorinated at one position due to our 
knowledge that [18F]F2 gas is a low specific activity [18F]fluorine source  comprising of 18F-
19F, Figure 4-1. This produced a mixture of two isomers 4.2 and 4.3, which were separated 
by gas-liquid partition chromatography (GLPC); hydrolysis with HCl, followed by three 
column purifications (ion retardation for neutralization, alumina column for excess fluoride 
removal, and another ion retardation column), gave [18F]FDG, [18F]4.4, in 8% 
Scheme 4-1: First synthesis of [18F]FDG using [18F]F2 gas. 
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radiochemical yield. While this yield can be seen as impressive for a novel radiotracer 
(some novel tracers are produced in 1-3% radiochemical yields), today [18F]FDG is 
regularly produced in yields in excess of 70% using nucleophilic [18F]fluoride in automated 
synthesis modules. The nucleophilic fluorination reaction (Scheme 4-2) uses mannose 
triflate precursor 4.9, which is radiofluorinated in a nucleophilic substitution reaction with 
[18F]KF prepared by azeotropic drying of cyclotron produced [18F]fluoride in the presence 
of the crown ether Kryptofix-2.2.2 (K2.2.2), potassium carbonate (K2CO3), water and 
acetonitrile. The resultant 2-[18F]-fluo-1,3,4,6-tetra-O-acetyl D-glucose ([18F]FTAG, 4.10) 
is then trapped on a tC18 cartridge and converted to [18F]FDG through the alkaline 
hydrolysis of the acetyl protecting groups with 2 N NaOH. It is neutralized with a citrate 
Figure 4-1: Alternative by-products that may 
have been formed in Scheme 4-1. 
Scheme 4-2: Synthesis of [18F]FDG as it takes place in 
the GE FASTLab DUO Citrate cassette. 
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buffer before [18F]FDG is eluted off the tC18 cartridge using water. For further purification 
the neutralized [18F]FDG solution is passed through a tC18 plus cartridge for the removal 
Figure 4-2: Clinical-PET utilization at the University of Michigan PET Center (*estimated). 
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of non-polar by-products as well was partially hydrolyzed intermediates. Final purification 
is through an alumina cartridge to remove any residual unreacted [18F]fluoride ions.   
  The first in human scan of [18F]FDG took place in August of 1976 at the Hospital 
of the University of Pennsylvania in collaborating with scientists at BNL,4 and its use 
increased with the advancement of the technology of cyclotrons for production of 
radionuclides, as well as the development of more sophisticated PET imaging scanners 
(see Chapter 1). 1994 saw approval of FDG by the US FDA,5 and the radiotracer was 
indicated for use in oncology,6–8 neurology,9,10 and cardiology.11–13 Following approval, 
reimbursement by the Centers for Medicare and Medicaid has led to steady growth in 
FDG PET, and the tracer continues to be used almost 25 years later. Reflecting this, an 
estimated 1.945 million FDG PET (and PET/CT) studies occurred in the United States in 
2017, an increase of 15% from 2015, and makes FDG PET a multimillion dollar market in 
its own right.14 The last 20 years have shown a steady increase in demand for clinical 
PET scans within Michigan Medicine (Figure 4-2). In 1997, three years after FDA approval 
of FDG, 151 patients received clinical PET scans (0.6 per day over 250 scanning days), 
compared to 6,777 in 2017 (26.79 per day over 253 scanning days), a 45-fold increase in 
scans each year over 20 years. In addition, Michigan Medicine has received a number of 
inquiries about the possibility of our center supplying FDG to various outside entities. 
 
ii. Clinical Utility and Importance of [18F]FDG 
As a fluorinated glucose analog, [18F]FDG is able to take advantage of the 
increased glucose uptake of tumors. Similar to glucose, [18F]FDG is taken up by cells 
through the cell membrane assisted by glucose transporter 1 (GLUT1), and then is 
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phosphorylated by hexokinase yielding FDG-6-phosphate (FDG-6-P). At this point, the 
FDG-6-phosphate is now trapped inside the cell: once phosphorylated it cannot leave the 
cell, and it cannot be further metabolized as the 2’-hydroxyl group of glucose has been 
replaced with [18F]fluorine and prevents FDG from entering the glycolysis pathway (Figure 
4-3). In healthy cells, FDG-6-P can be dephosphorylated by the enzyme glucose-6-
phosphatase to regenerate FDG. Levels of glucose-6-phosphatase are reduced in cancer 
cells resulting in preferential accumulation of [18F]FDG-6-phosphate in tumors.15 Notably, 
accumulation of [18F]FDG does not happen in tumors alone, and can also be found in 
sites of inflammation or infection.16 
 Not long after [18F]FDG was approved by the FDA in 1994, it found utility in the 
imaging of multiple cancer types; it is instrumental in the differentiation between benign 
and malignant lesions, determining the stage of malignant lesions, as well as detecting 
any recurrence and monitoring treatment progression.8 A comprehensive discussion of 
the use of FDG in tumor imaging is beyond the scope of this thesis, but its use can be 
Figure 4-3: Biology of FDG and glucose uptake into cells. 
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highlighted through several representative examples. In 2016, Avril and colleagues 
discussed the usefulness of [18F]FDG in monitoring treatment response of breast cancer 
in a review covering multiple clinical studies.6 Two notable studies evaluated the 
usefulness in HER2 positive breast cancer as well as triple negative breast cancer 
(TNBC), the two most aggressive subtypes. Groheux and coworkers demonstrated that 
in HER2 positive breast cancer patients, [18F]FDG imaging was a good early indicator of 
whether the patients would respond positively to neoadjuvant therapy or if they were at 
high risk for residual tumors.17  This can be seen in comparing Figure  4-4 to Figure 4-5; 
figure 4-4 shows a patient who responded well to two cycles of therapy (SUV A and B, 
16.1, compared with SUV C and D, 1.6), while figure 4-5 shows a patient with a small 
increase in SUV (SUV A and B, 11.1, compared with SUV C and D, 12.7). After this 
treatment monitoring scan, a new therapy was initiated for the patient in figure 4-5.  
Although cancer-specific PET agents are continually being developed and moved to the 
clinic (for example [68Ga]PSMA and [11C]choline for the imaging of prostate cancer18), 
[18F]FDG continues to be the most employed radiotracer for oncology PET imaging to 
date. 
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Figure 4-4: :(A and B) Baseline [18F]FDG PET (A) and fused [18F]FDG PET/CT 
(B). (C and D) After 2 cycles of neoadjuvant therapy, significant reduction in 
tumor [18F]FDG uptake, 10-fold decrease in SUV was seen in [18F]FDG PET 
(C) and fused [18F]FDG PET/CT (D). This  research was originally published in 
JNM. Avril, S. et al. [18F]FDG PET/CT for Monitoring of Treatment Response in 
Breast Cancer. J Nucl Med. 2016;57:34S-39S. © SNMMI. 
Figure 4-5:(A and B) Baseline [18F]FDG PET (A) and fused [18F]FDG PET/CT (B). 
(C and D) After 2 cycles of neoadjuvant therapy, with little change in SUV, was seen 
on [18F]FDG PET (C) and fused [18F]FDG PET/CT (D). This research was originally 
published in JNM. Avril, S. et al. [18F]FDG PET/CT for Monitoring of Treatment 
Response in Breast Cancer. J Nucl Med. 2016;57:34S-39S. © SNMMI 
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 Use of [18F]FDG for the imaging of cardiac sarcoidosis takes advantage of the 
tendency for the tracer to accumulate in inflammatory tissue. Cardiac sarcoidosis is the 
accumulation of inflammatory cells into non-caseating granulomas on the heart.12 
Currently immunosuppressants are used for the treatment of cardiac sarcoidosis, 
although data to support this is limited. Ahmadian and coworkers sought to evaluate the 
effectiveness of this treatment via [18F]FDG PET imaging of patients prior to and after 
immunosuppressant therapy.11 Although a decrease in [18F]FDG uptake was observed 
visually in patients post-therapy, more studies are necessary to develop a quantitative 
method for interpretation of these types of scans. 
 While [18F]FDG works as a positive indicator for cancer, in neurodegeneration a 
decrease in [18F]FDG accumulation indicates an area of lower brain activity. Alzheimer’s 
disease (AD), accounts for 50-60% of all dementia cases, and is the fourth leading cause 
Figure 4-6: Example images of how FDG can be used to stratify different types of dementia. Uptake 
between Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) differs especially in the lateral 
cortices (arrows). Other dementia types represented are Lewy body variant of Alzheimer’s disease (LBVAD), 
and pure diffuse Lewy body disease (DLBD) This research first published in Minoshima, S.; Foster, N. L.; 
Sima, A. A. F.; Frey, K. A.; Albin, R. L.; Kuhl, D. E. Ann. Neurol. 2001, 50 (3), 358–365. 
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of death in individuals over 65 years.19 Minoshima and coworkers found in 2001, that it is 
possible to differentiate between AD and Dementia with Lewy Bodies (DLB) using FDG; 
an important characterization, as the dementias are caused by different protein 
aggregates, and therefore require different treatment, Figure 4-6.20  
Outside of dementia, [18F]FDG is also used for imaging of patients with partial 
epilepsy.21 Temporal lobe epilepsy (TLE) is the most common of the types of partial 
epilepsy in adults; it is often medically intractable, leaving the patients with only the option 
of brain surgery. [18F]FDG PET imaging has assisted in pre-operative evaluations where 
magnetic resonance (MR) is not successful in identifying the epileptic focus.22  
  
iii. cGMP methods & Regulation of FDG and other PET drugs 
  [18F]FDG was developed in an academic setting as a research tool. As it 
transitioned into clinical use, it was manufactured according to the US Pharmacopeia and 
regulated by State Boards of Pharmacy but was outside the jurisdiction of the FDA. When 
[18F]FDG was found to have widespread clinical utility, and the use of the radiotracer in a 
clinical setting increased drastically, the FDA determined that it was necessary to regulate 
the manufacturing of [18F]FDG, as well as other radiopharmaceuticals, in a way similar to 
traditional drug manufacturing. In 1995, the first rule for current Good Manufacturing 
Practices (cGMP) in PET drugs was proposed.23 As stated earlier, radiopharmaceuticals 
are unique among pharmaceuticals in that they contain short-lived radioisotopes, making 
the manufacturing, and regulation of them drastically different in some respects to 
traditional therapeutic pharmaceuticals. These short-lived radioisotopes necessitate the 
daily synthesis of the tracers, while limiting the shelf life or time window that they can be 
used. These obvious differences made it incredibly difficult for PET centers to adhere to 
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the same regulations in place at traditional pharmaceutical manufacturers, such as pre-
release sterility testing.24 The FDA regulation of PET drugs was in limbo until 1997, when 
a Congress initiated bill, the Food and Drug Modernization Act (FDAMA), included a 
provision directing the FDA to create a new pathway for the approval of PET drugs as 
well as cGMP for the production thereof “[in] order to take account of the special 
characteristics of compounded positron emission tomography drugs and the special 
techniques and processes required to produce these drugs.”25 Three years after this bill 
was signed into law by President Bill Clinton, the FDA published its own review of the 
PET literature in the Federal Register.26 This document allowed PET drug manufacturers 
to apply for an ANDA by referencing the Federal Register notice for safety and 
effectiveness of the produced drugs, instead of applying for a New Drug Application 
(NDA), which is lengthier, requires extensive clinical trial data and is subject to high filing 
fees.27 This is especially of interest in academic hospital settings, such as at the University 
of Michigan. Early site-specific NDA approvals served as a precedent for other sites of 
PET drug manufacturing; by 2011, not just [18F]FDG, but the use of [18F]NaF (used for 
bone scans), and [13N]ammonia (used in cardiac imaging) were approved. 
 Current good manufacturing practice guidelines are useful for the production of 
radiopharmaceuticals for standard of care, ensuring safety through the testing of each 
human dose for purity, strength, identity, and quality. cGMP guidelines (coupled with 
NDAs or ANDAs) are heavily responsible for the safety and regulation of PET drug 
manufacturing in the United States today. These are culminated in title 21 of the Code of 
Federal Regulations part 212 (21 CFR 212).27 For PET drugs that are used for clinical 
research purposes (i.e. they are not used for standard of care and insurance companies 
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are not charged), manufacturers are required to have FDA approval through an 
investigational new drug (IND) application, or have local Radioactive Drug Research 
Committee Approval if the studies are for basic science purposes. 
In the United States, Federal agencies besides the FDA involved in regulating PET 
drugs include the Nuclear Regulatory Commission (NRC), while local regulatory bodies 
such as Radiation Safety Devices (RSS) and Occupational Safety and Environmental 
Health (OSEH) provide regulatory oversight at the University of Michigan.   
 
B. Results and Conclusions 
i. Current Methods for FDG production 
Due to the widespread use and need for production of [18F]FDG, multiple companies 
offer synthesis modules and reagent kits or cassettes so that FDG manufacturers and 
researchers across the globe are able to produce [18F]FDG according to cGMP, as well 
as other pertinent regulatory guidelines. Recently there has been an update in the 
technology for the production of [18F]FDG, with the introduction of the General Electric 
(GE) FASTLab 2, Figure 4-7. This new technology enables PET manufacturing sites to 
purchase assorted cassettes to produce different radiotracers, including FDG. 
Specifically, the [18F]FDG Duo Citrate cartridges, Figure 4-8, allow for the synthesis of 
two doses per cassette, using only one synthesis modules and therefore one hot-cell 
(lead-lined box where automated synthesis modules are housed). Where before labs like 
the facility at U of M would use two hot-cells and two synthesis modules each day, only 
one is now necessary. 
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Before the implementation of the FASTLab modules, each of two mini-cells (lead lined 
cells, smaller than the other “hot-cells”) housed a TracerLab MX-FDG synthesis module. 
Reagent kits were purchased from either ABX or Rotem companies that were compatible 
with these synthesis modules. Each day, both modules would be used, one for the 
morning dose, and one for the afternoon dose; this in turn irradiated both of these mini-
cells. Now, with the implementation of the FASTLab 2 synthesis module using the FDG 
Duo Citrate cassette, it is possible to produce both the morning and the afternoon doses 
from a single module and mini-cell. The introduction of the FASTLab 2 synthesis modules 
has simplified the daily routine of [18F]FDG production chemists and increased the yields 
produced, allowing the Michigan Medicine Radiology department to complete more scans 
and extend their scanning hours, better serving patient need.  
 
Figure 4-7: FASTLab 2 synthesis module. Image courtesy of GE. 
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ii. Production of [18F]FDG using the FASTLab 2 Synthesis Module 
 The [18F]FDG synthesis begins with the cleaning of the mini-cell. This includes 
removal of the previously used cassette and disposal of it in an appropriate radioactive 
waste container, as well as emptying of the main waste container and removal of old 
[18O]-water from the cyclotron target. When the cassette and waste has been removed, 
the inside of the mini-cell is cleaned with non-shedding wipes and sterile, 70% isopropyl 
alcohol (IPA); this is done once per day, before the first synthesis in a given mini-cell. For 
each synthesis of [18F]FDG there is a production chemist, and a quality control (QC) 
chemist. The production chemist begins by starting the FASTLab automated synthesis 
program and assembling a new cassette in a Class 5 laminar flow hood which has also 
been cleaned with sterile 70% IPA. Assembly of the FASTLab cassettes is simple and 
straightforward; it requires the attachment of a sterile filter to the air inlet and visual 
inspection of each of the pre-assembled reagent vials, cartridges and syringes. The 
cassette can then be installed on the FASTLab module, two product transfer lines are 
attached to the cassette and fed through to the product collection area, and the program 
Figure 4-8 FASTLab Duo Citrate cassette for [18F]FDG synthesis. Image courtesy of GE. 
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can be directed to initiate tests on the cassette. These tests are to ensure proper 
activation of syringes, and integrity of the cassette. 
While the tests are running, the production chemist again cleans the laminar flow hood 
with sterile 70% IPA and assembles the intermediate dose vial. This assembly includes 
a 30 mL sterile vial connected to a 10 mL sterile vent vial and a 4-way stopcock. To the 
30 mL vial is added sterile water and sodium phosphate buffer. These are to ensure that 
each dose has the appropriate osmolality (270-330 mOsmol/kg, as indicated by the 
ANDA). The 10 mL sterile vent vial is a vial connected to an extension line fitted with a 
0.20 μm filter to ensure that the intermediate vial can vent without chance of overspill of 
radioactive product. The 4-way stopcock is how the whole intermediate/vent assembly is 
attached to the cassette via a 21” product transfer line and to the dispensing cassette 
used for final purification and dose separation. The 30 mL vial is placed into a lead “pig” 
with the extension lines and vent vial on the outside; the stopcock is connected to the 
appropriate product transfer line (depending on first or second synthesis). (A lead “pig” is 
a lead vial holder which is used for shielding radioactive samples when they must be 
transported).  
During this time the QC chemist initiates irradiation of the cyclotron target for 
production of [18F]fluoride (starting the beam). The time and current of this beam varies 
based on factors including how much activity the cyclotron has been producing, or how 
much activity the PET imaging suite has indicated they need. The beam current is typically 
between 40-50 µA, and the beam is typically 20-30 minutes long. While the beam is 
running, and the production chemist is preparing the synthesis module, the QC chemist 
will start the gas chromatography so that reference standards for system suitability can 
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be run prior to the dose sample. They will also set up the rest of the necessary QC tests. 
It is also necessary to strip the Manuela (a dispensing hot-cell which houses the drug 
dispensing module) and clean it with sterile 70% IPA. The production chemist will, for the 
third and final time, clean the laminar flow hood with sterile 70% IPA, and assemble the 
dispensing cassette. Assembly of the dispensing cassette includes ensuring all 
connections on the pre-assembled cassette are tight and inserting vent needles into each 
of four vials before attaching them to the cassette using the included needles. These vials, 
from left to right, are the waste vial, dose vial (30 mL), sterility test vial (10 mL) and the 
QC vial (2 mL). This assembly must be aseptic and sterile; to monitor this two agar touch 
plates are placed in the hood and the chemist will place each finger on the left and right 
touch plates. Monitoring the left and right hand separately can assist in troubleshooting a 
method if there is consistent contamination on only a single hand. The assembled 
dispensing cassette can then be mounted onto the dispensing module (Figure 4-9) in the 
clean Manuela following the prompts on the dispensing program.  
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  The sterile dispensing cassette aliquots a small volume (~0.5 mL) for immediate 
QC testing and 2.5 mL for sterility testing to be completed later. Lastly, the remaining 
volume that is the patient dose (24-26.0 mL) is dispensed into a sterile dose vial. The 
sterile filter on the dispensing cassette is the first QC test; ensuring that the filter is intact 
is of the utmost importance in producing a safe and sterile dose. When dispensing is 
finished, the QC vial is given to the QC chemist so that they may begin testing. The sterility 
vial is placed in a lead pig so that sterility can be completed when the dose has been 
allowed to decay. The dose vial is weighed inside the Manuela using a simple balance, 
and the dose activity measurement is taken in the dose calibrator in the hot cell. The 
sterile filter that the dose was dispensed through is tested by a bubble point test. This 
requires the filter to be connected to a gas line, then to a needle, and the needle placed 
in water. Nitrogen is then pushed over the filter until a steady stream of bubbles appears. 
For the filter to pass, it is necessary to hold to a pressure above 30 psi.  
 
iii. Quality Control of [18F]FDG 
QC testing takes about 30 minutes. Prior to the synthesis of FDG, when the cyclotron 
beam is running, the QC chemist assembles the tests they will need in a lead shielded 
work area as described above. This includes pH paper, a Kryptofix test strip, TLC plate 
spotted with FDG standard compound, a labeled vial for GC sample, a labeled vial for 
half-life testing, and a plastic tube containing 3.9 mL sterile water for both TLC and 
endotoxin testing. The QC chemist takes up the dose (~0.4 mL) and deposits 0.1 mL into 
the plastic tube (creating a dilution of 1:40), 0.1 mL into the GC vial, 0.1 mL into the half-
life vial, adds one drop to the Kryptofix test strip, and three drops across the pH test strip. 
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Then the GC and half-life tests are started, followed closely by the endotoxin test, as 
these take the longest amount of time. The diluted sample is spotted onto the TLC plate, 
and the TLC plate set up to run. Then sterile water and Kryptofix standard are spotted on 
to the Kryptofix test strip below the dose spot. At this point all tests should be running, 
and the chemist can record them each as they are completed (pH and Kryptofix being the 
first as they have immediate readouts). Each QC chemist has their own order of 
operations to ensure that each test is done and in a timely fashion. 
Testing of FDG doses is conducted according to the guidelines outlined in 
21CFR212. Daily QC testing consists of visual inspection (doses must be clear, colorless 
and free of particulates), pH (pH paper, must be 4.5 – 7.5), residual K2.2.2 (spot test, must 
be ≤50 µg/mL), radiochemical purity (TLC, must be >90%), radiochemical identity (TLC, 
RF of radiotracer and reference standard match), radionuclidic identity (half-life must be 
105 – 115 min), residual solvent analysis (GC, <410 ppm MeCN; <5000 ppm EtOH), 
sterile filter integrity (bubble point, ≥50 psi), bacterial endotoxin analysis (Endosafe, ≤175 
endotoxin units / dose), and sterility per USP Chapter 71 (fluid thioglycolate media and 
soybean casein digest agar media tubes, no evidence of microbial growth found). 
Additional periodic QC testing including radionuclidic purity (MCA, ≥99.5%) and 
osmolality (osmometer, 270-330 mOsmol/kg) was conducted quarterly. All doses of FDG 
discussed in this article met or exceeded all of these quality control release criteria and 
were stable for 24 h after end-of-synthesis (EOS). 
Once all QC testing is completed and all tests on a given batch of FDG passed, 
the dose vial is placed into a lead pig, which is placed into a second pig as part of a 
Department of Transportation (DoT) certified radioactivity transportation box. Before the 
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dose can be delivered to the hospital (via a route approved by RSS) the dolly and box 
containing the dose must be monitored and swiped to ensure the absence of any 
radioactive contamination on the surface. These numbers are documented on a transport 
record that is signed by the nuclear pharmacist who receives the dose in the hospital so 
there are records of how much activity is delivered. 
 For the second dose of [18F]FDG, typically the afternoon dose, the same procedure 
is followed except for the initial assembly of the FASTLab cassette, instead the production 
chemist is able to follow the prompts on the computer to prepare the synthesis module 
for the second synthesis. A new intermediate and vent vial can be attached to the second 
product transfer line, and the Manuela will be carefully stripped of the previous dispensing 
cassette and cleaned in preparation for the next synthesis. 
 
iv. Updating the [18F]-cyclotron target and FDG Synthesis Modules 
  For the last ten years, the U of M PET center has generated fluorine-18 on a GE 
PETTrace cyclotron equipped with Ag fluorine-18 targets, and manufactured FDG using 
the GE TRACERLabMX-FDG synthesis module. Daily production of [18F]FDG began by 
generating [18F]fluoride with the PETTrace cyclotron via the 18O(p,n)18F reaction.  The 
previously used Ag target was filled with [18O]H2O (~1.6 mL) and bombarded with a 40 
μA proton beam for 22 minutes. This nuclear reaction produced 1011 ± 116 mCi of 
[18F]fluoride. FDG was then prepared by nucleophilic substitution fluorination of mannose 
triflate (4.9), followed by base hydrolysis (Scheme 4-2). Yields of [18F]FDG using this 
method were 527 ± 95 mCi (n = 2137), corresponding to 52% non-corrected 
radiochemical yield. As mentioned earlier, there has been a drastic increase in patients 
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scanned per day at Michigan Medicine (Figure 4-3). Doses of ~500 mCi, twice a day, 
were adequate when scanning up to ~15 or 16 patients per day.  However, the increase 
in daily scans, as well as inquiries about the possibility of our center supplying FDG to a 
number of outside entities dictates a need for higher yielding doses of [18F]FDG. During 
this time of incredible growth, GE released an “end-of-life” announcement for the 
TRACERLabMX-FDG due to obsolete parts. As a result, it was necessary to update to our 
FDG production operation with the replacement of two TRACERLabMX-FDG modules with 
FASTLab 2 synthesis modules. 
Transitioning [18F]FDG synthesis from TRACERLabMX-FDG modules to FASTLab 2 
occurred without incidence. Replacement of both modules was staggered, safeguarding 
clinical production, but was completed within 7 business days. In accordance with FDA 
regulations, the update was documented in the annual report for our ANDA. As mentioned 
above, FASTLab cassettes are available for multiple PET tracers. The FDG DUO Citrate 
cassettes allow manufacture of two batches of FDG within a 26-h period. With the 
installation of two FASTLab 2 modules and choice of DUO cassettes our production 
capacity increased to 200% of our previous levels. Before the installation of the FASTLab 
2 modules, FDG production capacity of our lab doubled from 2 batches of FDG per day 
on 2 x TRACERLabMX-FDG modules. Now it is possible to produce 4 batches of FDG per 
day on 2 x FASTLabs. A combination of the size of the new modules (their size allows 
installation in existing mini-cells), with the availability of the DUO Citrate cassette allowed 
for increase of capacity without the need to install costly new hot-cells in the 
laboratory. Also due to the relatively small size of the modules, it would have been 
possible to install both into a single mini-cell; this would have left one of the mini-cells 
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unoccupied and available for other applications. However, splitting the FASTLabs 
between min-cells allows for uninterrupted [18F]FDG production while maintenance is 
performed on one FASTLab, and also decreases the FDG chemists’ radiation exposure 
as it is possible to give over 24 hours for decay of any residual radionuclides before it is 
necessary to open and clean the mini-cell.  The workflow and inventory management has 
also been simplified by this transition, as all the reagents needed for two FDG production 
runs are contained in a single FASTLab DUO Cassette. Compared to ordering, receiving 
and utilizing separate hardware kits, reagent vials, and other components required for 2 
separate runs a day using the TRACERLabMX-FDG modules, the FASTLab modules and 
cassettes are obviously an upgrade. 
With the new FASTLab modules installed, and an anticipated increase to ~25 
patients scanned with FDG per day at our facility, the beam time was increased to 30 min 
for FDG production. Thus, bombarding the Ag target containing  ~1.6 mL of [18O]H2O with 
a 40 µA proton beam for 30 min produced 1179 ± 106 mCi of [18F]fluoride. FDG was then 
produced using the FASTLab 2 in yields  of 839 ± 77 mCi (n = 383), corresponding to 
71% non-corrected RCY. This observed ~20% increase in yield was an excellent reward 
for the optimized manufacturing process developed for the FASTLab.  
A short 6 months after the installation and validation of the FASTLabs (late 2017), 
the number of patients scanned with FDG per day was again increased; this time to 30 – 
32 per day. One method for producing larger doses of FDG is to increase the cyclotron 
beam time, in turn delivering more radioactivity to the FASTLabs for production of higher 
activity doses of FDG. Due to the complex, and often incredibly full, schedule of the PET 
Center at U of M, running the cyclotron for hours a day for FDG alone is not an option. It 
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was necessary to determine the best way to increase the amount of FDG produced, while 
still maintaining the production of 4 radiotracers for routine clinical use, 35 other 
radiotracers produced for clinical research, as well as basic science research developing 
radiochemistry methodology and novel PET radiotracers. It is also not possible to deliver 
doses more than 750 mCi of FDG, due to the compatibility of the multi-dose Bayer 
Medrad® Intego PET Infusion System (Figure 4-10). Any dose above 700-750 mCi cannot 
be reliably shielded, and proper dose preparation could be compromised (Bayer Medrad 
Intego Brochure, 2017). In short, we needed an efficient way to increase our yields of 
[18F]fluoride from the cyclotron (and the corresponding yields of FDG), without running a 
long beam (≤30 min), such that 2 FDG beams (morning and afternoon) could be efficiently 
slotted in around 10 – 12 other beams that are run on our cyclotron during a typical work 
day. 
Fortunately, in January 2018, a second round of updates occurred at the U of M 
PET Center. The PETTrace cyclotron underwent the manufacturer-recommended ten-
year life extension and refurbishment (TYLER) maintenance. This maintenance overhaul 
updated numerous aspects of the cyclotron, including updating the outdated Ag body 
fluorine-18 targets with new high yield niobium (Nb) body self-shielded fluorine targets. 
These new Nb targets use 2.7 mL of [18O]H2O and can be run on our updated system at 
increased beam currents (up to 85 µA) on a single target, allowing the production of more 
activity in the same amount of time. Self-shielding refers to the tungsten-copper alloy in 
which the target is housed; this alloy is specified to lead to a 10 to 20-fold reduction in 
exposure resulting from the target foil, and 100-fold reduction in exposure due to any 
residual 18F in the target.  
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With the new Nb targets in place, the Center’s goal was to generate ~950 mCi of 
FDG at end of synthesis (EOS). Removal of sterility (2.5 mL) and QC (0.5 mL) samples, 
would provide ~850 mCi in the patient vial to be transported to the PET imaging suite. A 
further 0.5 h can be allotted  for radioactive decay for the time associated with completion 
of QC testing and transporting FDG to the PET suite. This would lead to the delivery of a 
~700 mCi dose, which is compatible with the limits of the Intego PET Infusion system 
(discussed above). As with all new instruments several optimization studies with the 
updated cyclotron were required before a 55 µA proton beam for 22 min was decided 
upon. This generates 1330 ± 153 mCi of [18F]fluoride (n = 235).  These cyclotron beam 
parameters combined with the DUO cassettes on FASTLab 2 results in radiochemical 
yields (RCYs) of 957 ± 102 mCi at EOS, corresponding to 72% non-corrected 
radiochemical yield. Production of this sized dose of FDG twice daily, once at 8:00 am 
Figure 4-10: Bayer Medrad® Intego PET Infusion System. 
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and once at 2:00 pm allows for the scanning of up to 32 patients a day with FDG over 12 
hours on two clinical PET scanners. 
 
C. Experimental Methods 
i. Synthesis of [18F]Fludeoxyglucose ([18F]FDG, FDG) 
Synthesis of FDG was performed on either a GE TRACERLabMX-FDG as previously 
described,28 or GE FASTLab 2 synthesis module as follows: [18F]fluoride (produced on a 
GE PETTrace via the 18O(p,n)18F) was delivered from the cyclotron and trapped on a 
quaternary methylammonium (QMA) cartridge. Potassium carbonate (K2CO3) and  
kryptofix-2.2.2 (K2.2.2) were used to elute the [18F]fluoride from the QMA into the reactor, 
followed by azeotropic drying. A solution of mannose triflate 4.9 in acetonitrile was added 
to the reaction vial and radiofluorination of the mannose triflate precursor was conducted 
at 125 C for 2 min to give [18F]fluoro-1,3,4,6-tetra-O-acetyl-D-glucose  ([18F]FTAG, 4.10, 
Scheme 4-2). The reaction mixture containing 4.10 was diluted with water and passed 
through a C-18 Sep-Pak cartridge, trapping the intermediate 4.10. Base hydrolysis 
occurred on the cartridge at room temperature using 2N NaOH for 3 min to give [18F]FDG. 
The hydrolyzed product was then eluted from the cartridge with citrate buffer, passed 
through a second C-18 Sep-Pak (to remove any un-hydrolyzed [18F]FTAG), followed by 
an alumina-N cartridge (to remove any residual [18F]fluoride ion). The final product was 
then transferred into a sterile intermediate vial pre-charged with water for injection, USP, 
and sodium phosphate buffer for injection, USP. Dispensing of the resulting solution (~28 
mL) took place by passing the solution through a 0.22 m sterile filter, and into patient 
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(~25 mL), quality control (~0.5 mL) and sterility (2.5 mL) vials using an Eckert and Ziegler 
Modular Lab automated dispensing system (Figure 4). 
 
 
ii. Quality Control of [18F]Fludeoxyglucose 
Quality control testing of each FDG doses was conducted according to the guidelines 
outlined in 21CFR212 as described below.  
a. Visual Inspection  
The [18F]FDG dose must be clear, colorless, and free of particulate matter. This must be 
inspected behind proper shielding. A PET L-block barrier system was used.  
b. Radiochemical Identity and Purity  
Radiochemical identity and purity was determined by thin layer chromatography (TLC) 
using silica gel chromatography plates and a Bioscan AR-2000 TLC scanner (Figure 4-
11). The plate was spotted with approximately 10 µg of FDG reference standard solution 
and then spotted with a sample of [18F]FDG dose. The FDG TLC reference standard 
solution was prepared by dissolving 10 mg of 2-fluoro-2-deoxy-d-glucose in a 1:1 mixture 
of MeCN and water (50 µL:50 µL). The developing solution, or mobile phase, contained 
95% acetonitrile and 5% water. The plate was developed in this solvent system in a glass 
Scheme 4-2. Synthesis of FDG 
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TLC jar reserved for FDG analysis, and the solution allowed to run just to the top of the 
plate. The developed plate was dried using a warm laboratory hot plate (temperature 
setting 5) and placed on the TLC scanner for analysis. The Bioscan TLC Scanner 
measured the radiochemical purity, which must be greater than or equal to 90%.  
Radiochemical identity was determined by analysis and comparison of the retention factor 
of the standard and dose on TLC. Both purity and identity analysis are completed from a 
single TLC plate that was developed and dried, as described above. Heating the plate 
caused the standard to appear visibly brown, after which the plate was removed and 
placed on the TLC scanner for analysis. The Rf was calculated for the radiolabeled 
[18F]FDG sample by the TLC scanner. The “cold” FDG reference standard retention factor 
was calculated manually and compared with the [18F]FDG sample, the radioactivity 
distribution of which is determined by use of the Bioscan AR-2000 TLC scanner. This 
method provides excellent separation of free [18F]fluoride, desired [18F]FDG, and 
acetylated (non-hydrolized) [18F]FDG ([18F]FTAG) with Rf values of about 0.45, 0.0, and 
0.85, respectively. 
Figure 4-11: BioScan RadioTLC scanner. 
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c. Radionuclidic Identity  
A Capintec CRC-15R Radioisotope Dose Calibrator was used to measure 
activities. A sample of the [18F]FDG product was placed in the Capintec Dose Calibrator 
located behind an L-block lead shield and measured, noting both the time and activity. 
After a period of at least 15 min, time and activity was noted again. The half-life was 
calculated using Equation 4-1, which must be within the range of 105–115 min for the 
dose to be released to the clinic.  
t1
2
=-ln2(
time difference
ln [
ending activity
starting activity
]
) 
Equation 4-1: Calculation of half-life. 
d. Residual Solvent Analysis  
  Residual solvent analysis (RSA) of [18F]FDG was performed on a Shimadzu GC-
2010 Gas Chromatograph. The [18F]FDG doses were tested for acetonitrile and ethanol 
concentration levels and compared with a standard solution in accordance with the US 
Pharmacopeia (USP). The standard solution contained known concentrations of 
acetonitrile and ethanol, 0.01% and 0.1%, respectively. GC conditions were as follows: a 
Restek Stabilwax with Integra-Guard 30 m × 0.25 mm GC column, with helium carrier 
gas. Concentration percentages were calculated, and no more than 0.5% ethanol and 
0.04% acetonitrile can be found in the dose, according to the USP. ICH Hamonised 
Tirparitite Guildlines limit acetonitrile, a class 2 solvent, levels to <410 ppm per patient 
per day. Ethanol, a class 3 solvent, has a limit of <5000 ppm/day.  
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e. Dose pH  
Dose pH of a small amount [18F]FDG dose was analyzed with colorpHast© 
nonbleeding pH strips. The chosen colorpHast nonbleeding pH strips have specification 
range of 2.0–9.0, and the determination of pH was done by visual comparison of the pH 
strip with the reference card supplied with the strips. The pH must be within the range of 
4.5–7.5 to meet the release criteria.  
f. Residual Kryptofix-[2.2.2] Analysis  
Kryptofix-[2.2.2] (K222) is a phase transfer catalyst (PTC) used to facilitate the 
nucleophilic fluorination reaction for [18F]FDG. Toxicity of K222 necessitates the verification 
of the absence of this PTC in the dose before its release. Residual Kryptofix-[2.2.2] levels 
in [18F]FDG were analyzed using the established spot test. Both water (negative control) 
and a 50-µg/mL standard (positive control) were used in this test.  
Kryptofix standards were prepared by serial dilution of a 1.0 mg/mL stock solution 
using deionized water. Indicator strips were prepared by immersing pre-cut strips of thin-
layer silica gel in a stock iodoplatinate reagent for 5-10 seconds, when complete 
saturation occurred. Once the strips had been completely saturated by the reagent, they 
were allowed to dry overnight and then stored at room temperature in a vented glass jar. 
This stock reagent was prepared using 5 mL of water mixed with 0.26 g of chloroplatinic 
acid, and then mixing this solution with 45 mL of water and 5 g of potassium iodide and 
diluted with an additional 100 mL of water.  
A single droplet of the [18F]FDG dose was applied to the indicator strip, before the 
additional droplets of both the negative water control and the Kryptofix standard (50 
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µg/mL) were applied and allowed to dry for 5–10 min. All three spots were analyzed, and 
a visual determination of the relative concentration of Kryptofix-[2.2.2] was made for the 
[18F]FDG dose.  
Kryptofix-[2.2.2] presents as an appearance of a blue-black ring around a white circle 
of silica surrounded by a pink ring of unreacted reagent. At very low or no concentrations 
of Kryptofix, a faint pink core remains in the center of the white circle, with no visible blue-
black ring, and the spot will look more similar to the sterile water negative control, than 
the 50 μg/mL positive standard. The dose must contain <50 µg/mL for the dose to be 
acceptable for release.  
g. Sterile Filter Integrity Test  
The integrity of the sterile filter used for sterile dispensing of the dose must also be 
validated before the release of the dose to the clinic. The dose sterility results will not be 
available until 14 days post-production of the [18F]FDG  dose, and so the filter integrity 
test is essential in testing [18F]FDG product sterility. The Millex-GS sterile filter from the 
[18F]FDG dispensing was attached to the nitrogen supply through a calibrated regulator. 
The filter is then connected to a needle so that the filter does not need to be submerged 
in water. The tip of the needle was then submerged in water. The nitrogen flow was 
gradually turned on to increase the nitrogen pressure on the filter. The pressure was 
increased to greater than 30 psi, which is the acceptance criterion for the Millipore-GS 
filter. If the pressure reaches 30 psi or more without resulting in a stream of bubbles in 
the water, the filter is considered intact. The pressure at which a steady stream of bubbles 
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appears is recorded. If a steady stream of bubbles is seen before the minimum bubble 
point pressure is reached, the test fails, and the dose is rejected.  
h. Endotoxin Analysis  
The Charles River Portable Testing System (PTS) with Limulus Amoebocyte Lysate (LAL) 
test cartridges, purchased from Charles River were used to determine the endotoxin 
content in the [18F]FDG doses. A volume of 0.1 mL of the [18F]FDG dose was added to a 
plastic tube containing 3.9 mL of Endosafe LAL Reagent water and mixed for 10 s using 
a vortex. A 25 µL sample of the diluted [18F]FDG sample was added to each well on the 
Charles River PTS cartridge, and the test began. This was performed in accordance with 
the USP. The dose must contain ≤175 Endotoxin Units (EU) per dose.  
i. Sterility Testing  
To verify that the process by which each PET radiopharmaceutical is produced is 
consistently sterile and suitable for human use, sterility testing must also be performed 
on all doses of [18F]FDG produced. Sterility testing was performed by inoculating samples 
of [18F]FDG into both a fluid thioglycolate media (FTM) and a soybean casein digest 
media (SCDM). SCDM is used for the detection of aerobic bacteria and fungi, while the 
general purpose of FTM is to detect common aerobic, facultative, and anaerobic 
microorganisms.  
The [18F]FDG inoculated medium was incubated along with positive and negative 
controls for 14 days. Incubation temperatures were 32◦C and 22◦C for FTM and SCDM, 
respectively, according to current USP guidelines for sterility testing. The media was 
visually inspected on the third, eighth, and fourteenth days of the incubation test period 
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and compared to the positive and negative controls. The positive control must show 
growth (cloudiness or turbidity) in the medium, and the [18F]FDG samples and negative 
control must show no growth after 14 days of incubation in order for the dose to pass the 
sterility test.  
iii. Experimental Results and Conclusion 
For comparison of the TRACERLabMX-FDG module produced [18F]FDG doses with 
those produced by the new FASTLab 2 modules, yields, as well as all QC results were 
compiled for comparison. Table 4-1 represents the QC results for all of the FASTLab 
[18F]FDG doses produced in the U of M PET Center in 2017. Each dose meets or 
exceeds the necessary specifications. 
 The plots in figure 4-11 demonstrate the vast increase in overall yield produced 
by the FASTLab synthesis module as compared to the TracerLab MX-FDG module 
(left,747.8±76.7 mCi and right, 449.3±60.4 mCi, averages ± StDev respectively). 
Although the overall average yields for the FASTLab were higher, the standard 
For [18F]FDG Doses Produced 
by FastLab (n= 386) 
Specification Results 
Yield @ EOS N/A 747.8 ± 76.7 mCi 
Visual Inspection 
Clear, colorless, 
no precipitate 
Passes 
Identity (difference in TLC 
plate) 
<0.05 0.02 ± 0.01 
Purity >90% 98.5 ± 1.7 % 
pH 5.0 - 7.0 5.9 ± 0.2 
RSA Acetonitrile <0.5% (v/v) 0.215 ± 0.046% 
RSA Ethanol <0.04% (v/v) 0.003 ± 0.001% 
Filter integrity (bubble point) >30 psi 54 ± 4 
Endotoxin <9.00 2.00 ± 0.04 
Sterility Sterile Passes 
 
Table 4-1: Tabulated results for n = 386 production runs of [18F]FDG on the FASTLab 2 modules. 
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deviation indicates that there are still some issues with consistency. This is due to a 
multitude of factors including how often the cyclotron has been run in a given day, as 
well as any maintenance that may have taken place either in the hot cell, on the module 
itself, or on the cyclotron or targets. It is expected that the next year of FASTLab 
production will be more consistent, the cyclotron just having had its 10-year preventative 
maintenance and target replacements.  
This chapter has discussed the history, regulation, utility and daily production of 
[18F]FDG. Also discussed was the recent update of the [18F]FDG production workflow in 
the U of M PET Center. The combination of the FASTLab 2 synthesis modules and self-
shielded Nb fluorine-18 cyclotron targets has been shown to be reliable, demonstrating 
repeatable manufacture of high yielding doses of FDG.  The FASTLab modules haven 
proven to be a robust and reliable platform with an uptime >99% over the past 18 months 
of continued twice daily FDG production. The simplification of our workflow, inventory 
management and regulatory compliance as a result of the synthesis module and cyclotron 
upgrade, leading to a decrease in patient wait times for FDG PET by half, from four days 
to two days at our nuclear medicine clinic, as a result of our increased FDG production 
capacity. 
 
Figure 4-12: End of synthesis (EOS) yields for the FASTLab (left) and the TRACERLabMX-FDG. 
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Chapter 5  
Overall Conclusions and Future Outlook 
A. Summary and Future Outlook 
Reported in this thesis are the most recent efforts towards development of GAT-1 
selective PET radiotracers. Through the synthesis, radiolabeling, and evaluation, both in 
vivo and in vitro, it has been found that the classical GABA uptake inhibitors modeled 
after tiagabine are not suitable for PET imaging of the potentially underutilized biological 
target GAT-1. These classical GAT-1 inhibitors utilized nipecotic acid as the biologically 
active moiety, with a lipophilic side chain to increase blood-brain barrier (BBB) 
penetration. Such compounds have proven effective for therapeutic dosing, where it is 
possible to titrate a dose over a timespan of weeks to accumulate enough drug in the 
brain to elicit a pharmacological effect. However, we have shown such strategies are not 
applicable to the PET field, where the amount of tracer used is on the microgram scale 
and the short-lived radionuclides employed dictate the necessity for rapid uptake in the 
brain at sufficient levels to obtain a PET scan, in only ~60-90 minutes post-injection.  
The work reported in Chapters 2 and 3 of this thesis demonstrate that simple 
nipecotic acid derivatives do not penetrate the blood-brain barrier, and even incorporation 
of highly lipophilic side chains to increase log P of the radiotracer does not facilitate brain 
uptake. While reasons for the lack of brain uptake of compounds like (R, E/Z)-[18F]2.11 
have not been confirmed, studies presented in this thesis suggest that the highly 
zwitterionic character of the carboxylic acid moiety on nipecotic acid could be a 
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contributing factor. It has been hypothesized that one way to overcome this challenge 
and adapt classical GABA uptake inhibitors for application in PET imaging is through the 
use of a bioisosteric replacement of the carboxylic acid functionality. Preliminary work 
towards addressing this issue has been discussed in Chapter 3 of this thesis. The 
preliminary studies included initial evaluation of bioisosteres in a brain homogenate GABA 
uptake inhibition assay, and attempted synthesis of various bioisosteres such as the 
piperidinyl-3-tetrazole and piperidinyl-3-thiazole. While synthesis of the piperidinyl-3-
tetrazole has proved challenging to date, it remains a scaffold of interest for future 
development.  
In lieu of the tetrazole, a more lipophilic 5-membered hetero-ring, the thiazole, was 
evaluated. Derivatives of nipecotic acid bearing the thiazolyl bioisostere have proven to 
be readily accessible, and it has been shown that a [11C]3.31 is readily prepared in high 
yields (131 ± 61 mCi) and high specific activity (2500 ± 1000 mCi). Initial in vitro evaluation 
of [11C]3.31 determined that it has high affinity for GAT-1 (Kd = 2.26 nM), while in vivo 
evaluation showed excellent brain uptake in rodents and nonhuman primates. There was 
high uptake in the cortex, which is to be expected for a GAT-1 radiotracer. 
Figure 5-1: Select examples of classical GABA uptake inhibitors 
employing nipecotic acid and selective for GAT-1 (5.1, 5.2, 2.11). And 
the successful thiazole bioisostere (3.31). 
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 Future work will be focused on further evaluation of [11C]3.31 to determine its 
imaging properties and selective target engagement. This can be achieved by using 
nipecotic acid and tiagabine in competition assays. If selectivity between GABA 
transporter subtypes is not achievable with 3.31, further investigation of a thiazole as a 
successful bioisostere could include the incorporation of the thiazole into the scaffold of 
the GAT-1 selective scaffolds described throughout this thesis (Figure 5-1).  
A triazole based scaffold could also be of interest for bioisosteric replacement of 
the carboxylic acid. A triazole, such as 5.4, still contains an acidic proton, while retaining 
slightly more lipophilicity than the tetrazole based scaffold. 
Since the nipecotic acid core is the most-well known GAT pharmacophore, it is 
also worth determining if it can be modified in other ways to enhance brain uptake. One 
attractive approach often used in drug design is the incorporation of fluorine atoms into a 
given scaffold.1 It is known that careful introduction of fluorine into drug molecules can 
drastically alter pKa and pharmacokinetics (See Figure 5-3). Thus it is worth exploring the 
difluorinated nipecotic acids such as 5.6 (Figure 5-3); incorporation of such difluorinated 
Figure 5-2: Tetrazole and triazole molecules 
for use as nipecotic acid bioisosteres. 
Figure 5-3: Comparison of pKas of non- and di-fluorinated nipecotic acid. 
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piperidines has been shown in the literature to improve BBB permeability.2 The 
fluorination of the piperidine of nipecotic acid would make the amine much less basic, 
alleviating the hypothesized zwitterionic character of the parent nipecotic acid, and 
allowing for the use of the carboxylic acid pharmacophore in a GAT-1 PET radiotracer. 
Radiotracers incorporating such a fluorinated nipecotic acid moiety could potentially be 
radiolabeled with high specific activity fluorine-18 or carbon-11 using the radiochemistry 
methods described throughout this thesis. In vitro and in vivo evaluation using the same 
imaging, autoradiography and immunohistochemistry techniques described herein will be 
required to determine the effects of fluorine incorporation on BBB permeability and the 
pharmacological profile of the GAT pharmacophore. 
 Finally, other GABA transporters continue to be relatively under investigated, but 
recent studies have reported selective and potent inhibitors of other subtypes such as 
GAT-2 and GAT-3.3,4 For example, a small library of amino-methyl tetrazoles were 
recently reported (5.7).5 These non-classical GABA uptake inhibitors are based on a 
bioisostere of glycine. Another attractive scaffold that shows selectivity for inhibition of 
glial GABA uptake was reported by Clausen and coworkers in 2006 (5.8).6 These 
molecules are lipophilic derivatives of exo-THPO, a muscimol analog. Both of these 
scaffolds could prove to be interesting for development of a PET tracer for imaging of the 
glial GABA transporter.  
Figure 5-4: Molecules for the potential targeting of glial uptake PET 
imaging. 
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B. Overall Conclusions 
In summary, we and others have spent considerable research effort to enable PET 
imaging of GABA transporters, with a focus on neuroimaging of GAT-1. However, 
challenges with brain uptake of classical GAT-1 inhibitors in the time frame of a PET scan 
means that PET imaging of GAT-1 currently remains elusive. Nevertheless, this thesis 
provides an important contribution to the GAT-1 literature as it suggests that we will never 
be able to develop PET radiotracers for GAT-1 by employing the nipecotic acid core 
because its highly polar zwitterionic nature is not conducive to BBB permeability. As the 
acid group is necessary for high affinity binding to GAT-1, it cannot be simply removed or 
esterified. Therefore, future efforts in GAT-1 radiotracer design will need to investigate 
carboxylic acid bioisosteres or analogs of nipecotic acid (such as fluorinated nipecotic 
acid  derivatives) in an attempt to improve brain uptake while maintaining affinity for GAT-
1. Our preliminary efforts in this direction have shown good promise and will be pursued 
further going forward. 
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